

BAL PHARMA LIMITED



Your Preferred Partner in **Quality Health Care**



$23^{\rm rd}_{\rm ANNUAL \ REPORT \ 2009-2010}$

Bal Pharma Limited



MANAGEMENT, BANKERS AND AUDITOR

Board of Directors

- Mr. Shailesh Siroya Dr. S. Prasanna Mr. Shrenik Siroya Dr. G.S.R. Subba Rao Mr. Arun Bhan Mr. David Rasquinha
- Company Secretary

Mr. S. Ramji

Registered Office

21 & 22, Bommasandra Industrial Area, Hosur Road, Bangalore - 560 099.

Plant Locations

Unit I : Formulations # 21 & 22, Bommasandra Industrial Area, Hosur Road, Bangalore - 560 099.

Unit II : R & D Centre & Bulk Drugs # 61/B, Bommasandra Industrial Area, Hosur Road, Bangalore - 560 099.

Unit III : Parenterals

732/735, Off. National Highway, No. 4, Village Kenjal, Dist. Bhor, Maharashtra - 412 217.

Unit IV : Formulations plant at Uttarakhand

Plot # 1,2,3 & 69, Sector 4, IIE-Pantnagar, Rudrapur, Udham Singh Nagar, Uttarakhand - 263 153.

Managing Director

- Whole-time Director

- Non-executive Director
- Independent Director
- Independent Director
- Nominee Director

Bankers

Canara Bank Punjab National Bank EXIM Bank

Statutory Auditors

Ostawal & Jain

Internal Auditors Ishwar & Gopal

.

Registrar & Share Transfer Agent

TSR Darashaw Limited, # 6-10, Haji Moosa Patrawala Industrial Estate, 20, Dr. E. Moses Road, Mahalaxmi, Mumbai - 400 011.

CONTENTS

	Page Nos.
Notice	I
Directors' Report	3
Report on Corporate Governance	H
Auditor's Report of Bal Pharma Limited	19
Auditor's Report on the Consolidated Financial Statements	21
Financial Statements of Bal Pharma Limited	22
Consolidated Financial Statements	44
Auditor's Report of Basav Chem Limited	64
Financial Statements of Basav Chem Limited (100 % subsidiary)	66
Attendance Slip & Proxy Form	Attached
ECS Mandate Form	Attached

Bal Pharma Limited

NOTICE



NOTICE IS HEREBY GIVEN THAT the 23rd (Twenty third) Annual General Meeting of the members of Bal Pharma Limited, will be held at 10.00 AM, on Monday, the 27th September, 2010 at Bharatiya Vidya Bhavan, Race Course Road, Bangalore - 560001 to transact the following business:

ORDINARY BUSINESS:

- To receive, consider and adopt the audited Balance Sheet as at L. 31st March, 2010, and the Profit and Loss Account for the financial year ended on that date and the Reports of the Directors and the Auditors thereon;
- 2. To appoint a Director in place of Mr.Shrenik Siroya, who retires by rotation and being eligible, offers himself for re-appointment.
- 3 To appoint a Director in place of Dr.G.S.R Subba Rao, who retires by rotation and being eligible, offers himself for re-appointment.
- To appoint Auditors and to authorize the Board to fix their 4. remuneration.

By order of the Board

Bangalore	S. Ramji
09-08-2010	Company Secretary

NOTES:

I. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING MAY APPOINT A PROXY TO ATTEND AND ON A POLL TO VOTE ON HIS/HER BEHALF A PROXY NEED NOT BE A MEMBER.

Proxy, in order to be effective must be deposited the proxy instrument duly filled, at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting. Proxy Form is forwarded as detachable part of Annual Report;

- 2. Corporate Members intending to send their authorised representative to attend the meeting are requested to send a certified copy of the Board resolution authorizing their representative to attend and vote on their behalf at the meeting.
- For convenience of the Members and for proper conduct of the 3. meeting, entry to the place of meeting will be regulated by an attendance slip, which is forwarded as detachable part of Annual Report. Members are requested to affix their signature at the place provided in the attendance slip and hand it over at the entrance;
- The Register of Members and Share Transfer Books of the Company 4 will remain closed on 27-09-2010.
- 5. Members, who hold shares in dematerialized form, are requested to bring in their Client ID and DP ID nos. for easier identification of attendance at the meeting and those who hold shares in physical form are requested to write their folio number in the attendance slip for attending the meeting.
- 6. A member desirous of getting any information on the accounts or operations of the Company is requested to forward his/her queries to the Company at least 7 days prior to the meeting, so that, the required information can be made available at the meeting.

- 7. Members holding shares in physical form are requested to notify immediately any change in their address to the Company's Registrar and transfer Agent TSR Darashaw Limited. Members holds shares in electronic form may intimate any such changes to their respective Depository participants (DPs).
- Members holding more than one share certificate in different folios 8 are requested to kindly apply for consolidation of the folios and send the relative share certificates to the Company's Registrar and Share Transfer Agent, TSR Darashaw Limited, 503, Barton Centre, 84, M.G. Road, Bangalore - 560 001
- 9. Members are kindly requested to bring Annual Report 2009-10 along with them to the 23rd Annual General Meeting, since extra copies will not be supplied at the meeting.
- 10. In order to protect the investors from fraudulent encashment of their dividend warrants or Demand Drafts, the Company hereby offers Electronic Clearing Services (ECS) facility to the shareholders having Bank Accounts at Centers notified for ECS by RBI. RBI is continuously adding more centers for ECS and Members are kindly requested to check with their banker whether their place has been notified by RBI for the purposes of ECS. ECS mandate form is forwarded as detachable part of Annual Report. The Members from the ECS notified centers desirous of payment of dividend through ECS are requested to forward the ECS mandate form duly signed with the required annexure to Company's present Registrar and Share Transfer Agent, TSR Darashaw Limited, Bangalore, on or before 07.09.2010.
- 11. Pursuant to Section 205A (5) of the Companies Act, 1956, as amended, any money transferred to Unpaid Dividend Account and remaining unclaimed for a period of 7 (seven) years from the date of such transfer to the Unpaid Dividend Account shall be transferred by the Company to the Investor Education and Protection Fund (IEPF) established by the Central Government, and thereafter, the shareholders shall not be able to claim any Unpaid Dividend from the said fund or from the Company. The Company has since transferred the amount lying in the credit of Unpaid Dividend Account for the financial year 2001-02 to Investor Education and Protection Fund established by the Central Government as stipulated under Section 205C of the Companies Act, 1956 read with Investor Education and Protection Fund (Awareness and Protection of Investors) Rules, 2001. The members who have not enchased the Dividend Warrants for the financial years 2003 to 2004 onwards are requested to write to, TSR Darashaw Limited, the Registrars and Share Transfer Agents of the Company.
- 12. The Members may now avail of the facility of nomination by nominating, in the prescribed form, a person to whom your shares in the company shall vest in the event of death of member. Interested members may write to the Company's Registrar & Share Transfer Agent for the prescribed form.

By order of the Board

Bangalore 09-08-2010

S. Ramji Company Secretary

ADDITIONAL INFORMATION ON DIRECTORS SEEKING APPOINTMENT AT THE ANNUAL GENERAL MEETING:

Name of the Director	Mr. Shrenik Siroya	Dr. G.S.R Subba Rao
Date of Birth	10-09-1964	21-08-1937
Date of Appointment 30-09-1997		08-07-2000
Qualification	B.E (UK)	B.Sc (Honors), M.Sc, D.Sc, PhD, F.A.Sc, F.N.A
contracts and in managing pharmaceutical Companies.		Formerly Professor and Dean in Indian Institute of Science, (IISc) Bangalore, is also a consultant to many Indian and Foreign Pharmaceutical companies on synthesis of Drugs, intermediates, natural products, Steriod Hormones, combinatorial Synthesis.
Other Directorships I) Siroya Exports (P) Limited – Director 2) Siroya Developers (P) Limited (Erstwhile Siroya Trading Co. (P) Limited) – Director 3) Mokalsar Stone Private Limited – Director 4) Siroya FM Construction Private Limited – Director 5) Siroya Nabar Housing Private Limited - Director 6) Mannath Developers (P) Limited - Director 7) Siroya FM Infradevelopment (P) Limited - Director 8) Basav Chem Limited – Director		I) Basav Chem Limited - Director
Other Committee Memberships in the Company	 Bal Pharma Limited a) Audit Committee : Member b) Shareholders & Investors Grievances Committee : Member 	Bal Pharma Limited : a) Audit Committee : Chairman b) Remuneration Committee : Chairman c) Shareholders & Investors Grievances Committee : Chairman
Number of shares held directly or indirectly	374,700 (3.59%) – Equity Shares	4,000 (0.4%)

Bal Pharma Limited



DIRECTORS' REPORT



To The M

The Members

Your Directors have pleasure in presenting the 23rd Annual Report together with the Audited Accounts of the Company for the financial year ended on 31st March, 2010.

I. FINANCIAL RESULTS:

	(₹. in Lakhs)								
Pai	rticulars		2009-10		2008-09				
I)	Total Income	I	08,15.16		10667.67				
2)	Profits before Depreciation and provision for Taxation		195.47		598.59				
Les	ss: Depreciation		285.90		188.58				
	Profits before Taxation and prior year adjustments		(90.43)		410.01				
Les	ss :								
3)	Provision for Taxation	7.33		3.52					
4)	Fringe Benefit Tax	-		23.47					
5)	Deferred Tax	44.94		79.30					
6)	Extraordinary/ Non Recurring items	-		-					
7)	Prior year adjustment	(0.18)	52.08	4.44	110.73				
Ad	d:								
8)	Profit & Loss Account balance at the beginning of the year		142.89		299.28				
9)	Profit made available for appropriation		906.62		699.32				
			763.74		998.60				
Less:									
10)	Proposed Dividend on Equity Shares	-		78.62					
11)	Tax on dividends	-	-	13.36	(-) 91.98				
 Balance Carried to Balance Sheet 			763.74		906.62				

2. DIVIDEND:

In view of the results, your Directors have decided not to recommend payment of dividend for the year, 2009-10.

3. MANAGEMENT DISCUSSION AND ANALYSIS:

Global Pharmaceutical Industry Challenges

The global pharmaceutical business is becoming more complicated than ever before. Older business models are being challenged by competition; new verticals are coming into play. There will be new developments and alliances, as well as new opportunities and challenges. In such an environment only the rapid, clever and nimble will win.

If present industry overview is taken in to consideration, the global pharmaceutical market in 2010 is projected to grow 4% to 6% exceeding US\$ 825 billion. This growth will be largely driven by strong overall growth in the emerging countries, as well as the rising influence of healthcare access and funding on market demand. Moreover, the global market is expected to grow at 4-7% Compound Annual Growth Rate (CAGR) through 2013. Global pharmaceutical market value is expected to expand to \$975 plus billions by 2013.

EMERGING TRENDS:

Emerging markets are set to play a pivotal role in future pharmaceutical success. Emerging pharmaceutical markets are typically small. However, their rapid growth vis-à-vis the more regulated markets make them attractive prospects for the pharmaceutical industry. Rapidly growing economies, increasing population and greater health awareness combined with larger incomes to spend on healthcare will drive the growth of pharmaceuticals in emerging markets. By 2017, IMS forecasts revenues from emerging markets at US\$ 290 billion to US\$ 320 billion, with a CAGR of 12% to 15%.

INDIAN PHARMACEUTICAL INDUSTRY:

The Indian Pharmaceutical Industry ranks as a frontrunner among the Country's science based industries with wide ranging capabilities in the complex field of drug manufacture and technology. The industry has been growing at an impressive CAGR in excess of 8-9%, and will touch \$10 billions by 2010.

Indian pharmaceutical industry is the world's 13th largest in terms of value and 14th in terms of volume with over all 60,000 brands in over 60 therapeutic categories. India has world class facilities and expertise in manufacturing with the largest number



of US FDA approved manufacturing units in the world out side US. Ancillary industries are also well developed with support available locally. Quality bulk drugs at competitive prices are assured.

• Global pharma looks to India: Prospects for growth:

The huge potential of the Indian pharmaceuticals market is impossible for foreign companies to ignore, given that it will be one of the top 10 sales markets by 2020. India's population is growing rapidly, as is its economy – creating a large middle-class able to afford western medicines. India's epidemiological profile is also changing and the population is ageing, so demand is likely to increase for drugs for cardiovascular problems, disorders of the central nervous system and other chronic diseases such as diabetes which is increasing at an alarming rate. The total market is expected to rise to a value of approximately US \$50 billions by 2020.

4. **BUSINESS OPERATIONS:**

During the year, 2009-10 your Company has achieved an over all turnover of ₹ 108.15 crores as against ₹ 106.67 crores of the previous year. Thus registering a marginal growth of 1.39% on the top line. Despite a marginal increase in sales, the net results after tax decreased from ₹ 2.99 crores of the previous year to a net loss of ₹ 1.42 crores during the current year. The main reason for the fall in net profit is commissioning of our Uttarakhand plant, difference in product mix, and cut-throat competition from large pharma players in Indian and international markets.

The exports formulations division registered a growth of 42.34% by increasing its turnover from ₹ 22.39 crores in the previous year to ₹ 31.87 crores in the current year. Your Company expanded its presence in many new global markets such as Latin America and many African countries.

The bulk drug business both domestic and exports have been very encouraging with the growth of 44.36% as the turn over of the division reached ₹ 42.24 crores as against ₹ 29.26 crores in the previous year. Utilization of facility at Basav Chem Limited (wholly owned subsidiary Company) has also been to its full capacity. Regular supplies of the products are made to developed markets such as Europe, Japan, Australia and Canada where the products are already registered. Various DMF have been filed across the globe to increase our presence in other markets.

The over all exports of your Company increased (by 54.7%) to ₹ 57.35 crores as against 37.07 crores during the year 2008-09.

The govt. Institutional business made a turnover of \gtrless 4.44 crores and the Ayurvedic Division has made a turn over of \gtrless 2.04 crores during the year 2009-10.

Your Company's branded formulations divisions mainly consisting of Diabetic and Cardiac Products made a net sale of $\overline{<}$ 23.36 crores as against $\overline{<}$ 35.21 crores during the last year. This reduction in sales in branded formulation has affected the profit margins of the Company (34% shortfall during the year). This short fall in sale is due to mass attrition of a number of employees from major divisions of the Company.

Appropriate measures are being taken by your management to overcome the reduction in branded formulation sales and to retain the existing market.

5. RESEARCH & DEVELOPMENT:

The Research and Development division is actively engaged in the development, scale-up and commercialization of processes for the manufacture of high value API's in niche areas. Production of these products has enabled the Company to market them, both nationally and internationally.

All the products manufactured through the processes developed by the R&D division are backed by complete, internationally accepted, documentation and controls. The quality and purity of these products are established and maintained by sophisticated analytical methods and protocols developed in-house by the R&D and QC divisions.

The ready acceptance of our products in the international market is a clear indicator of their high quality. This is further reinforced by tight quality controls at every stage of the manufacturing process, leading to excellent quality characteristics in our APIs.

All this developmental work has resulted in the generation of valuable intellectual property (IP) which the Company is now in the process of patenting. Simultaneously, Bal Pharma has made a beginning in the development of new chemical entities and some promising leads have been obtained in this direction.

6. AUDIT COMMITTEE:

The Audit Committee, a sub-committee of the Board consists of Mr. David Rasquinha (nominee Director of EXIM Bank), Dr. G. S. R. Subba Rao, Independent Director and Mr. Shrenik Siroya, Non-Executive Director.

This Committee headed by Dr.G.S.R Subba Rao, has been discharging its duties under SEBI Guidelines read with the Listing Agreement. The said Committee is also functioning as Audit Committee under Section 292A of the Companies Act, 1956.



7. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:

Your Company has an adequate system of internal controls with clearly defined authority limits. They ensure that the Company's assets are protected against loss from unauthorised use or disposition and all transactions are authorised, recorded and reported in conformity with generally accepted accounting principles. These systems are designed to ensure accuracy and reliability of accounting data, promotion of operational efficiency and adherence to the prescribed management policies. These policies are periodically reviewed to meet current business requirements.

Internal Audit is carried out by Messrs. Ishwar & Gopal an independent firm of Chartered Accountants. They interact with the Audit Committee and have reported to the Directors that there is adequate internal control systems in respect of areas carried out by them.

8. DIRECTORS' RESPONSIBILITY STATEMENT:

In compliance to the provisions of Section 217(2AA) of the Companies Act, 1956, your Directors wish to confirm with reference to statement of Accounts for the financial year ended 31.03.2010:

- that in preparing the Annual Accounts, all applicable Accounting Standards have been followed;
- (ii) that the accounting policies adopted are consistently followed and the judgements or estimates made are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the Profit and Loss Account of the Company for the financial year;
- (iii) that the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing/detecting fraud and other irregularities;
- (iv) That the Directors have prepared the annual accounts on going concern' basis.

9. SUBSIDIARY COMPANIES:

The Company had two wholly owned Subsidiary Companies during the financial year, 2009-10. One of the subsidiary companies, Novosynth Research Labs Private Limited applied for striking off its name from the register under Section 560 of the Companies Act, 1956 and the Amalgamation proceedings of Basav Chem Limited with Bal Pharma Limited is before the Honourable High Court of Karnataka. Statement pursuant to Section 212 of the Companies Act, 1956, relating to Company's interest in subsidiary company, Basav Chem Limited is as given in Annexure I forming part of the Director' Report.

10. PARTICULARS OF EMPLOYEES:

A statement of particulars of employees as required under Section 217(2A) of the Companies Act, 1956, is given as Annexure II and forms part of this report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

As per provisions of Section 217(1)(e) of the Companies Act, 1956, read with the Companies (Disclosure of Particulars in the Report of the Board of Directors) Rules, 1988, details relating to the Conservation of Energy and Technology Absorption and Foreign Exchange Earnings and Outgoings are given in Annexure forming part of the Directors Report.

12. PUBLIC DEPOSITS:

As on date of the Report, the Company has not accepted any public deposits.

13. DIRECTORS:

As on date, your Board consists of 6 (six) Directors, 3 (three) of whom are Non-Executive Directors and of which 2 (two) are Independent Directors. I (one) of who is Nominee Director of Export Import Bank of India. 2 (two) of whom are Executive Directors. Mr. Shrenik Siroya, Non-Executive Director and Dr. G.S.R. Subba Rao, Independent Director of the Company who retire by rotation at the 23rd Annual General Meeting of the Company and being eligible, offer themselves for reappointment. Your Directors have pleasure in recommending their reappointments.

14. AUDITORS:

Messrs Ostawal & Jain, Chartered Accountants, Auditors of the Company, retire at the Annual General Meeting and are eligible for re-appointment.

15. COST AUDIT:

Pursuant to Section 233B of the Companies Act, 1956, the Central Government has prescribed Cost Audit of the Company's Formulations Division.

Subject to the approval of the Central Government, the Board has appointed Mr. G.I. Srinivasamurthy as Cost Auditor of the Company for the financial year, 2010-11. The Cost Audit is under process and the Company will submit the Cost Auditors' Report to the Central Government in time.

16. EMPLOYEE STOCK OPTION SCHEME:

Pursuant to the provisions of Guideline 12 of the Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme), Guidelines, 1999, as amended, the details of stock options as on 31st March, 2010 under the "Bal Pharma Limited Employees Stock Option Scheme, 2006" is set out in the Annexure – III to the Directors Report.

17. CORPORATE GOVERNANCE AND ADDITIONAL INFORMATION TO SHARE HOLDERS:

A detailed report on the Corporate Governance System and practices of the Company are given in a separate section in this Annual Report. Detailed information for the shareholders is given in Additional Shareholders information section.

18. INSURANCE COVERAGE:

The Board reports that your Company has adequately insured all the assets of the Company.

19. APPRECIATION:

Your Directors place on record their sincere appreciation for significant contribution made by the employees through their dedication, hard work and commitment and the trust reposed on us by the medical fraternity and the patients. Your Board also acknowledges the support and wise counsel extended by Canara Bank, Punjab National Bank, Exim Bank, State Bank of Indore and other Banks and financial institutions, government agencies, shareholders and investors at large. The Directors look forward to having the same support in the our endeavor to help people lead healthier lives.

For and on behalf of the Board of Directors

Bangalore 9th August, 2010 **Dr. S. Prasanna** Executive Director Shailesh Siroya Managing Director

Bal Pharma Limited

ANNEXURE TO THE DIRECTORS' REPORT

ANNEXURE I

Information under Section 217(1)(e) of the Companies Act, 1956, read with the Companies (Disclosure of particulars in the Report of Board of Directors) Rules, 1988, and forming part of Directors' Report for the financial year ended on 31st March, 2010:

I. Conservation of Energy:

A. POWER AND FUEL CONSUMPTI	2009-10	2008-09	
I. Electricity			
(a) Purchased Unit	(kwhr)	2,7,86,290	20,88,962
Total Amount	(₹.)	12,852,495	103,11,288
Rate/Unit	(₹.)	4.61	4.94
(b) Own Generation			
(i) Through Diesel Generator Units	(kwhr)	380,107	12,26,027
Units per ltr of Diesel	(kwhr)	3.17	3.28
Cost/unit	(₹.)	16.31	11.01
(ii)Through Steam Turbine / Generator		Nil	Nil

B. CONSUMPTION PER UNIT OF PRODUCTION

Standards * (if any)

2009-10** 2008-09**

- i. Electricity Furnace Unit
- ii.
- iii. Coal
- Others iv.

* Owing to the range of products manufactured and the ever changing product mix, it has not been possible to establish standards relating to consumption of energy per unit of production;

** For the same reasons and as per the Records and Books, maintained by the Company, under the Companies Act, 1956, the Company is not in a position to furnish the required information in the prescribed format for the current year and the previous year.

Disclosure of Particulars with respect to Technology 2. absorption:

I.Re	I. Research and Development (R & D)						
(a)	•	The Company's Research and Development department is involved in the development of synthetic processes and procedures for new active pharmaceutical ingredients (APIs).					
(b)	Benefits derived as a result of the above R & D	These efforts of the Research & Development department have resulted in the Company being in a position to introduce relatively new medicines in the market. The therapeutic categories to which these medicines belong are antihistamine, antiseizure, anticancer, and dermatology.					

(c)	Future plan of action	The Company is now laying greater
		emphasis on such Research and
		Development activities with a result
		of which there will be continued and
		increased activity in this field.

(d) E	Expenditure on R & D:	2009-10	2008-09
(i)	Capital	Nil	NIL
(ii)	Recurring	85.31	87.34
(iii)	Total	85.31	87.34
(iv)	Total expenditure as a percentage of total	0.79%	084%
	turn over		

3. Technology Absorption, Adaptation and Innovation:

(i)	Effo tech adap	Several innovative methodologies to prepare new drugs have been developed in-house in the R&D division. These have been absorbed and adopted and made applicable in scale-up operation in pilot plant and manufacturing sections of the company.	
(ii)	the a impr	above efforts e.g., product rovement, cost reduction,	The new drugs so manufactured in the plant, adopting technologies developed in-house, are being offered in international markets where they have found ready acceptance.
(iii)			gy (imported during the last 5 years information may be Furnished:
	(a)	Technology imported	Nil
	(b)	Year of import	Nil
	(c) Has the technology been fully absorbed		Not applicable
	(d)	If not fully absorbed, areas where this has not taken place, reason therefore and future plan of action:	Not applicable

4. Total Foreign Exchange Earnings and Outgo: (₹. in 000')

	2009-10	2008-09
	(in ₹)	(in ₹)
Total Foreign Exchange Earnings	5,73,528.36	349,531.75
Total Foreign Exchange Outgo	329,380.48	199,073.16
(a) Raw Materials	322,103.58	186,572.88
(b) Other Foreign currency payments		
(i) Travelling Expenses	1,612.47	2,462.11
(ii) Export Promotion Expenses	5,612.83	5,421.77
(iii) Others - Capital import	51.60	4,616.40



5. Statement pursuant to Section 212 of the Companies Act, 1956 :

(I)	Name of the Company	:	Basav Chem Limited
(2)	The financial year of the subsidiary Company ended on	:	31st March, 2010
(3)	Date from which it became subsidiary	:	16-12-2007
(4)	Number of shares held by Bal Pharma with its nominees in the Subsidiary Company at the end of the financial year of the subsidiary company	:	1,00,000 shares of ₹ 10/- each
(5)	Extent of interest of holding Company at the end of the financial year of the Subsidiary Company	:	100%
(6)	Net aggregate amount of the Subsidiary Company's profits (loss) so far it concerns the members of Holding Company	:	(₹ 879,777)
	a. Not dealt within the holding Company's accounts:		
	(i) for the financial year ended on 31-3-2010	:	Nil
	(ii) for the previous financial years	:	Nil
	b. Dealt within the holding Company's accounts		
	(i) for the financial year ended on, 31-3-2010	:	(₹ 879,777)
	(ii) for the previous financial year	:	(₹ 99,281)

ANNEXURE II

Statement pursuant to Section 217(2A) of the Companies Act, 1956, read with the Companies (Particulars of Employees) Rules, 1975

SI. No.	Name & Designation	Qualification	Age	Gross Remuneration	Date of Commencement	Total Experience	Last Employment	Share holding 31-03-09
I	Shailesh Siroya* Managing Director	MBA (Finance)		₹ 40,00,000**	01.08.1994	18 years	Business	6.40%

* Mr. Shailesh Siroya is relative of Mr Shrenik Siroya, Non- Executive Director of the Company.

** Remuneration includes all costs incurred by the Company on the respective personnel i.e. basic salary & Allowances etc.



ANNEXURE III

Pursuant to the provisions of Guideline 12 of the Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme), Guidelines, 1999, as amended, the discloser of the particulars of stock options scheme as on 31st March, 2010 under the "Bal Pharma Limited Employees Stock Option Scheme, 2006"

SI.No	Description	Det	tails		
I	Options Granted	2,19	9,500		
2	The Pricing Formula	Bal Pharma Limited Employee Stock Option Scheme, 2006 provides for the grant of options as follows:			
		The	total number of options g	granted under ESOP, 2006 sł	nall not exceed 5,22,300
			ons convertible in to shares sent issued equity share cap	s of ₹10/- each approximately vital of the Company	equivalent to 5% of the
		to t Sto	he meeting of the Remuner	all be 50% of the latest availab ation Committee, in which op as of the Company are listed a e.	ptions are granted, on the
3	Options vested	43,9	900 (20% of Options grante	ed)	
4	Options Exercised	29		·	
5	The total number of shares arising as a result of exercise of option	37,0	000		
6	Options Lapsed	Due	e to rejection of options gra	nted: 6100	
		Due	e to Termination of employr	ment: 800	
7	Variation of terms of options	N.A	N Contraction of the second se		
8	Money realised by exercise of options	₹ 582,750/-			
9	Total number of options in force	Nil			
10	Details regarding option granted to Directors and Senior managerial personnel				
			Name	Exercise Price (in ₹.)	No.of options
	(i) Directors		Dr. S. Prasanna	15.75	20,000
			Dr. G.S.R. Subba Rao	15.75	20,000
			Mr. Arun Bhan	15.75	20,000
	(ii) Senior managerial personnel				
			Mr. M.Sundar	15.75	8,000
			Dr. Nagarajan	15.75	8,000
			Dr. Sivaramakrishnan	15.75	8,000
			Mrs. Archana Mitra	15.75	8,000
			Mr. Kotian. C	15.75	8,000
			Mr. Raju Krishna Ekden	15.75	8,000
	(iii) Any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during the year.	NIL			
	 (iv) Identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the Company at the time of grant. 				



SI.No	Description	Details
11	Diluted Earnings Per Share (EPS) pursuant to issue of	(₹ 1.36/- per share)
	shares on exercise of option calculated in accordance	
	with Accounting Standard (AS) 20 'Earning Per Share'.	
12	The difference between the employee compensation	₹ 1,37,800/-
	costs computed under Intrinsic Value Method and	
	the employee compensation cost that shall have been	
	recognized if the Company had used the Fair Value	
	Methods and its impact on profits and on EPS of the	
	Company.	
		₹ 0.01/-
13	Weighted-average exercise prices and weighted-average	₹ 15.75/-
	fair values of options for an option whose exercise price	
	either equal or exceeds or is less than the market price	
	of the stock.	
14	Description of the method and significant assumptions	Black Schole Method
	used during the year to estimate the fair values of	
	options.	
	(i) Risk-free interest rate	8%
	(ii) Expected life	60 months
	(iii) Expected volatility	-
	(iv) Expected dividends, and	NIL
	(v) The price of the underlying share in market at the	₹31.45/-
	time of option grant	

For and on behalf of the Board of Directors

Bangalore 9th August, 2010

Dr. S. Prasanna Director Shailesh Siroya Managing Director

Bal Pharma Limited

REPORT ON CORPORATE GOVERNANCE FOR THE FINANCIAL YEAR, 2009-10

Bal Pharma Limited has a philosophy of Corporate Governance which stems from the belief that, timely disclosures, transparent accounting policies and a strong and independent Board of Directors to go a long way in preserving shareholders trust while maximizing long-term corporate values.

The report on Corporate Governance is pursuant to revised Clause 49 of the Listing Agreement entered in to with the stock exchanges and form part of the report of the Board of Directors. The Company has complied with all applicable requirements of the revised Clause 49 of the Listing Agreement.

I. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE:

Corporate Governance is a journey for constantly improving sustainable value creation and is an upward moving target. We are committed to meeting the aspirations of our stake holders, including shareholder employees, the government, lenders and society. The Company believes that all of its operations and actions must serve the underlying goals of enhancing overall enterprise value and retain shareholders trust over a sustained period of time.

2. BOARD OF DIRECTORS & BOARD COMMITTEES

2.1 Board Meetings:

In accordance with the provisions of the revised Clause 49 of the Listing Agreement, the Board meets at least once in every quarter to review the quarterly financial results and other items of the Agenda and, if necessary, additional meetings are held. The Board meets at least 4 (four) times in a year and the gap between two Board Meetings is not more than four months as per the revised Clause 49 of the Listing Agreement. The Board is appraised and informed of all the important information relating to the business of the Company. The Chairman of the Board, The Managing Director and the Company Secretary discuss the items to be included in the Agenda.

The Board comprises of 6 (six) Directors as on 31st March, 2010, with a Managing Director, 1 (one) Whole-time Director, 1 (one) non-executive Director, 3 (three) Independent Directors (including one nominee Director from Export Import Bank of India). 50% of the Board comprises of independent Directors as per the revised Clause 49 of the Listing Agreement. During the financial year, 2009-10 under review 5 (five) Board meetings were held on 28-05-2009, 29-06-2009, 27-07-2009, 31-10-2009, 27-01-2010 Compositions of the Board, attendance of the members of the Board at the Board meetings and Annual General Meeting along with their Chairmanship/Membership on Boards/Committees during the financial year, 2009-10 are furnished.

2.2 Information placed before the Board :

Information placed before the Board of Directors broadly covers the items specified in revised Clause 49 of the Listing Agreement and such other items which are necessary to facilitate meaningful and focused deliberations on issues concerning the Company and taking decisions in an informed and efficient manner. Besides, the Directors on the Board have complete access to all information as and when necessary.

			Attendance	Attendance at		membe	umber of erships in ees of Public	
SI No.	Name of the Director	Category Bo	Board Meetings	Last AGM on	in Boards of public Limited companies	Limited Co	Limited Companies on the date of this report	
			Doard Freedings	25.09.2010	on the date of this	As	As	
				report	Chairman	Member		
I	Mr. Shailesh Siroya	Executive	05	Yes	03	-	3	
2	Dr. S Prasanna	Executive	05	Yes	02	I	-	
3	Mr. Shrenik Siroya	Non-executive	02	No	02	-	3	
4	Dr. G.S.R. Subbarao	Independent	03	Yes	01	3	-	
5.	Mr. Arun Bhan	Independent	03	No	05	No	Ι	
6.	Mr. David Rasquinha	Nominee Director	05	No	02	No	2	

2.3 BOARD COMMITTEES

Currently, the Board has 4 (four) Committees namely viz. (i) Audit Committee, (ii) Remuneration Committee (iii) Shareholders & Investors Grievances Committee, (iv) Banking Transaction Committee. The Board decides the terms of reference of these Committees and the assignment of its Members thereof.



3. AUDIT COMMITTEE :

As a measure of good Corporate Governance and to provide assistance to the Board of Directors in fulfilling the Board's overall responsibilities, an Audit Committee has been constituted by the Board comprising of Three directors, majority of them are Independent Directors including one Nominee Director .The Chairman of the Audit Committee is an independent Director. The Company Secretary acts as the Secretary to the Audit Committee. The Audit Committee consists of the following Members;

SI No.	Name of the Member	Category
Ι.	Dr. G.S.R Subba Rao, Chairman	Independent Director
2.	Mr. David Rasquinha, Member	Nominee Director
3.	Mr. Shrenik Siroya, Member	Non-executive Director

The primary objective of the Audit Committee is to monitor and provide effective supervision of our financial reporting process with a view towards ensuring accurate, timely proper disclosure and the transparency, integrity and quality of financial reporting. Our Audit Committee oversee the work carried out in the financial reporting process – by our management, the internal auditors and the independent auditors – and reviews the process and safeguards employed as per the Listing Agreement.

5 (five) Audit Committee meetings were held during the financial year, 2009-10, under review, and the gap between two meetings did not exceed 4 (four) months. These were held on 28-05-2009, 29-06-2009, 27-07-2009, 31-10-2009, 27-01-2010. The following table gives attendance of the Members in the Audit Committee Meeting:

SI No.	Name of the Member	Number of meetings attended
I	Dr. G S R Subba Rao, Chairman	3
2	Mr. Shrenik Siroya, Member	2
3	Mr. David Rasquinha , Member	5

The terms of reference of the Committee also cover the matters specified under Section 292A of the Companies Act, 1956;

4. **REMUNERATION COMMITTEE AND REMUNERATION TO DIRECTORS:**

- 4.1 Remuneration policy: The Managerial remuneration to Executive Directors of the Company is paid in terms of all applicable provisions / schedules of the Companies Act, 1956 and the rules made thereunder;
- 4.2 Remuneration Committee is functioning with the following members as on 31st March, 2010.

SI No.	Name of the Member	Category
1	Dr. G.S.R Subba Rao, Chairman	Independent Director
2	Mr. Arun Bhan, Member	Independent Director
3	Mr. Shrenik Siroya, Member	Non-Executive Director

- 4.3 The terms of reference of the Committee cover the matters specified under revised Clause 49 of the Listing Agreement with the Bombay Stock Exchange Limited and National Stock Exchange of India Limited. The Committee also functions as 'Remuneration Committee' under Schedule XIII of the Companies Act, 1956;
- 4.4 The Remuneration Committee was also authorised to function as 'Compensation Committee' under SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;
- **4.5** The Remuneration paid to Mr. Shailesh Siroya, Managing Director, Dr. S. Prasanna, Whole-time Director and sitting fee paid to Non-executive Director & Independent Directors during the financial year, 2009-10 are as under:

SI No	Particulars	Mr. Shailesh Siroya	Dr. S Prasanna	Mr. Shrenik Siroya	Dr. G S R Subba Rao	Mr. Arun Bhan	Mr. David Rasquinha
T	Salary & Perquisites	₹ 40,00,000/-	₹ 20,40,000/-	N.A	N.A.	N.A.	N.A.
2	Sitting Fees	N.A	N.A	₹ 11,000/-	₹ 8,000/-	₹ 3,000/-	₹ 10,000/-
	Total	₹ 40,00,000/-	₹ 20,40,000/-	₹ 11,000/-	₹ 8,000/-	₹ 3,000/-	₹ 10,000/-

5. SHAREHOLDERS' AND INVESTORS' GRIEVANCES COMMITTEE:

5.1 The Committee consists of the following members of the Board:

SI No.	Name of the Member	Category
I	Dr. G S R Subba Rao, Chairman	Independent Director
2	Mr Shrenik Siroya,Member	Non Executive Director
3	Mr. Shailesh Siroya, Member	Managing Director

- 5.2 The terms of reference of the Committee cover the matters specified under revised clause 49 of the Listing Agreement with the Bombay Stock Exchange Limited and National Stock Exchange of India Limited;
- 5.3 The Committee regularly meets every fortnight to dispose of the matters under its reference;
- 5.4 Name and designation of the Compliance Officer: Mr. S.Ramji, Company Secretary;
- **5.5** Investor complaints handled:

Year	Opening balance as on 01.04.2009	Received	Resolved	Pending as on 31.03.2010
2009-10	NIL	61	61	NIL

6. OTHER COMMITTEES:

6.1 BANKING TRANSACTIONS COMMITTEE:

Considering the size and the continuous growth of both the Company and its banking transactions, a Sub-Committee of Board, named Banking Transactions Committee was constituted on 30th April, 2006 for approving specific banking transactions, illustrated below:

- a) To review periodically the banking transactions of the Company;
- b) To open new bank accounts for the business purposes of the Company, wherever required;
- c) To close bank accounts of the Company, where required;
- d) To change signatories to the bank accounts of the Company, where required;
- e) To borrow funds from various Banks and financial institutions, not exceeding ₹ 50, 00,000/- (Rupees Fifty Lakhs only) for purchase of immoveable assets like motor vehicles and utilities and to create charge on these assets;

The Committee comprises of Mr. Shailesh Siroya, Managing Director and Dr. S. Prasanna, Whole-time Director.

7. GENERAL BODY MEETINGS:

7.1 The last 3 Annual General Meetings were held as under:

Financial Year	Date	Time	Location
2006-07	20-09-2007	4.00 PM	Bharatiya Vidya Bhavan, Race Course Road, Bangalore – 560001.
2007-08	23-09-2008	4.00 PM	Bharatiya Vidya Bhavan, Race Course Road, Bangalore – 560001.
2008-09	25-09-2009	10.30 AM	Bharatiya Vidya Bhavan, Race Course Road, Bangalore – 560001.

7.2 The special resolutions passed by the Company in its 20th 21st, 22nd Annual General Meeting(s) held on 20-09-2007, 23-09-2008, 25-09-2009 are as under ;

Date of AGM	AGM No.	Business Transacted by Special Resolution	
20-09-2007	20	NIL	
23-09-2008	23-09-2008 21 Revision in remuneration of Dr.S. Prasanna, Whole time Director		
25-09-2009	22	Revision in remuneration of Mr. Shailesh Siroya, Managing Director	



08. POSTAL BALLOT - The Company has not passed any resolution by way of Postal Ballot during the financial year 2009-10.

09. DISCLOSURES:

Messers Desa Marketing International, Bangalore, under an agreement with the Company, provides service support for enhancing and promoting business interests of the Company and also sourcing various products for the Company. Mr. Shailesh Siroya, Managing Director, is interested in the said agreement and the company has already got approval from the Central Govt. under Section 297 (1) of the Companies Act, 1956 and this agreement has been revised w-e-f 07.06.2008 for a period of three years.

10. MEANS OF COMMUNICATIONS:

Unaudited quarterly/half yearly financial results are published in widely circulating national dailies. Press release on the highlights of the quarterly/ half yearly results is also given. These are, however, not sent individually to the shareholders. The results are also promptly forwarded to Bombay Stock Exchange Ltd., and National Stock Exchange of India Ltd., wherein the shares are listed. During the financial year 2009-10, the Company has not made any presentation to the institutional investors or analysts.

II. GENERAL SHAREHOLDER INFORMATION:

SI. No.	Item	Particulars
I	Date of Incorporation	May 19, 1987
2	Date and Time of Annual General Meeting	27th September, 2010 at 10.00 AM
3	Venue of Annual General Meeting	Bharatiya Vidya Bhavan, Race Course Road, Bangalore - 560001.
4	Date of Book Closure	27-09-2010
5	Financial Calendar	Ist April, 2010 - 31st March, 2011
6	Financial reporting for the first quarter ended on 30-06-2010	Last week of July 2010
7	Financial reporting for the second quarter ended on 30-09-2010	Last week of October 2010
8	Financial reporting for the third quarter ended on 31-12-2010	Last week of January 2011
9	Financial reporting for the year ended on 31-03-2011	Last week of April, 2011
10	Listing on Stock Exchanges	Bombay Stock Exchange Ltd., (BSE)
		National Stock Exchange of India Ltd., (NSE)
11	Stock Code	BSE Scrip Code - 524824
		NSE symbol – BALPHARMA
12	ISIN Number	INE083D01012
13	Outstanding GDR/ADR Warrants	Not Applicable


12. MARKET PRICE DATA:

Monthly high and low quotations as well as the volume of shares traded at Bombay Stock Exchange Ltd., during 2009-10 are as under:

Month	High (₹)	Low (₹)	Trade Volume
April 2009	19.90	15.29	13,00,489
May 2009	27.00	16.50	26,34,403
June 2009	29.00	20.4	58,41,506
July 2009	22.45	18.00	28,53,848
August 2009	31.60	18.00	1,91,42,700
September 2009	27.10	23.50	27,56,387
October 2009	26.50	23.50	19,22,107
November 2009	27.65	23.10	22,81,356
December 2009	28.25	25.05	25,60,064
January 2010	34.45	26.25	63,55,972
February 2010	29.95	23.15	15,53,588
March 2010	36.00	23.75	2,17,64,665

* Share price movements with reference to BSE Index





12.1 DISCLOSURES REGARDING SUSPENSE ACCOUNT PURSUANT TO SEBI CIRCULAR NO. SEBI/CFD/DIL/LA/1/2009/24/04 DATED APRIL 24, 2009:

As per the above mentioned Circular, Clause 5A stands for shares issued pursuant to the public issues or any other issue which remain unclaimed and are lying in the escrow account and any unclaimed benefits like Dividend, Bonus shares etc., which are to be credited to the Demat Suspense Account. Your Company is taking steps to streamline all the requirements.

13. SHARE TRANSFER SYSTEM:

The Company's shares are traded in the Stock Exchanges compulsorily in the Demat mode. Share Certificates are either demated or returned within the time prescribed by the authorities.

Periodically, audits are carried out at the office of the Share Transfer Agents by independent Practicing Company Secretary and requisite Certificates/Reports are obtained.

TSR Darashaw Limited, Mumbai is Registrar and Share Transfer Agents of the Company for both physical and electronic mode of transfer of share. Transfer of shares held in the physical mode are approved within a maximum period of 15 days, if found in order, in all respects. Shares under objection are returned within 7 days.

13.1 Share Transfers are registered and returned within a period of 30 days from the date of receipt, if the documents are clear in all respects. The Demat Requests are processed within 21 days from the date of electronic request. The Shareholders and Investors Grievances Committee whose terms of reference includes approving transfer of shares meets every fortnight. Besides, the Company also engages a Practising Company Secretary to carry out periodical audits.

Shareholders' correspondence should be addressed to the Company's Registrar and Transfer Agents at the below – mentioned address. Members may also write to the Compliance Officer at the Office of the Company as stated below:

Company Secretary & Compliance Officer

Bal Pharma Limited, Corporate Office : 5th Floor, 'Lakshmi Narayan Complex', 10/1, Palace Road, Bangalore – 560 052. Tel: 080 - 41379500 Fax: 080 - 22354057



13.2 Registrars & Share Transfer Agents:

TSR Darashaw Limited,

6-10, Haji Moosa Patrawala Industrial Estate 20 Dr. E. Moses Road, Mahalaxmi, Mumbai - 400 011. Phone:-91-22-66568484 Fax :-91-22-66568494 Email: - csg-unit@tsrdarashaw.com

Shareholders can also contact the branch offices/Agencies of TSR Darashaw Limited whose addresses are given below:

- i. TSR Darashaw Limited, 503, Barton Centre, 84, MG Road, Bangalore 560 001, Tel: 080-25580019/25320321, Fax: 080-25580019, Email: tsrdlbang@tsrdarashaw.com
- ii. TSR Darashaw Limited, Bungalow No: I E Road, Northern Town, Bistupur, Jamshedpur 831001, Tel: 0657-2426616, Fax: 0657-2426937, Email: tsrdljsr@tsrdarashaw.com
- iii. TSR Darashaw Limited, Tata Centre, 1st floor, 43, Jawaharlal Nehru Road, Kolkata 700071. Tel: 033- 22883087, Fax: 033-22883062, Email: tsrdlcal@tsrdarashaw.com
- iv. TSR Darashaw Limited, Plot No: 2/42, Sant Vihar, Ansari Road, Darya Ganj, New Delhi 110002, Tel: 011-23271805, Fax: 011-23271802, Email: tsrdldel@tsrdarashaw.com

Agent: Shah Consultancy Services Ltd, Sumatinath Complex, 2nd Dhal Pritam Nagar, Ellisbridge, Ashram Road, Ahmedabad – 380006, Telefax: 079 – 26576038, Email ID: shahconsultancy@hotmail.com

13.3 Statistics under physical transfer during the period from 01.04.2009 to 31.03.2010 :

SI. No.	Process Period	No. of Transfers	% to total Transfers	No. of Shares
I	01 -07 days	6	35.29	6400
2	08 - 15 days	10	58.82	1456
3	16 – 21 days	I I	5.9	100
4	22 - 25 days	0	0	0
5	26 - 30 days	0	0	0
6	Beyond 30 days	0	0	0
	TOTAL	17	100	7956

14. DISTRIBUTION OF SHAREHOLDINGS :

SI. No.	No. of Equity Shares Held	No. of A/c Holders	% of Shareholding of A/c holders	No. of share Holdings	% of Shareholding
I	I TO 500	6990	85.31	1,093,392	10.43
2	501 TO 1000	619	7.55	518,005	4.94
3	1001 TO 2000	275	3.36	429,891	4.10
4	2001 TO 3000	101	1.23	258,006	2.46
5	3001 TO 4000	62	0.76	222,337	2.12
6	4001 TO 5000	28	0.34	134,721	1.29
7	5001 TO 10000	61	0.74	438,309	4.18
8	ABOVE 10000	58	0.71	7388,563	70.48
	TOTAL	8,194	100	1,04,83,224	100

15. CATEGORIES OF SHAREHOLDING:

Distribution Schedule – category wise as on 31.03.2010

SI. No	Category	No. of Shareholders	No. of Shares held	Percentage shareholding
١.	FII	0	0	0.00
2.	Non-Resident	61	821476	7.84
3.	Other Banks	I	1800	0.02
4.	Mutual Fund	I	200	0.00
5.	Bodies Corporate	301	721964	6.89
6.	Promoters, Directors & Relatives	30	5421638	51.72
7.	Indian Public	7800	3516146	33.54
	Grand Total	8194	10483224	100



16. DEMATERIALISATION OF SHARES AND LIQUIDITY:

The Company has signed agreements with Central Depository Services (India) Limited (CDSL) and National Securities Depository Limited (NSDL) for dematerialisation of the Company's shares. The ISIN number allotted for the Company is INE 083D01012.

17. DEMAT PROCESSING SYSTEM:

Demat Processed during the period 01.04.2009 to 31.03.2010

SI No.	Process Period	No. of Demat Requests	% to total Requests	No. of Shares
I	I - 7 days	11	28.95	2924
2	8 - 10 days	22	57.89	728673
3	11 - 15 days	4	10.53	657
4	16 - 20 days	1	2.63	100
5	21 - 25 days	0	0	0
6	26 - 30 days	0	0	0
7	Beyond 30 days	0	0	0
	Total	38	100	732354

18. DETAILS OF DEMAT THROUGH THE DEPOSITORIES:

Holding break up in NSDL and CDSL as on 31.03.2010

Depository Name	Number of Shareholders	No. of Shares Dematerialised	% to total holding
NSDL	4631	7585233	72.36
CDSL	1750	1469544	14.02
TOTAL	6381	9054777	86.38

19. EMPLOYEES ACCESS TO AUDIT COMMITTEE (WHISTLE BLOWER POLICY):

The Company promotes ethical behaviour in all its business activities and has put in place mechanism of reporting illegal or unethical behaviour. As per the requirement of revised Clause 49 of the Listing Agreement, the Company has issued a circular informing the employees about their right to access Audit Committee for the purpose of bringing to the Committee's notice unethical or improper practices in the Company. The Company affirms that no employee has been denied access to the Audit Committee. The Directors and management personnel are obliged to maintain confidentiality of such reporting and ensure that the whistle blowers are not subjected to any discriminatory practices.

20. MANDATORY REQUIREMENTS UNDER CLAUSE 49 OF THE LISTING AGREEMENT :

(I) (a) Non Executive Chairman (b) Tenure of Independent Directors	The Company has no Non-Executive Chairman None of the Independent Directors are on Board for more than 9 years on date.
(2) Remuneration Committee	The Board constituted a Remuneration Committee; a Sub-Committee of the Board.
(3) Audit qualifications	The statutory financial statements of the Company are unqualified.
(4) Whistle Blower Policy	A Whistle blower policy is in place

The Company is keen and shall be implementing other Non-mandatory requirements in phases in due course.

21. ADDRESS FOR CORRESPONDENCE:

Mr. S. Ramji, Company Secretary & Compliance Officer Bal Pharma Limited

Corporate Office:

5th Floor, 'Lakshmi Narayan Complex', 10/1, Palace Road, Bangalore – 560052 Tel: 080 - 41379500 Fax: 080 - 22354057

 $\label{eq:entropy} E\text{-mail: secretarial@balpharma.com, investor@balpharma.com}$



Ъ

CORPORATE GOVERNANCE COMPLIANCE CERTIFICATE

To the Members of Bal Pharma Limited

- 1) I have examined the compliance of conditions of Corporate Governance by Bal Pharma Limited for the year ended, 31st March, 2010, as stipulated in Clause 49 of the Listing Agreement of the said Company with the Stock Exchanges, Mumbai.
- 2) The compliance of conditions of Corporate Governance is the responsibility of the Management. My examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.
- 3) In my opinion and to the best of my information and according to the explanations given to me, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above mentioned Listing Agreement.
- 4) I state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.
- 5) I state that in respect of investors' grievances received during the year ended on 31st March, 2010 no investor grievances are pending against the Company as on 31st March 2010, as per the records maintained by the Company and presented to the Shareholders and Investors Grievances Committee.

Bangalore- 560052 23rd August, 2010

ct

Vijayakrishna K. T. Practising Company Secretary FCS – 1788; CP – 980

ю



TO THE MEMBERS OF M/s. BAL PHARMA LIMITED

We have audited the attached Balance Sheet of Bal Pharma Limited as at 31 March 2010, the Profit and Loss Account for the year ended on that date annexed thereto and the cash flow statement for the year ended on that date, which we have signed under reference to this report. These financial statements are the responsibility of the Company's Management. Our responsibility is to express an opinion on these financial statements based on our audit.

We have conducted our audit in accordance with auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes, examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by Management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

As required by the Companies (Auditor's Report) Order, 2003 as amended by the Companies (Auditor's Report)(Amendment) order, 2004 issued by the Central Government of India in terms of section 227 (4A) of the Companies Act, 1956 and on the basis of such checks as we considered appropriate and according to the information and explanations given to us, we set out in the annexure a statement on the matters specified in paragraphs 4 and 5 of the said order.

Further to our comments in the Annexure referred to in paragraph 3 above, we report that:

- We have obtained all the information and explanations which, to the best of our knowledge and belief, were necessary for the purpose of our audit;
- In our opinion, proper books of accounts as required by law, have been kept by the Company so far as appears from our examination of those books;
- The Balance Sheet, the Profit and Loss Account and the Cash Flow Statement dealt with by this report are in agreement with the books of account;
- (iv) In our opinion, the Balance Sheet, the Profit and Loss Account and the Cash Flow Statement dealt with by this report comply with the Accounting Standards referred to in sub-section (3C) of Section 211 of the Companies Act, 1956 to the extent applicable;
- (v) On the basis of the written representations received from the directors, as on 31 March 2010 and taken on record by the Board of Directors, we report that none of the directors is disqualified as on 31 March 2010 from being appointed as a Director in terms of clause (g) of sub-section (1) of section 274 of the Companies Act, 1956 ; and
- (vi) In our opinion and to the best of our information and according to the explanations given to us, the said accounts, together with the notes thereon and attached thereto and subject to Note no.13

regarding non-confirmation of balances in parties accounts and pending review of old balances, give in the prescribed manner the information required by the Act and give a true and fair view in conformity with the accounting principles generally accepted in India:

- (a) in the case of the Balance Sheet, of the state of affairs of the Company, as at 31st March 2010;
- (b) in the case of the Profit and Loss Account, of the Loss for the year ended on that date; and
- (c) in the case of the Cash Flow Statement, of the cash flows for the year ended on that date.

For **Ostawal & Jain** ICAI FRN NO. 002491S Chartered Accountants

Bangalore Date: 09.08.2010 T. D. JAIN Partner M.M.No: 12034

ANNEXURE TO THE AUDITOR'S REPORT

Annexure referred to in Paragraph 3 of the report of the Auditors to the members of Bal Pharma Limited for the year ended 31st March 2010:

- 1. The Company has maintained proper records showing full particulars including quantitative details and situation of its fixed assets. These fixed assets were physically verified by management according to a phased programme designed to cover all the items over a period of three years. Pursuant to the programme, physical verification of certain assets was carried out during the year and we have been informed that no material discrepancies were noticed on such physical verification. Substantial part of fixed assets have not been disposed off during the year, which will affect its status as going concern.
- 2. The stock of inventory has been physically verified during the year by the management at reasonable intervals. In our opinion, the procedures of physical verification of inventory followed by the management is reasonable and adequate in relation to the size of the Company and the nature of its business. The Company is maintaining proper records of inventory. The discrepancies noticed during the physical verification of stocks as compared to book records were not material; however, the same has been properly dealt with in the books of account.
- (a) As per the records of the Company, it had granted interest free unsecured loan to Companies, firms or other parties covered in the register maintained under Section 301 of the Companies Act, 1956. The Company has granted interest free unsecured advance to its subsidiary companies. The maximum amount involved ₹ 64, 86,537/- and the year end balance of loan was ₹ 64, 60,000/-.
 - (b) Based on the information received and the explanations given, the terms and conditions of the advance are prima facie not prejudicial to the interest of the Company.

AUDITOR'S REPORT

- (c) As informed to us, no repayment was due during the year.
- (d) As per records of the Company, it has not taken any loans, secured or unsecured from companies, firms or other parties covered in the register maintained under Section 301 of the Companies Act, 1956. Accordingly sub-clauses (f) and (g) of clause 4(iii) of the order is not applicable.
- 4. In our opinion, there is an adequate internal control procedure commensurate with the size of the Company and nature of its business, for the purchase of inventory and fixed assets and for the sale of goods and services. We have not observed any major weakness in the internal control system during the course of our audit.
- 5. In our opinion, and according to the information and explanations given by the management, we are of the opinion that contracts and arrangements referred to in section 301 of the Act have been entered in the register required to be maintained under that section and such transactions have been made at prices which are reasonable having regard to the prevailing market prices at the relevant time.
- 6. The Company has not accepted any deposits from the public and consequently, the directives issued by the Reserve Bank of India and the provisions of Section 58A, 58AA or any other relevant provisions of the Act and the rules framed there under are not applicable to the Company.
- 7. In our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- 8. We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central government for maintenance of cost records under Section 209(1) (d) of the Act; and are of the opinion that prima facie the prescribed accounts and records have been made and maintained. We have not however made a detailed examination of records with a view to determining whether they are accurate and complete.
- 9. a) According to the information and explanations given to us and on the basis of our examination of books of account, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Investor Education and Protection Fund, Employees' State Insurance, Income Tax, Sales Tax, Wealth Tax, Customs duty, Excise duty, Cess and any other material statutory dues during the year with the appropriate authorities.
 - b) According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Sales Tax, Income Tax, Wealth Tax, Service Tax, Customs Duty, Excise Duty, Cess and other material statutory dues were in arrears as at 31 March 2010 for a period of more than six months from the date they became payable.
 - c) According to the information and explanations given to us, there are no amounts in respect of Provident Fund, Income Tax, Sales Tax, Wealth Tax, Service Tax, Customs Duty, Excise duty and Cess that have not been deposited with appropriate authorities on account of any dispute other than those mentioned in Annexure I to this report.

- 10. The Company has no accumulated losses. The Company has not incurred cash losses in the financial year under report and in the immediately preceding financial year.
- 11. The Company has not defaulted in repayment of dues to its bankers or to any financial institution. The Company did not have any outstanding debentures during the year.
- 12. The Company has not granted any loans and advances on the basis of security by way of pledge of shares, debentures and other securities. Accordingly, clause 4(xii) of the Order is not applicable.
- The Company is not a chit fund, nidhi or mutual benefit fund/ society. Accordingly, clause 4(xiii) of the Order is not applicable.
- 14. Accordingly to the information and explanations given to us, the Company is not dealing or trading in shares, securities, debentures and other investments. Accordingly clause 4(xiv) of the Order is not applicable.
- 15. Based on the information and explanations given to us, the Company has not given any guarantee for loans taken by others from bank or financial institutions.
- 16. In our opinion and according to information and explanations given to us and on the basis of examination of books of accounts, the term loans obtained by the Company were applied for the purpose for which such loans were obtained.
- 17. According to the information and explanations given to us, and on an overall examination of balance sheet of the Company, we are of the opinion that the funds raised on short-term basis have not been used for long-term investments.
- 18. The Company has not made any preferential allotment of shares to parties and companies covered in the register maintained under section 301 of the Act during the year. Accordingly, clause (xviii) of the Order is not applicable.
- 19. The Company has not issued any debentures. Hence the requirements of clause (xix) of paragraph 4 of the Order are not applicable to the Company.
- 20. The company has not raised any money by way of public issue during the year.
- 21. During the course of our examination of the books of account carried out in accordance with the generally accepted auditing practices in India and according to the information and explanations given to us, we have neither come across any instance of fraud on or by the Company, noticed or reported during the year, nor have we been informed of such case by the Management.

For **Ostawal & Jain** ICAI FRN NO. 002491S Chartered Accountants

Bangalore Date : 09.08.2010 T. D. JAIN Partner M.M.No: 12034



Annexure I as referred to para 9 of annexure to the auditor's report

Name of the Statue	Nature of dues	Amount in ₹	Period to which Amount relates	Forum where dispute is pending
The Central Excise Act, 1944	Central Excise Duty and penalty	8,68,598	2000-01	Customs, Excise, Service Tax Appellate, Mumbai
The Kerala General sales Tax Act,1963	Local Sales Tax	7,49,720	2002-03	The Deputy Commissioner (Appeals), Ernakulam
The Central Excise Act, 1944	Central Excise Duty	10,34,757	1996-97	Supreme court of India
The Central Excise Act, 1944	Central Excise Duty	8,98,929	1997-98	Supreme court of India
The Income Tax Act 1961	TDS	89,50,429	2004-05 to 2008-09	Commissioner of Income Tax Appeals

On the Consolidated Financial statements of M/s. BAL PHARMA LTD., and its subsidiaries

We have examined the attached Consolidated Balance Sheet of M/s. Bal Pharma Ltd., ("the company") and its subsidiaries (collectively referred to as the "Bal Pharma's Group") as at 31 March 2010 and also the Consolidated profit and loss account and Consolidated cash flow statement for the year ended on that date annexed thereto. These Consolidated financial statements are the responsibility of the Company's Management. Our responsibility is to express an opinion on these Consolidated financial statements based on our audit.

We have conducted our audit in accordance with auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes, examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by Management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

The consolidated financial statements have been prepared by the company's management in accordance with the requirements of Accounting Standard (AS) '21-consolidated financial statements', issued by the Institute of Chartered Accountants Of India and on the basis of the separate audited financial statements of M/s. Bal Pharma Ltd., and

its subsidiary M/s. Basav Chem Ltd included in the consolidated financial statements.

In our opinion and to the best of our information and according to the explanations given to us and on the consideration of the separate audit reports on individual audited financial statements of M/s. Bal Pharma Ltd., and its aforesaid subsidiaries, the Consolidated financial statements give a true and fair view in conformity with the accounting principles generally accepted in India:

- in the case of the Consolidated Balance sheet of the consolidated state of affaires of Bal Pharma's Group as at 31 March 2010;
- (ii) in the case of Consolidated Profit and Loss Account, of the consolidated results of operations of Bal Pharma's Group for the year ended on that date; and
- (iii) in the case of Consolidated Cash Flow Statement, of the Consolidated cash flows of Bal Pharma's Group for the year ended on that date.

For **Ostawal & Jain** ICAI FRN NO. 002491S Chartered Accountants

Bangalore Date : 09.08.2010 **T. D. JAIN** Partner M.M.No: 12034

Bal Pharma Limited



ANNUAL ACCOUNTS 2009 - 2010

BALANCE SHEET AS AT 31.03.2010

	SCH	AS AT 3 ₹	I.03.2010 ₹	AS AT 31 ₹	.03.2009 ₹
SOURCES OF FUNDS I. SHAREHOLDERS' FUND a. Share Capital b. Reserves & Surplus	 2	104,832,240 255,465,692	360,297,932	104,832,240	374,142,385
II. LOAN FUNDS a. Secured Loans b. Unsecured Loans	3 4	544,090,068 97,470	544,187,538	463,390,933 8,292,182	471,683,115
III. DEFERRED TAX LIABILITY (NET)	5		61,775,598		57,147,344
TOTAL			966,261,068		902,972,844
APPLICATIONS OF FUNDS I. FIXED ASSETS a. Gross Block b. Less: Accumulated Depreciation c. Net Block d. Capital Work in Progress	6	639,234,491 145,403,116 493,831,375 -	493,831,375	663,911,101 118,821,898 545,089,203 3,987,740	549,076,943
II. INVESTMENTS	7		550,000		896,000
 III. CURRENT ASSETS, LOANS & ADVANCES a. Inventories b. Sundry Debtors c. Cash & Bank Balances d. Loans & Advances 	8	286,224,499 319,172,267 16,148,069 76,012,898		239,369,107 292,858,622 14,478,522 72,516,877	
Total (A)		697,557,733		619,223,128	
CURRENT LIABILITIES & PROVISIONS a. Current Liabilities b. Provisions	9	269,999,020 7,999,658		291,923,669 23,363,348	
Total (B)		277,998,678		315,287,017	
NET CURRENT ASSETS (A-B)			419,559,055		303,936,111
IV. INTANGIBLE ASSETS Gross Carrying Amount Less: Cumulative Amortisation & impairment loss Net Carrying Amount	10	91,254,578 38,933,940	52,320,638	82,723,689 33,659,899	49,063,790
TOTAL			966,261,068		902,972,844
	20				

Chartered Accountants ICAI FRN No. 002491S

T. D. Jain Partner M. No. 012034 S. Ramji AVP Finance & Company Secretary **Dr. S. Prasanna** Director Shailesh Siroya Managing Director

Bangalore 09.08.2010

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

	Particulars	SCH	Year Ended ₹	31.03.2010 ₹	Year Ended ₹	31.03.2009 ₹
I.	INCOME					、
	Sales & Services	11	1,081,515,642		1,065,543,117	
	Less : Excise Duty			1,062,252,452	29,564,312	1,035,978,805
	Other Income	12		29,404,630		1,168,577
				1,091,657,082		1,037,147,382
II.	EXPENDITURE					
	Cost of Materials Consumed	13	600,000,868		532,067,548	
	Manufacturing Expenses	14	61,954,384		48,876,970	
	Employees Remuneration & Benefits	15	111,757,438		102,132,216	
	Selling & Distribution Expenses	16	185,346,254		195,146,762	
	Administration Expenses	17	44,431,900		46,856,384	
	Financial Expenses	18	62,603,973		47,120,796	
	Amortization of Intangible Assets	19	5,274,041		5,657,090	
	Depreciation	6	28,070,198	1,099,439,056	18,341,061	996,198,827
III .	Profit for the year			(7,781,974)		40,948,555
	Add/(Less) : Prior Year Adjustment			-		(411,280)
IV.	Profit Before Income Tax			(7,781,974)		40,537,275
	Provision for Income Tax - Current Year			-		I,628,385
	Provision for wealth tax			52,795		40,613
	(Excess) / Short Provision for Tax - Earlier Years			945,441		(1,318,398)
	Deferred Tax (As Per AS 22)			4,628,254		7,822,681
	Fringe Benefit Tax			-		2,336,116
V.	Profit After Tax			(13,408,464)		30,027,878
VI.	Balance Brought Forward From Previous Year			94,364,195		73,534,953
				80,955,731		103,562,831
VII	. Appropriations					
	Proposed Dividend:					
	- Equity Shares		-		7,862,418	
	Provision for Corporate Tax on Dividend					
	- Equity Shares		-	-	1,336,218	9,198,636
VII	I. Balance Carried to Balance Sheet			80,955,731		94,364,195
	EARNINGS PER SHARE					
	Basic EPS			(1.28)		2.87
	Diluted EPS			(1.20)		2.85
	No: of Equity Shares			10,483,224		10,483,224
NC	OTES ON ACCOUNTS	20				

As per our report of even date

For **OSTAWAL & JAIN** Chartered Accountants ICAI FRN No. 0024915

T. D. Jain Partner M. No. 012034 **S. Ramji** AVP Finance & Company Secretary FOR & ON BEHALF OF THE BOARD

Dr. S. Prasanna Director Shailesh Siroya Managing Director

Bangalore 09.08.2010



SCHEDULES FORMING PART OF THE BALANCE SHEET AS AT 31.03.2010

	AS ₹	AT 31.03.2010 ₹	AS . ₹	AT 31.03.2009 ₹
SCHEDULE - I	۲	ζ	Χ	
SHARE CAPITAL				
AUTHORISED				
11,000,000 (P Y 11,000,000) Equity Shares of ₹ 10 each	110,000,000		110,000,000	
400,000 (P Y 400,000) Redeemable Preference Shares of ₹ 100 each	40,000,000	150,000,000	40,000,000	150,000,000
ISSUED, SUBSCRIBED & PAID UP EQUITY SHARE CAPITAL		104 032 240		104 022 240
10,483,224(P Y 10,483,224) Equity Shares of ₹ 10 each fully paid		104,832,240		104,832,240
Note:		104,032,240		104,032,240
 3,040,000 equity shares of ₹10/- each have been issued as Bonus Shares by capitalisation of reserves NIL (PY 37000)equity shares of ₹10/-each have been allotted to the eligible employees of the Company on exercise of the vested 				
stock in accordance with the terms of the 'Bal Pharma Limited ESOP (Refer note 16, Schedule 20)				
SCHEDULE - 2				
RESERVES & SURPLUS		3,000,000		3,000,000
Capital Reserve Securities Premium		3,000,000		3,000,000
Opening Balance	145,637,950		144,720,350	
Add: Premium on ESOP Allotment	-	145,637,950	917,600	145,637,950
3. General Reserve		24,015,000	· · · · · · · · · · · · · · · · · · ·	24,015,000
4 Employee Stock options outstanding				
Balance at the beginning	3,293,745		4,038,600	
Add : Options granted Less: Transferred to securities premium account on exercise of options			- 704,850.00	
Less : Options forfeited/surrendered	1,190,625		40,005	
Balance at end of the Year (A)	2,103,120		3,293,745	
Deferred stock compensation cost				
Balance at the beginning	1,000,745		1,750,844	
Add : Options granted	-			
Less : Options forfeited/surrendered	1,190,625		40,005	
Less : Amorizaton	(435,989)		710,094	
Balance at end of the Year (B)	246,109		1,000,745	2 202 000
(A) - (B) 5. P & L Acount -Surplus		1,857,011	-	2,293,000
Opening Balance	94,364,195		73,534,953	
Add: Surplus for the year	(13,408,464)	80,955,731	20,829,242	94,364,195
		255,465,692		269,310,145
SCHEDULE - 3				
SECURED LOANS				
TERM LOANS				
AXIS Bank	-		1,433,132	
EXIM Bank	175,154,637		189,660,800	
State Bank of Indore	32,488,866		17,398,455	
Others	4,466,087	212,109,590	5,545,977	214,038,364
WORKING CAPITAL LOAN Canara Bank	166,419,609		92,594,271	
Exim Bank	34,530,834		14,100,334	
Punjab National Bank	129,204,629		88,691,617	
ICICI Bank Ltd.,	1,825,406	331,980,478	53,966,347	249,352,569
		544,090,068	· ;	463,390,933

SCHEDULES FORMING PART OF THE BALANCE SHEET AS AT 31.03.2010 (Contd...)

	AS AT 31.03.2010	AS AT 31.03.2009
	₹₹₹	₹₹₹
SCHEDULE - 4		
UNSECURED LOANS		
Punjab National Bank	97,470	6,169,002
Department of Scientific and industrial Research	- · · · · · · · · · · · · · · · · · · ·	2,123,180
	97,470	8,292,182
SCHEDULE - 5		
DEFFERED TAX LIABILITY		
Opening Balance	57,147,344	49,324,663
Add: Liability created for the year	4,628,254	7,822,681
	61,775,598	57,147,344
SCHEDULE 6		

FIXED ASSETS AS ON 31.03.2010

		GROSS	BLOCK		DEPRECIATION				NET BLOCK	
ASSETS	As at 01.04.2009	Additions	Deletions	AS AT 31.03.2010	AS AT 01.04.2009	For the Year	Deletions	AS AT 31.03.2010	AS AT 31.03.2010	AS AT 31.03.2009
Leasehold Land	12,493,430	-	-	12,493,430	-	146,982	-	146,982	12,346,448	12,493,430
Freehold Land	29,015,735	-	23,318,252	5,697,483	-	-	-	-	5,697,483	29,015,735
Building	199,862,832	2,034,757	10,762,500	191,135,089	23,625,195	6,478,175	1,108,167	28,995,203	162,139,886	176,237,637
Plant & Machinery	194,015,100	2,168,999	297,329	195,886,770	32,579,494	9,267,262	41,876	41,804,880	154,081,890	161,435,606
Utilities	105,779,371	2,333,780	3,222,911	104,890,240	24,752,527	4,967,695	338,937	29,381,285	75,508,955	81,026,844
Furniture & Fixtures	14,616,846	2,924,145	-	17,540,991	5,158,252	1,016,753	-	6,175,005	11,365,986	9,458,594
Misc Fixed Assets	90,992,369	I,965,483	-	92,957,852	26,968,344	4,544,391	-	31,512,735	61,445,117	64,024,025
Vehicles	17,135,418	1,497,218	-	18,632,636	5,738,086	I,648,940	-	7,387,026	11,245,610	11,397,332
Total	663,911,101	12,924,382	37,600,992	639,234,491	118,821,898	28,070,198	I,488,980	145,403,116	493,831,375	545,089,203
Previous Year	363,648,835	302,376,908	21,114,642	663,911,101	101,175,038	18,341,061	694,201	118,821,898	545,089,203	262,473,797
Capital Work-in Progr	ess								-	3,987,740

	AS AT 31.0	03.2010	AS AT 31.03.200	
	₹	₹	₹	₹
SCHEDULE - 7				
INVESTMENTS				
QUOTED :				
Non Trade :(at Cost) (Market Value as on 31.03.2010 not available)				
(i) Lamina Foundries Limited				
10,000 (P.Y. 10,000) Equity Shares of ₹ 10 each fully paid	371,850		371,850	
(ii) Sri Jayalakshmi Autospin Limited	736,000		736,000	
73,600 (P.Y. 73,600) Equity Shares of ₹ 10 each fully paid				
Less: Provision for diminuition in value	(1,107,850)		(1,107,850)	-



SCHEDULES FORMING PART OF THE BALANCE SHEET AS AT 31.03.2010 (Contd...)

		AS ₹	AT 31.03.2010 ₹	AS AT 31.03. ₹	
	QUOTED :	<	χ	ζ	₹
Trade					
In	n Subsidiary Company	346,000	-	346,000	
	Novosynth Research Labs Pvt. Ltd.,				
	(346 Equity Shares(PY 346) of ₹ 1000 each fully paid)				
	Less : Provision for diminition	346,000	_		346,000
	Basav Chem Limited	510,000	500,000		500,000
	(100,000 Equity Shares (P.Y-NIL) of ₹ .10 each fully paid)		500,000		500,000
Non	Trade :				
	ITY SHARES of				
	Shamrao Vithal Co- Operative Bank Ltd.,				
	0 Shares(PY 5,000) of ₹ 10 each fully paid)		50,000		50,000
(3,000			550,000	-	896,000
SCHI	EDULE- 8		550,000	=	070,000
	RENT ASSETS, LOANS & ADVANCES				
	INVENTORIES				
	(As valued & certified by the Management)				
	Raw Materials	75,208,578		78,991,015	
	Packing Materials	20,233,352		14,635,467	
	Work in Progress	41,316,481		50,193,765	
	Finished Goods	148,136,117		94,513,402	
	Stores & Consumables	1,329,971	286,224,499	1,035,458	239,369,107
	SUNDRY DEBTORS	1,327,771	200,224,477	1,033,436	239,309,107
	(Unsecured, considered good) Debts outstanding for more than six months	58,903,510		55,148,859	
	Other Debts	260,268,757	319,172,267	237,709,763	292,858,622
	CASH & BANK BALANCES	200,200,757	517,172,207	237,709,703	272,030,022
	Cash in Hand	206,487		260 270	
	Balance with Scheduled Banks:	200,407		269,279	
	- In EEFC	733,208		050 222	
		· ·		852,333	
	- In Fixed Deposit	12,282,950	14 149 040	,630,59 ,726,3 9	14 479 522
	- in Current Account LOANS & ADVANCES	2,925,425	16,148,069	1,720,317	14,478,522
	(Unsecured, considered good)			17 220 707	
	Advances recoverable in cash or in kind or for value to be received	35,407,576		17,229,787	
	Deposit with Govt. dept. & Others Advance Income Tax & TDS	24,310,790		30,655,908	
	Advance income Tax & TDS Advance to suppliers	1,389,068 8,207,783		11,643,250	
				6,166,124	
	Indira Vikas Patra	3,000		3,000	
	National Savings Certificate	10,725		10,725	
	Advance to Subsidiary Companies	6,460,000	74 012 002	6,462,755	70 517 075
	Interest Accrued but not due on deposits	223,956	76,012,898	345,328	72,516,877



		1.03.2010	AS AT 31	
	₹	₹	₹	₹
SCHEDULE- 9				
CURRENT LIABILITIES & PROVISIONS				
CURRENT LIABILITIES				
Trade Creditors :				
- Dues to medium and small enterprises(Refer notes SI No 25)	-		-	
- Other Dues	171,732,096		164,167,683	
Capital Creditors	4,725,428		17,434,076	
Creditors for Expenses	40,084,356		44,236,325	
Advances from customers	20,308,091		27,166,447	
Dues to Subsidiaries	I,095,649		817,121	
Other Current Liabilities	19,860,424		27,739,581	
Book Overdraft on account of issue of cheques	I,609,80I		1,280,091	
Deposits received from customers	9,196,954		8,021,954	
Unclaimed Rights Issue Application Money	141,750		141,750	
Unclaimed Dividends- Equity (Refer Notes SI No 26)	1,244,471	269,999,020	918,641	291,923,669
PROVISIONS				
Gratuity	7,921,645		7,435,580	
Provision for Tax	78,013		4,393,016	
Provision for Fringe Benefit Tax	-		2,336,116	
Dividend Payable(Equity Shares)	-		7,862,418	
Corporate Tax on Dividend Payable:				
Equity Shares	-	7,999,658	1,336,218	23,363,348
		277,998,678		315,287,017

SCHEDULES FORMING PART OF THE BALANCE SHEET AS AT 31.03.2010 (Contd...)

SCHEDULE 10

INTANGIBLE ASSETS AS ON 31.03.2010

Gross Carrying Amount			Cumulative Amortization				Net Carrying amount			
INTANGIBLE ASSETS	As on 01.04.2009	Additions	Gross carrying amount adjust- ments	As at 31.03.2010	As on 01.04.2009	Amor- tization during the year	Retire- ment/ Disposal adjust- ments	As at 31.03.2010	as at 31.03.2010	As at 31.03.2009
R & D expenses	71,033,217	8,530,889	-	79,564,106	23,114,378	5,045,057	-	28,159,435	51,404,671	47,918,839
Development expenditure	11,690,472	-	-	11,690,472	10,545,521	228,984	-	10,774,505	915,967	1,144,951
Total	82,723,689	8,530,889	-	91,254,578	33,659,899	5,274,041	-	38,933,940	52,320,638	49,063,790
Previous Year	73,990,185	8,733,504	-	82,723,689	28,002,809	5,657,090	-	33,659,899	49,063,790	45,987,376

SCHEDULES FORMING PART OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

SCHEDULE - 11 INCOME FROM SALES & SERVICES Seports: Seports: Seports: Set 31,332,443 563,360,998 375,029,328 Sales 13,322,443,355 368,455,596 573,528,355 368,455,596 Incentives 13,322,643,635 725,861,412 1,100,890,940 7,652,094 Domessic Sales 532,014,635 725,861,412 1,008,909,400 7,652,094 Less: Goods Returns 40,159,483 1,079,225,148 42,999,917 1,057,891,023 Conversion charges 2,200,494 7,652,094 7,652,094 7,652,094 Conversion charges 2,200,494 1,065,543,117 1,065,543,117 1,065,543,117 SCHEDULE 12 OTHER INCOME 8,888 8,888 8,888 8,888 8,888 8,888 8,888 8,888 576,949,9579 - <th></th> <th></th> <th>-2010</th> <th></th> <th>-2009</th>			-2010		-2009
INCOME FROM SALES & SERVICES Image: Second Se		₹	₹	₹	₹
Exports: 38 368,465,586 Sales 573,528,355 368,465,586 Incentives 3832,643 6,563,942 Domestic Sales 532,014,635 725,861,412 I,119,375,633 1,100,890,940 1,000,890,940 Conversion charges 1,019,175,633 1,100,890,940 7,652,094 Conversion charges 1,081,515,642 1,065,543,117 7,652,094 SCHEDULE - 12 71,612,013 7,652,094 7,652,094 OrtHER INCOME 8,888 8,888 8,888 Interest. 8,888 8,888 8,888 Foreign excharge fluctuation (Net) 7,249,759 - - Dividend Income 8,888 8,888 8,888 Foreign excharge fluctuation (Net) 72,849,759 - - Misc. Income 724,9453 - - Provisions / Creditors no longer payable written back 72,916,03 - - Qpening Stock 78,991,015 82,853,951 - - Opening Stock 78,991,015					
Sales 573,528,355 368,465,586 Incentives 13,832,643 6,563,942 Domestic Sales 587,360,998 375,029,528 Domestic Sales 522,014,633 11,109,375,633 11,008,90,440 Less: Goods Returns 40,150,485 1,079,225,141 42,999,107 1,057,091,023 Conversion charges 2,290,494 2,290,494 1,065,543,117 1,065,543,117 SCHEDULE - 12 1,081,515,642 1,065,543,117 1,065,543,117 1,065,543,117 SCHEDULE - 12 07HER INCOME 728,794 1,060,398 1,060,398 Dividend Income 8,868 8,888 8,888 8,888 Foreign exchange fluctuation (Net) 74,849,579 Profic on Sale of Flued Assets (Net) 18,882,954 SCHEDULE - 13 COST OF MATERIALS CONSUMED 727,0433 69,76 RAW MATERIALS 753,915,0784 56,939,221 77,899,1015 369,453,146 COST OF MATERIALS CONSUMED 78,991,015 82,853,951 369,453,146 369,453,146					
incentives 13,832,643 587,360,998 6,563,942 375,029,528 Domestic Sales 532,014,635 532,014,635 725,861,412 725,861,412 Less: Goods Returns 40,150,485 1,079,225,148 42,999,917 1,057,891,023 7,652,094 Conversion charges 2,290,644 7,652,094 7,652,094 SCHEDULE - 12 1,081,515,645 1,081,515,645 1,065,543,117 SCHEDULE - 12 1,081,515,645 1,080,951,645 1,080,951,645 Dividend Income 8,888 8,888 8,888 Prefit on Sale of Fixed Assets (Net) 18,882,954 - - Provisions / Creditors no longer payable written back 27,24,379 4,617,62 - COST OF MATERIALS CONSUMED RAW MATERIALS 78,991,015 82,853,951 - Opening Stock 76,939,91,015 373,316,082 - PACKING MATERIALS 78,991,015 373,316,082 - Opening Stock 14,635,467 17,291,457 - Add : Purchases 56,493,994 46,064,51 - Less : Closing Stock 14,635,467 17,291,					
S87,360,998 375,029,528 Domestic Sales 532,014,635 725,861,412 1,119,375,633 1,000,890,940 1,000,890,940 Conversion charges 2,290,494 7,652,094 Conversion charges 2,290,494 7,652,094 SCHEDULE - 12 0THER INCOME 1,081,515,642 1,060,398 Interest - 8,888 8,888 8,888 Foreign exchange fluctuation (Net) 7,849,579 - Profit on Sale of Fixed Assets (Net) 1,862,954 - Misc. Income 22,944,630 1,166,577 SCHEDULE - 13 29,404,630 - COST OF MATERIALS CONSUMED 78,991,015 82,853,951 Add : Purchases 556,939,221 78,991,015 373,316,082 Add : Purchases 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 75,081,546 369,453,116 373,316,082 Quening Stock 76,939,994 46,064,651 46,720,411 Opening Stock 20,233,352 50,893,735 72,08,713 Opening Stock<					
Domestic Sales 532,014,635 (1,119,375,633 725,861,412 (1,00,890,940 Less: Goods Returns 40,150,485 1,079,225,148 42,999,917 1,057,891,023 (7.652,094) Conversion charges 2,209,440 42,999,917 1,057,891,023 (7.652,094) 7.652,094 SCHEDULE - 12 1,081,515,642 1,065,543,117 7.652,094 1,065,543,117 SCHEDULE - 12 THER INCOME 728,794 1,080,398 8.888 Dividend Income 7,849,579 - - Bank 7,849,579 - - Profit on Sale of Fixed Assets (Net) 18,882,954 - - Misc. Income 72,2433 6,976 - Provisions / Creditors no longer payable written back 22,940,453 - - Opening Stock 78,991,015 82,853,951 - - Add: Purchases 553,156,784 369,453,146 - - Less: Closing Stock 78,991,015 82,853,951 - - Add: Purchases 553,156,784 369,453,146 - -	Incentives				
I,119,375,633 I,100,890,940 Less: Goods Returns 40,150,485 1,079,225,148 42,999,917 I,057,891,023 Conversion charges 2,290,494 7,652,094 7,652,094 SCHEDULE - 12 I.081,51642 I.065,543,117 SCHEDULE - 12 OTHER INCOME 8,888 8,888 Interest: Bank 728,794 I.080,398 Dividend Income 8,888 8,888 8,888 Foreign exchange fluctuation (Net) 7,849,579 - Protit on Sale of Flxed Assets (Net) 18,882,954 - Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back 272,633 6,976 SCHEDULE - 13 29,404,630 - - Opening Stock 75,208,578 556,939,221 78,991,015 373,316,082 Add : Purchases 553,156,784 369,453,146 - - Less: Closing Stock 75,208,578 556,639,721 78,991,015 373,316,082 PACKING MATERIALS 20,233,352 50,896,199					
Less: Goods Returns 40,150,485 1,079,225,148 42,999,917 1,057,891,023 Conversion charges 2,290,494 7,652,094 Interest. 1,081,515,642 1,085,543,117 SCHEDULE - 12 OTHER INCOME 1,081,515,642 1,080,398 Interest. 8ank 728,794 1,080,398 Bank 728,797 4 1,080,398 Dividend Income 8,888 8,888 8,888 Foreign excharge fluctuation (Net) 7,849,757 - - Profit on Sale of Fixed Assets (Net) 18,882,954 - - Misc. Income 29,404,630 6,976 - - Provisions / Creditors no longer payable written back 1,661,772 - - COST OF MATERIALS CONSUMED 78,991,015 82,853,951 - - Add: Purchases 553,156,784 82,853,951 - - - Add: Purchases 56,493,994 46,064,651 - - - - - - - - - - - - - - - - <td< td=""><td>Domestic Sales</td><td></td><td></td><td></td><td></td></td<>	Domestic Sales				
Conversion charges 2,290,494 7,652,094 I,081,515,642 I,065,543,117 SCHEDULE - 12 I OTHER INCOME I Interest - Bank Bank 728,794 Dividend Income 8,888 Foreign exchange fluctuation (Net) 7,849,577 Protit on Sale of Fixed Assets (Net) 18,882,954 Misc, Income 272,633 Provisions / Creditors no longer payable written back 1,661,782 COST OF MATERIALS CONSUMED 29,404,630 RAW MATERIALS 369,453,146 Cost of MATERIALS CONSUMED 369,453,146 Parching Stock 75,208,578 556,939,221 PACKING MATERIALS 73,316,082 PACKING MATERIALS 369,453,146 Less : Closing Stock 14,633,467 17,291,457 Add : Purchases 56,493,994 46,064,651 Less : Closing Stock 50,193,765 50,896,109 Opening Stock 50,193,765 55,653,735 Closing Stock 50,193,765 54,59970 Opening Stock <td></td> <td></td> <td></td> <td></td> <td></td>					
I.081,515,642 I.065,543,117 SCHEDULE - 12 OTHER INCOME Interest - Bank 728,794 I.060,398 Dividend Income 8,888 8,888 Foreign exchange fluctuation (Net) 7,849,579 - Profit on Sale of Fixed Assets (Net) 18,882,954 - Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back 1,661,782 72,315 COST OF MATERIALS 29,404,630 1,168,577 COST OF MATERIALS 553,156,784 369,453,146 Less : Closing Stock 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 78,991,015 373,316,082 PACKING MATERIALS 20,233,352 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 20,233,352 50,693,924 46,064,651 48,720,641 Work IN PROGRESS 20,233,352 50,896,109 14,635,467 48,720,641 Opening Stock 20,233,352 50,896,109 14,635,467 48,720,641 Opening Stock		40,150,485	1,079,225,148	42,999,917	
SCHEDULE - 12 OTHER INCOME Image: Constraint of the sected s	Conversion charges		2,290,494		7,652,094
OTHER INCOME Interest - Interest - Interest - Interest - Bank 728,794 1,080,398 Dividend Income 8,888 8,888 Foreign exchange fluctuation (Net) 7,849,579 - Profit on Sale of Fixed Assets (Net) 18,882,954 - Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back 1,661,782 72,315 COST OF MATERIALS CONSUMED 1,168,577 1,168,577 RAW MATERIALS COST OF MATERIALS CONSUMED 88,83,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 77,91,91 Add : Purchases 553,156,784 369,453,146 1 Less : Closing Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 14,635,467 17,291,457 1 Add : Purchases 50,193,755 50,896,109 14,635,467 48,720,411 WORK IN PROGRESS 10,136,451 14,635,467 48,720,411			1,081,515,642		1,065,543,117
Interest - Bank 728,794 1,080,398 Dividend Income 8,888 8,888 Foreign exchange fluctuation (Net) 7,849,579 - Profit on Sale of Fixed Assets (Net) 18,882,954 - Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back 1,661,782 72,315 SCHEDULE- 13 29,404,630 1,168,577 SCHEDULE- 13 29,404,630 1,168,577 COST OF MATERIALS CONSUMED 78,991,015 82,853,951 RAW MATERIALS 369,453,146 1 Opening Stock 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,78 556,939,221 78,991,015 Opening Stock 14,635,467 17,291,457 373,316,082 PACKING MATERIALS 0 17,291,457 46,064,651 Less : Closing Stock 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS 50,193,765 55,653,735 55,653,735 55,653,735 Closing Stock 294,005,657 97,	SCHEDULE - 12				
Bank 728,794 1,080,398 Dividend Income 8,888 8,888 Foreign exchange fluctuation (Net) 7,849,579 - Profit on Sale of Flxed Assets (Net) 18,882,954 - Misc. Income 272,633 6,976 Provisors / Creditors no longer payable written back 1,661,782 72,315 SCHEDULE- 13 29,404,630 1,168,577 SCHEDULE- 13 29,404,630 1,168,577 COST OF MATERIALS CONSUMED 82,853,951 1,168,577 RAW MATERIALS 553,156,784 369,453,146 Less: Closing Stock 75,208,578 556,939,221 379,316,082 PACKING MATERIALS 75,208,578 556,939,221 373,316,082 Opening Stock 74,635,467 17,291,457 373,316,082 Add : Purchases 56,493,994 46,064,651 48,720,641 Vorentases 56,493,994 46,064,651 48,720,641 VORK IN PROGRESS 50,193,765 55,653,735 50,193,755 50,193,755 Closing Stock 41,316,481 8,877,284 50,193,755 5459700 FINISHED GOODS <td< td=""><td>OTHER INCOME</td><td></td><td></td><td></td><td></td></td<>	OTHER INCOME				
Dividend Income 8,888 8,888 Foreign exchange fluctuation (Net) 7,849,579 - Profit on Sale of Flxed Assets (Net) 18,882,954 - Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back 1,661,782 72,315 29,404,630 11,661,782 72,315 SCHEDULE- 13 29,404,630 1,168,577 COST OF MATERIALS CONSUMED 82,853,951 1,168,577 RAW MATERIALS 82,853,951 369,453,146 Less : Closing Stock 75,208,578 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 Add : Purchases 56,493,994 46,604,651 37,316,082 PACKING MATERIALS 11,291,457 37,316,082 369,453,146 Less : Closing Stock 20,233,352 50,896,619 48,720,641 WORK IN PROGRESS 11,316,481 8,877,284 50,193,765 55,653,735 Closing Stock 50,193,765 55,653,735 54,597,097 Opening Stock 41,316,481	Interest -				
Foreign exchange fluctuation (Net) 7,849,579 Profit on Sale of Fixed Assets (Net) 18,882,954 Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back 1,661,782 .72,315 29,404,630 1,168,577 SCHEDULE- 13 29,404,630 COST OF MATERIALS CONSUMED 82,853,951 RAW MATERIALS 78,991,015 82,853,951 Opening Stock 78,991,015 82,853,951 Add : Purchases 553,156,784 Opening Stock 77,208,578 256,939,221 Opening Stock 72,21,537 Opening Stock 20,233,352 556,939,221 MWKIN IN PROGRESS Opening Stock 41,316,481 8,877,284 <td< td=""><td>Bank</td><td></td><td>728,794</td><td></td><td>1,080,398</td></td<>	Bank		728,794		1,080,398
Profit on Sale of Flxed Assets (Net) 18,882,954 - Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back 1,661,782 72,315 SCHEDULE- 13 29,404,630 1,168,577 COST OF MATERIALS CONSUMED 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 PACKING MATERIALS 77,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 14,635,467 17,291,457 373,316,082 Opening Stock 14,635,467 17,291,457 46,064,651 Less : Closing Stock 20,233,352 50,896,109 14,635,467 VORK IN PROGRESS 90,913,765 55,653,735 5459970 Opening Stock 50,193,765 55,653,735 5459970 FINISHED GOODS 94,005,657 97,431,481 42,52,641 Opening Stock 148,136,117 (54,130,460) 94,005,657 3,425,824	Dividend Income		8,888		8,888
Profit on Sale of Flxed Assets (Net) IB,882,954 - Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back I,661,782 72,315 29,404,630 29,404,630 1,168,577 SCHEDULE- 13 29,404,630 1,168,577 COST OF MATERIALS CONSUMED 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 77,208,578 556,939,221 78,991,015 PACKING MATERIALS 77,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 77,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 14,635,467 17,291,457 373,316,082 PACKING MATERIALS 20,233,352 50,896,109 14,635,467 48,720,641 VORK IN PROGRESS 20,233,352 50,896,109 14,635,467 48,720,641 VORK IN PROGRESS 50,193,765 55,653,735 5459700 Closing Stock 50,193,765 55,653,735 5459700 FINISHED GOODS 79,431,481 50,193,765 5459700 <td< td=""><td>Foreign exchange fluctuation (Net)</td><td></td><td>7,849,579</td><td></td><td>-</td></td<>	Foreign exchange fluctuation (Net)		7,849,579		-
Misc. Income 272,633 6,976 Provisions / Creditors no longer payable written back 1,661,782 72,315 SCHEDULE- 13 29,404,630 1,168,577 COST OF MATERIALS CONSUMED 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 PACKING MATERIALS 369,453,146 369,453,146 373,316,082 PACKING MATERIALS 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 75,208,578 556,939,221 78,991,015 373,316,082 Opening Stock 14,635,467 17,291,457 373,316,082 PACKING MATERIALS 20,233,352 50,896,109 14,635,467 48,720,641 Vork IN PROGRESS 20,233,352 50,896,109 14,635,467 48,720,641 Opening Stock 20,233,352 50,896,109 14,635,467 48,720,641 Opening Stock 50,193,765 55,553,735 50,997,055 55,553,735 Closing Stock 50,193,765 55,553,735 50,997,05 5459970 F			18,882,954		-
Zey,404,630 1,168,577 SCHEDULE- 13 29,404,630 1,168,577 COST OF MATERIALS CONSUMED RAW MATERIALS 82,853,951 Opening Stock 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 75,208,578 556,939,221 78,991,015 373,316,082 Opening Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 0 17,291,457 446,064,651 17,291,457 Add : Purchases 56,493,994 46,064,651 48,720,641 WORK IN PROGRESS 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS 0,193,765 55,653,735 5459970 Opening Stock 41,316,481 8,877,284 50,193,765 5459970 FINISHED GOODS 94,005,657 97,431,481 101,145,031 Opening Stock 94,005,657 97,431,481 3425,824 <t< td=""><td></td><td></td><td>272,633</td><td></td><td>6,976</td></t<>			272,633		6,976
Zey,404,630 1,168,577 SCHEDULE- 13 29,404,630 1,168,577 COST OF MATERIALS CONSUMED RAW MATERIALS 82,853,951 Opening Stock 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 75,208,578 556,939,221 78,991,015 373,316,082 Opening Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 0 17,291,457 440,064,651 17,291,457 Add : Purchases 56,493,994 46,064,651 48,720,641 WORK IN PROGRESS 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS 0,193,765 55,653,735 5459970 Closing Stock 41,316,481 8,877,284 50,193,765 5459970 FINISHED GOODS 94,005,657 97,431,481 101,145,031 Opening Stock 94,005,657 97,431,481 3425,824 <t< td=""><td>Provisions / Creditors no longer payable written back</td><td></td><td></td><td></td><td>72,315</td></t<>	Provisions / Creditors no longer payable written back				72,315
COST OF MATERIALS CONSUMED RAW MATERIALS Raw materials consumed Raw materials Raw materials <thraw materials<="" th=""> Raw materials</thraw>	5 T /				-
RAW MATERIALS 78,991,015 82,853,951 Opening Stock 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 75,208,578 556,939,221 78,991,015 373,316,082 Opening Stock 14,635,467 17,291,457 46,064,651 17,291,457 Add : Purchases 56,493,994 46,064,651 48,720,641 Less : Closing Stock 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS 20,233,356 55,653,735 55,653,735 55,653,735 Closing Stock 50,193,765 55,653,735 55,5459,700 55,653,735 FINISHED GOODS 5 55,653,735 5459970 Opening Stock 94,005,657 97,431,481 5459970 PURCHASE OF TRADED GOODS 148,136,117 (54,130,460) 94,005,657 3,425,824 PURCHASE OF TRADED GOODS 101,145,031 101,145,031 101,145,031 101,145,031	SCHEDULE- 13				
Opening Stock 78,991,015 82,853,951 Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 75,208,578 556,939,221 78,991,015 373,316,082 Opening Stock 14,635,467 17,291,457 46,064,651 14,035,467 Add : Purchases 56,493,994 46,064,651 48,720,641 VORK IN PROGRESS 20,233,352 50,896,109 14,635,467 48,720,641 Opening Stock 20,233,352 50,896,109 14,635,467 48,720,641 VORK IN PROGRESS 50,193,765 55,653,735 55,653,735 Closing Stock 50,193,765 55,653,735 5459970 FINISHED GOODS 51 55,653,735 5459970 Opening Stock 94,005,657 97,431,481 5459970 Opening Stock 94,005,657 97,431,481 3425,824 PURCHASE OF TRADED GOODS 148,136,117 (54,130,460) 94,005,657 3425,824	COST OF MATERIALS CONSUMED				
Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 14,635,467 78,991,015 373,316,082 Opening Stock 14,635,467 17,291,457 17,291,457 17,291,457 Add : Purchases 56,493,994 46,064,651 48,720,641 Less : Closing Stock 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS 1 14,635,467 48,720,641 Opening Stock 41,316,481 8,877,284 50,193,765 5459970 FINISHED GOODS 14,8136,117 59,431,481 5459970 Opening Stock 94,005,657 97,431,481 42,526,41 PURCHASE OF TRADED GOODS 148,136,117 (54,130,460) 94,005,657	RAW MATERIALS				
Add : Purchases 553,156,784 369,453,146 Less : Closing Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS 14,635,467 17,291,457 1 Opening Stock 14,635,467 440,064,651 1 1 Add : Purchases 56,493,994 440,064,651 48,720,641 WORK IN PROGRESS 20,233,352 50,896,109 14,635,467 48,720,641 Opening Stock 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS 55,653,735 55,653,735 Closing Stock 41,316,481 8,8877,284 50,193,765 5459970 FINISHED GOODS 5459970 Opening Stock 94,005,657 97,431,481 425,824 PURCHASE OF TRADED GOODS 3425,824	Opening Stock	78.991.015		82.853.951	
Less: Closing Stock 75,208,578 556,939,221 78,991,015 373,316,082 PACKING MATERIALS I </td <td></td> <td></td> <td></td> <td></td> <td></td>					
PACKING MATERIALS I			556.939.221		373 316 082
Opening Stock 14,635,467 17,291,457 Add : Purchases 56,493,994 46,064,651 Less : Closing Stock 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS 48,720,641 Opening Stock 50,193,765 55,653,735 Opening Stock 50,193,765 55,653,735 Closing Stock 41,316,481 8,877,284 50,193,765 5459970 FINISHED GOODS 5459970 Opening Stock 94,005,657 97,431,481 3,425,824 PURCHASE OF TRADED GOODS 101,145,031 101,145,031 101,145,031	-				,
Add : Purchases 56,493,994 46,064,651 Less : Closing Stock 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS 50,193,765 55,653,735 5459970 Opening Stock 41,316,481 8,877,284 50,193,765 5459970 FINISHED GOODS Opening Stock 94,005,657 97,431,481 5459970 FINISHED GOODS Opening Stock 94,005,657 97,431,481 Less: Closing Stock 148,136,117 (54,130,460) 94,005,657 3,425,824 PURCHASE OF TRADED GOODS 101,145,031		14.635.467		17 291 457	
Less : Closing Stock 20,233,352 50,896,109 14,635,467 48,720,641 WORK IN PROGRESS					
WORK IN PROGRESS Image: Solar Stock Solar Stock Solar Stock Solar Stock St			50.896.109		48 720 641
Opening Stock 50,193,765 55,653,735 Closing Stock 41,316,481 8,877,284 50,193,765 FINISHED GOODS 7 7 7 Opening Stock 94,005,657 97,431,481 7 Less:Closing Stock 148,136,117 (54,130,460) 94,005,657 3,425,824 PURCHASE OF TRADED GOODS 101,145,031 101,145,031 101,145,031	-				,,.
Closing Stock 41,316,481 8,877,284 50,193,765 5459970 FINISHED GOODS		50,193,765		55 653 735	
FINISHED GOODS 94,005,657 97,431,481 Opening Stock 94,005,657 97,431,481 Less:Closing Stock 148,136,117 (54,130,460) 94,005,657 3,425,824 PURCHASE OF TRADED GOODS 37,418,713 101,145,031			8,877 284		5459970
Opening Stock 94,005,657 97,431,481 Less:Closing Stock 148,136,117 (54,130,460) 94,005,657 3,425,824 PURCHASE OF TRADED GOODS 37,418,713 101,145,031			3,077,207		5 137770
Less:Closing Stock 148,136,117 (54,130,460) 94,005,657 3,425,824 PURCHASE OF TRADED GOODS 37,418,713 101,145,031		94 005 657		97 431 481	
PURCHASE OF TRADED GOODS 37,418,713 101,145,031			(54 130 460)		3 475 874
	-	140,130,117		77,005,057	
			600,000,868		532,067,548



2009-2010 2008-2009 ₹ ₹ ₹ ₹ **SCHEDULE** -14 MANUFACTURING EXPENSES Consumables and Stores-opening stock 1,035,458 1,269,518 Add : Purchases 10,836,257 8,384,693 Less : Closing Stock 1,329,971 10,541,744 1,035,458 8,618,753 Power & Fuel 18,336,936 19,470,973 Water Charges 1,091,185 1,090,004 5,645,031 5,375,265 Laboratory and Testing 11,547,292 4,782,349 Labour charges paid 36,620,444 30,718,591 Repairs & Maintenance: Building 82,736 41,254 Machinery 4,352,638 3,575,707 7,116,889 Others 11,552,263 4,721,631 8,338,592 3,239,934 Excise duty on finished goods stock 1,201,034 61,954,384 48,876,970 **SCHEDULE - 15 EMPLOYEES REMUNERATION & BENEFITS** Salaries Wages & Allowances 88,601,547 76,557,537 Bonus & Exgratia 3,037,791 3,284,876 PF & E.S.I Contributions 6,936,567 6,961,730 **Employees Welfare** 6,380,049 6,137,197 **Recruitment & Training** 711,408 1.157.316 486,065 1,803,466 Gratuity (435,989) Amortization of deferred stock compensation cost 710,094 Remuneration to Directors 6,040,000 5,520,000 111,757,438 102,132,216 **SCHEDULE - 16 SELLING & DISTRIBUTION EXPENSES** Advertisement 221,768 246.578 2,925,755 Seminar, Conference & Exhibition Expenses 3,686,942 Freight & Handling Charges on Export Sales 26,913,697 15,980,426 4,188,078 Commission on Sales 4,896,422 Field Staff Salaries & Incentives 55,669,865 68,902,125 Field Staff Travelling Expenses 33,583,783 37,261,036 6,131,736 Freight Outwards & Others 8,741,193 Breakages & Expired Goods 21,719,582 7,761,790 Other Selling Expenses 20,119,804 32,646,992 Sales Promotional Items 13,110,999 15,784,445 185,346,254 195,146,762

SCHEDULES FORMING PART OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

SCHEDULES FORMING PART OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

	2009	-2010	2008-2009	
	₹	₹	₹	₹
SCHEDULE -17				
ADMINISTRATION EXPENSES				
Travelling expenses - Inland				
- Directors	280,313		422,825	
- Others	2,802,582		4,388,769	
Travelling expenses - Foreign				
- Directors	2,333,172		566,754	
- Others	3,521,625	8,937,692	2,694,781	8,073,129
Repairs and Maintenance - Office	1,408,611		I,876,063	
Rates & Taxes	2,541,171		829,463	
Conveyance	2,745,689		3,257,862	
Postage, Telegram & Telephone	3,659,616		3,787,144	
Legal & Professional charges	4,709,916		5,181,582	
Printing & Stationery	3,663,200		3,782,416	
Insurance	2,847,093		2,375,900	
Rent	5,917,704		7,655,948	
Donations	26,500		14,401	
Directors Sitting fees	34,200		69,550	
Electricity Charges	819,142		752,729	
Audit Fees	320,200		334,521	
Balances / Advances baddebts written off	23,554		2,140,852	
Security Charges	1,594,029		962,491	
Registration Fees	1,119,363		80,327	
Vehicle Operation and Maintenance	2,106,267		2,442,600	
Foreign exchange fluctuation (Net)	-		748,638	
Loss on Sale of Fixed Assets (Net)	_		177,771	
Subscription & Membership	1,087,118		1,983,785	
Diminition in the value of Investment	346,000		-	
Miscellaneous Expenses	524,835	35,494,208	329,212	38,783,255
This centarieous Expenses		44,431,900		46,856,384
SCHEDULE - 18		44,431,700	-	+0,000,00+
FINANCIAL CHARGES				
	22 000 222		7 045 102	
Interest on Term Loan	27,089,227		7,945,183	
Interest on Working Capital Loan	27,682,559	54 4 1 4 1 1 7	29,103,721	20.244.007
Other Interest	,842,331	56,614,117	2,218,093	39,266,997
Bank Charges		5,989,856	-	7,853,799
	-	62,603,973	=	47,120,796
SCHEDULE - 19				
AMORTISATION OF INTANGIBLE ASSETS				
Development Expenses		228,984		228,984
Research and Development Expenses		5,045,057	-	5,428,106
		5,274,041		5,657,090



SCHEDULE 20

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS FOR THE YEAR ENDED 31.03.2010

A. SIGNIFICANT ACCOUNTING POLICIES

a) BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements are prepared and presented in accordance with Indian Generally Accepted Accounting Principles ('GAAP') under the historical cost convention on the accrual basis. GAAP comprises accounting standards notified by the Central Government of India under section 211(3C) of the Companies Act, 1956, other pronouncements of Institute of Chartered Accountants of India, the provisions of Companies Act, 1956 and guidelines issued by Securities and Exchange Board of India. Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

The Management evaluates and adopts all recently issued or revised accounting standards on an ongoing basis.

b) USE OF ESTIMATES

The preparation of the financial statements in conformity with GAAP requires the management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to contingent liabilities as at the date of the financial statements and reported amounts of revenues and expenditure for the year. Actual results could differ from those estimates. Any revision to accounting estimates is recognized prospectively in the current and future periods.

c) **REVENUE RECOGNITION**

Revenue from domestic sale of goods is recognized when significant risks and rewards in respect of ownership of products are transferred to customers. Revenue from export sales is recognized when the significant risks and rewards of ownership of products are transferred to the customer, which is based upon the terms of the applicable contract.

Revenue from product sales is stated inclusive of Excise Duty and exclusive of returns, sales tax and applicable trade discounts and allowances.

Service income is recognized as per the terms of contracts with customers when the related services are performed, or the agreed milestones are achieved.

Dividend income is recognized when the unconditional right to receive the income is established. Income from interest on deposits, loans and interest bearing securities is recognised on the time proportionate method.

Export entitlements under the Duty entitlement Pass Book ('DEPB") and Focus Marketing incentive scheme are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Profit on sale of investments is recorded on transfer of title from the company and is determined as the difference between the sales price and the then carrying value of the investment.

d) FIXED ASSETS

Fixed assets are carried at the cost of acquisition or construction less accumulated depreciation. The cost of fixed assets includes non refundable taxes, duties, freight and other incidental expenses related to the acquisition and installation of the respective assets. Borrowing costs directly attributable to acquisition or construction of those fixed assets which necessarily take a substantial period of time to get ready for their intended use and all pre-operative expenses till the commencement of commercial production are capitalized.

Advances paid towards the acquisition of fixed assets outstanding at each balance sheet date and the cost fixed assets not ready for their intended use before such date are disclosed under capital work-in-progress.

e) **DEPRECIATION**

Depreciation on owned fixed assets is provided for on the straight line method as per the rates and in the manner pre \neg scribed under Schedule XIV of the Companies Act 1956. Depreciation is calculated on a pro-rata basis from the date of installation till the date the assets are sold or disposed. Premium on leasehold land is amortized over the initial period of lease. Individual low cost assets (acquired for less than ₹ 5,000/-) are entirely depreciated in the year of acquisition.

f) VALUATION OF INVENTORIES

Inventories are valued at the lower of cost and net realizable value. Cost of inventories comprises all cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition.

The methods of determining cost of various categories of inventories are as follows:

Raw materials	First in-first-out (FIFO)
Stores and spares	First in-first-out (FIFO)
Work-in-process and finished goods (manufactured)	FIFO and including an appropriate share of production overheads
Finished goods (traded)	Actual cost of purchase

g) **RETIREMENT BENEFITS**

A. Gratuity

In accordance with Indian laws, Bal Pharma Limited provide for gratuity, a defined benefit retirement plan covering all eligible employees of the Company. In accordance with the payment of Gratuity Act, 1972, the Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment of an amount based on the respective employee's salary and tenure of employment and vesting occurs upon completion of five years of service. The measurement date used for determining retirement benefits for gratuity is March 31.

Provision for gratuity & compensated absences is made on the basis of actuarial valuation at the balance sheet date, carried out by an independent actuary.

Contributions payable to the recognised provident fund, which is defined contribution scheme, are charged to the profit and loss account

B. Short Term Employees Benefits

Short term employee benefits are recognized as an expense at the undiscounted amount in the profit and loss account of the year in which the related service is rendered. These benefits include leave travel allowance, bonus / performance incentives.

h) INVESTMENTS

Investments are either classified as current or long-term based on the management's intention at the time of purchase. Current investments are carried at the lower of cost and fair value. Long-term investments are carried at cost and provisions recorded to recognize any decline, other than temporary, in the carrying value of each investment.

i) FOREIGN CURRENCY TRANSACTIONS AND BALANCES

Foreign currency transactions are recorded using the exchange rates prevailing on the dates of the respective transactions. Exchange differences arising on foreign currency transactions settled during the year are recognized in the profit and loss account.

Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date, not covered by forward exchange contracts, are translated at year-end rates. The resultant exchange differences are recognized in the profit and loss account. Non-monetary assets are recorded at the rates prevailing on the date of the transaction.

j) EXPENDITURE ON RESEARCH AND DEVELOPMENT

In accordance with the Accounting Standard 26 on Intangible Assets, the Management has recognized Revenue Expenditure, direct as well as allocated, on R & D projects for development of new products and processes as Intangible Assets, since it is of the opinion that future economic benefits that are attributable to the asset will flow to the enterprise and the cost of the asset can be measured reliably. These assets shall be amortized over a period of ten years starting from the year of commercial production. However, Revenue Expenditure on projects, which have become unsuccessful are charged off as an expense in the year in which they are abandoned. Capital expenditure incurred on research and development is capitalized as fixed assets and depreciated in accordance with the depreciation policy of the company.



k) LEASES

Leases under which the company assumes substantially all the risks and rewards of ownership are classified as finance leases. Such assets acquired on or after April 01, 2001 are capitalized at fair value of the asset or present value of the minimum lease payments at the inception of the lease, whichever is lower. Lease payments under operating leases are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

Lease payments under operating leases are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

I) INCOME TAX EXPENSE

Income tax expense comprises current tax and deferred tax charge or credit.

Current tax

The current charge for income taxes is calculated in accordance with the relevant tax regulations applicable to the Company.

Deferred tax

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantially enacted by the balance sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realization of such assets. Deferred tax assets are reviewed at each balance sheet date and is written-down or written-up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realised.

m) EARNINGS PER SHARE

In determining earnings per share, the company considers the net profit after tax and includes the post tax effect of any extraordinary / exceptional item. The number of shares used in computing basic earnings per Share is the weighted average number of shares outstanding during the period. The number of shares used in computing diluted earnings per share comprises the weighted average shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. The dilutive potential equity shares are deemed converted as of the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares have been adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. the average market value of the outstanding shares).

n) EMPLOYEE STOCK OPTION SCHEMES

In accordance with the Securities and Exchange Board of India guidelines, the excess of the market price of shares, at the date of grant of options under the employee stock option schemes, over the exercise price is treated as employee compensation and amortized over the vesting period.

o) PROVISIONS AND CONTINGENT LIABILITIES

The Company creates a provision when there is a present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

p) IMPAIRMENT OF ASSETS

The Company assesses at each balance sheet date whether there is any indication that an asset may be Impaired. If any such indication exists, the Company estimates the recoverable amount of the asset. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the profit and loss account. If at the balance sheet date there is an indication that if a previous assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of depreciated historical Cost.

B. NOTES ON ACCOUNTS

I) National Savings Certificates have been deposited with Commercial Tax Department.

2) EXPORT BENEFITS:

The Company has accounted an amount of \mathfrak{T} 13,832,643/- (P.Y. \mathfrak{T} 6,563,942/-) being the net amount of credit under the DEPB and other schemes as announced by the Import Export Policy. The same will be utilized for off-setting the customs duty on future imports. The accumulated amount outstanding on this account as on 31.03.2010 is \mathfrak{T} 11,415,647/- (P.Y. \mathfrak{T} 9,131,052/-) and the same is reflected under loans and advances.

3) MARKET DEVELOPMENT EXPENSES:

Expenditure incurred on Market development amounting to ₹ 228,984/- (P.Y.₹ 228,984/-) has been written off during the year. Balance on this account as on 31.03.2009 is ₹ 9, 15,967/- (P.Y.₹ 1,144,951/-).

4) RESEARCH & DEVELOPMENT REVENUE EXPENSES:

An amount of ₹ 8,530,889/- (PY. ₹ 8,733,504/-) has been incurred during the year on research and development of new products and processes in the R & D Centre. The same is proposed to be amortized over a period of 10 years commencing from the year of commercial production. Amount written off during the year on account of the above was ₹ 5,045,057/- (PY. ₹ 5,428,106/-). The balance on this account as on 31.03.2010 is ₹ 51,404,671/- (PY. ₹ 47,918,839/-).

- 5) During the year an amount of ₹ NIL (P.Y. ₹ 25,133,403/-) being interest on term loans for acquisition of qualifying capital assets was capitalised.
- 6) The Company has provided for ₹ 7, 15,595 /- (P.Y. ₹. 5, 99, 217/-) being Excise Duty on Finished Goods lying at various manufacturing units as at 31.03.2010.

7) BREAK-UP OF DEFERRED TAX ASSETS AND LIABILITIES:

	31.03.2010	31.03.2009
	₹.	₹.
Deferred tax Assets recognized for timing differences due to:		
A. Current Liabilities	3,180,792	2,903,912
B. Sec 40a(ia) Disallowances	229,700	229,700
C. Carried forward losses	2,584,977	-
D. Provision for diminution in the value of investment	114,933	-
	6,110,402	3,133,612
Deferred tax Liabilities recognized for timing differences due to:		
A. Depreciation and other differences in block of fixed assets	58,494,560	49,694,009
B. Others	9,391,440	10,586,949
	67,886,000	60,280,958
Net Deferred Tax Liabilities	61,775,598	57,147,344
Charge to Profit & Loss Account	4,628,254	7,822,681

8) CONTINGENT LIABILITIES NOT PROVIDED FOR (in Rupees)

- a) Guarantees issued by Company's bankers ₹. 6,810,977/- (P.Y. ₹. 20,936,720/-)
- b) Letter of credit ₹. 54,582,725/- (P.Y. ₹ 71,135,406/-).
- c) Estimated value of contracts remaining to be executed on capital account and not provided for ₹. NIL /- (PY. ₹. 1,434,335/-).



(in ₹)

9) CIF VALUE OF IMPORTS:

		31.03.2010	31.03.2009
l. 2.	Raw Materials Capital Goods (Including spares & components)	322,103,581 51,597	186,572,876 4,616,402
		320,975,758	191,189,278

10) A) EXPENDITURE IN FOREIGN CURRENCY

		31.03.2010	31.03.2009
a.	Travelling Expenditure	1,612,475	2,462,114
b.	Registration Fee	I,077,345	I,708,986
c.	Commission on Export sales	1,413,580	2,597,789
d.	Sales Promotion	4,027,898	1,114,997
		8,131,298	7,883,886

B) EARNINGS IN FOREIGN CURRENCY (in Rupees)

	31.03.2010	31.03.2009
a. FOB Value of Exports	538,692,125	349,531,750

II) Gratuity Plan:

The following table set out the status of the plan as required under AS 15(revised):

Change in defined benefit obligation

(Amount in ₹)

	Gratuity	Gratuity (Funded)	
	2009-10	2008-09	2009-10
Opening defined benefit obligation	10,291,331	8,901,687	-
Interest cost	705,401	646,197	-
Current Service Cost	1,750,962	2,032,201	819,123
Benefits paid	(428,340)	(667,198)	-
Actuarial losses / (Gain)	(1,741,782)	(621,556)	834,882
Closing defined benefit obligation	10,577,572	10,291,331	1,654,005

Change in plan assets

Plan Assets at beginning of the year, at fair value	2,855,751	3,269,573	-
Expected Return on plan Assets (estimated)	211,300	231,000	-
Contributions	-	-	-
Benefits settled	(428,340)	(667,198)	-
Actuarial gain/(loss) on plan assets	17,216	22,376	-
Plan Assets at end of the year, at fair value	2,655,927	2,855,751	-

Reconciliation of present value of the obligation and the fair value of the plan assets

Fair Value of plan assets at the end of the year	2,655,927	2,855,751	-
Present value of the defined benefit obligation at the end of the year	10,577,572	10,291,331	I,654,005
Asset/(Liability) recognized in the balance sheet	(7,921,645.00)	-7,435,580	(1,654,005)

Cost for the period

	Gratuity	(Funded)	Leave Encashment (unfunded)
	2009-10	2008-09	2009-10
Current Service Cost	1,750,962	2,032,201	819,123
Interest Cost	705,401	646,197	-
Expected Return on Plan Asset	(211,300)	-231,000	-
Net Actuarial (Gain)/Loss recognized for the year	(1,758,998)	643,932	834,882
Expense/(Income) recognized in the statement of P/L account	486,065	I,803,466	I,654,005

Movements in the Liability recognized in Balance sheet

Opening Liability	7,435,580	5,632,114	-
Expense/income recognized for the period, as above	486,065	I,803,406	I,654,005
Contribution paid	-	-	-
Closing Liability	7,921,645	7,435,580	I,654,005

Assumptions at the valuation date

Discount factor	7.00%	7.00%	8.00%
Salary Escalation rate	5.50%	5.50%	5.50%
Rate of Return (Expected) on plan Asset	8.00%	8.00%	-
Retirement age	58	58	58

12) SECURITY FOR LOANS IN SCHEDULE (3) TO BALANCE SHEET:

- 12.1 Hire purchase finance provided by various financial institutions is secured by a charge on the assets financed by the respective institutions.
- 12.2 The Working Capital Loan financed by Canara Bank, ICICI Bank, Punjab National Bank, and EXIM Bank under a Consortium arrangement with pari passu charge is secured against hypothecation of stock and book debts and first charge on fixed assets other than those financed by the term lending institutions.
- 12.3 Loan obtained from State Bank of Indore is secured by hypothecation of assets of Unit II and Unit IV funded by them.
- 12.4 Secured loans obtained from EXIM Bank of ₹.21.55 Crores towards establishment of Formulation Plant at Uttaranchal first pari pause charge on the entire immovable and Hypothecation of whole of moveable fixed assets, both present and future of the Company including.
 - (a) Movable plant and machinery, Equipment, Appliances, furniture, vehicles, machinery spares and stores, tools and accessories, whether or not installed and
 - (b) Related movables in the course of transit or delivery whether now belonging or which may hereafter belong to the Company or which may be held by any person at any place within or outside India to the order or disposition of the company and all document or title including bills of lading, shipping documents, policies of insurance and other instruments and documents relating to such movables together with benefits of all rights thereto.
- 12.5 All the Secured Loans have been guaranteed by two Directors including Managing Director in their personal Capacity.
- 13) Balances of Sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any.
- 14) In the opinion of the Board of directors adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.
- 15) The Company's significant leasing arrangements are in respect of operating leases for premises (office, stores, godowns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rentals payable are charged as rent under Schedule 17.



16) EMPLOYEE STOCK OPTION SCHEME

Bal Pharma Limited's Employee Stock Option Scheme – 2006 (ESOP 2006) : The Company instituted the 2006 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on 23-09-2004. The Scheme covers all non promoter directors and employees and its subsidiaries. Under the scheme, the compensation Committee of the Board ('the Committee') shall administer the Scheme and grant stock options to eligible directors and employees of the Company and its subsidiaries. The Committee shall determine the employees eligible for receiving the options, the number of options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for the options issued on the date of the grant.

The market value of a share on each grant date is defined as the average of the two weeks high and low price of the share preceding the date of grant of option on the stock exchange where there is highest trade volume during that period.

In case of termination of employment, all non-vested options would stand cancelled. Options that have vested but have not been exercised can be exercised within the time prescribed under each option agreement by the Committee, failing which they would stand cancelled.

The company under ESOP-2006 had granted 2, 19,500 options to eligible employees. The vesting period for the options granted varies from 12 to 60 months.

*Stock option activity under ESOP-2006 was as follows:

Particulars	31.03.2010	31.03.2009
Options outstanding at the beginning	172,900	2,12,000
Add: Options Granted	-	-
Less: Options forfeited/Surrendered	62,500	2,100
Less: Options exercised	-	37,000
Options outstanding at the end	110,400	172,900

* Exercise Price : ₹. 15.75/-

17) During the year, Novosynth Research labs Private Limited, a 100% subsidiary of Bal Pharma Limited applied for striking off its name from the register as defunct company under section 560 of the Companies Act, 1956. Pursuant to the above, the company has provided for diminution in the value of its investment in the said subsidiary

18) RELATED PARTY DISCLOSURES:

Subsidiaries:

i)

- A. The related parties where control exists are the subsidiaries. There are no other parties over which the Company has control.
- B. Related parties where control / significant influence exist or with whom transactions have taken place during the year:

	,
ii)	Enterprises where principal / promoter shareholders have control or significant influence (Significant interest entities) :
	Micro Labs Ltd – Enterprise owned by some of the promoter shareholders

iii)	Others:- (a) Desa Marketing International	- Enterprise owned by the Managing Director of the Company.
	(b) Siroya Developers (P) Ltd.	 Enterprise owned by relatives of Managing Director of the Company.
	(c) Siroya Constructions	- Enterprise over which the Managing Director of the Company exercises joint control with other Partners.

C. Key managerial Personnel represented on the board:

Basav Chem Limited

Novosynth Research Labs Private Ltd

Shailesh D.Siroya	- Managing Director
Dr.S.Prasanna	- Whole time Director

D. Particulars of related party transactions :

The following is a summary of significant related party transactions

(Amount in ₹)

		31.03.2010	31.03.2009
i)	Sales to Significant entities	16,860,572	3,757,522
íí)	Purchase from Significant entities	6,851,437	27,001
iii)	Commission paid to Enterprises owned by the Managing Director of the company	7,891,216	4,505,022
iv)	Rent paid to subsidiaries	-	1,980,000
v	Job work charges paid to subsidiaries	4,732,622	-
vi)	Loans to subsidiaries	-	600
vii)	Repayment of advance to significant interest entities	8,000,000	-
viii)	Customer advances from significant interest entities	-	8,000,000
ix)	Interest paid to significant interest entities	466,667	-
x)	Repayment of loan by subsidiaries	1,537	-
xí)	Advance given to enterprises over which Managing Director of the Company exercises joint control with other partners	32,352	-
xii)	Repayment of advance from enterprises over which Managing Director of the Company exercises joint control with other partners	90,620	-

- E. Details of remuneration paid to the Managing Director and whole time Director are given in Note.No.19 of Schedule 20.
- F. The Company has the following amounts due from / to related parties:

Particulars	31.03.2010	31.03.2009
i) Due from related parties		
a) Subsidiaries : (Included in loans and advances)	6,460,000	6,462,155
b) Significant interest entities (Included in Sundry Debtors)	6,014,741	104,730
c) Enterprise in which Managing Director of the Company exercises joint	. –	58,268
Control with other partners (included in loans and advances)		
ii) Due to related parties		
Enterprises owned by Managing Director of the Company	3,475,539	4,607,429
(Included in current liabilities)		
iii) Subsidiaries (Included in current liabilities)	1,095,641	817,121
iv) Significant interest entities(included in current liabilities)	-	8,000,000

19) Particulars of Managerial Remuneration:

The remuneration paid to Managerial personnel during the year :

	Managing Director		Whole time Directors	
	31.3.2010	31.3.2010 31.3.2009		31.3.2009
Salaries & Allowances	4,000,000	3,600,000	20,40,000	19,20,000
Commission	Nil	Nil	Nil	Nil
Perquisites	Nil	Nil	Nil	Nil

20) Computation of net profit in accordance with Section 349 of the Companies Act, 1956 :

Particulars		Amount (₹.)
Net Profit before taxation as per profit and loss account		(7,781,974
Add :		
Depreciation provided in the accounts	28,070,198	
Managerial Remuneration	6,040,000	
Provision for diminution in value of investment	346,000	
Directors' sitting fee	34,200	34,490,398
		26,708,42
Less :		
Depreciation under Section 350 of the Act	28,070,198	
Profit on sale of fixed assets	18,882,954	46,953,152
Net Profit/Loss for the purpose of Section 269		(20,244,728
Managerial Remuneration to Whole time Directors		60,40,000

The remuneration paid to Mr. Shailesh D Siroya, Managing Director and Dr. S. Prasanna, Wholetime Director, is in accordance with the stipulations under Schedule XIII, Part II, Section II(B) of the Companies Act, 1956, and in terms of the shareholders approval by way of special resolution in the 17th Annual General Meeting held on 23rd September 2004, and 19th Annual General Meeting held on 20th September, 2006, and 21st Annual General meeting held on 23rd September 2008 and 22nd Annual General Meeting held on 25th September 2009.

21) Auditor's Remuneration:

	31.3.2010	31.3.2009
Statutory Audit Fees	2,00,000	1,70,000
Tax Audit Fees	50,000	50,000
Other services	40,200	84,521
Reimbursement of out of pocket expenses	50,000	30,000
	340,200	334,521

22) Details of Imported & Indigenous Raw Materials, Stores & Spare Parts consumed :

	31.03.2010	% of Total Consumption	31.03.2009	% of Total Consumption
Raw Materials				
Imported	195,507,115	31.5%	192,601,014	51.6%
Indigenous	361,432,106	64.9%	180,715,068	48.4%
Total	556,939,221		373,316,082	
Stores & Spares				
Imported	NIL	0%	NIL	0%
Indigenous	10,541,744	100%	86,18,753	100%

23) QUANTITATIVE INFORMATION

a) Installed capacity (as certified by the Management)

PRODUCT	UNIT	31.03.2010	31.03.2009
Tablets	Million Nos.	3770	3770
Capsules	Million Nos.	100	100
Liquids	Kilo Litres	750	750
Ointment	Metric Tonne	75	75
IV-Fluids	Million Nos.	07	07
Eye/Ear Drops	Million Nos.	19	19
Bulk Drugs	Metric Tonne	38	38

b) Licensed Capacity-- Not Applicable

Notes : Installed capacities are as certified by Management and have not been verified by the auditors as this a technical matter.

c) Particulars of Production, Sale and Stock

SI. No.	Particulars	Unit	Opening	g Stock	Produc	tion and Pure	chase	Sa	les	Closing	Stock
		No.	qty	value	qty	qty	Value	qty	Value	qty	Value
Ι	Tablets	000 Nos	29754.6	55282.7	426455.12	705.06	13324.39	446103.73	409807.71	10811.04	109773.75
			(23523)	(86568)	(674973)	(119759.3)	(57864.6)	(788500.7)	(533711.3)	(29754.6)	(55282.7)
2	Capsules	000 Nos	5625	6468.7	32933.42	126.42	5850.80	32610.48	71097.63	6074.35	23970.11
			(2507)	(3824)	(24950)	(24260.5)	(32330.7)	(46092.5)	(61164.8)	(5625)	(6468.7)
3	Liquids	Kilo Ltrs	91.5	3296.1	26487.96	1704.36	15404.30	8841.21	103913.57	19442.61	4881.72
			(72.1)	(2590)	(1299.7)	(48.1)	(9738.1)	(1328.4)	(70780.2)	(91.2)	(3296.1)
4	Ointments	Kgs	19439.9	28666.I	35551.41	179.14	3839.23	51538.92	21881.43	3631.618	2813.62
			(2216)	(3235)	(62985.6)	(3983)	(1211.6)	(49744.7)	(84566)	(19439.9)	(28666.1)
5	EED	Million	0.1	265.7	3.73			1.8	5692.22	2.028	1999.43
			(0.001)	(7.00)	(5.4)	()	()	(5.3)	(8462.9)	(0.1)	(265.7)
6	Bulk Drugs	Kgs	4.0	26.3	64733.75			61960.00	449112.19	2777.50	4697.48
			(194)	(1208)	(38650.3)	()	()	(38840.3)	(292642)	(4.0)	(26.3)

Bal Pharma Limited



(Amount in ₹)

d)

RAW MATERIALS CONSUMED	UNIT	QUANTITY	VALUE (₹.000)
Powder	Kgs	1,029,731	523,943
		(807,985)	(358,183)
Liquids	Ltrs	608,125	25,327
		(431,381)	(10,430)
Capsule	000'Nos	123,703	7,669
		(59,390)	(4,703)

- 24) (a) The claim for differential excise duty of ₹. 1,034,757 on Physi¬cian Samples demanded by the Central Excise Dept in the year 1999-2000 was decided in Company's favor by CESTAT in the year 2006-2007. However, the Commissioner of Central Excise, Bangalore filed a civil appeal in the Supreme Court of India against the said order of CESTAT, which is still pending.
 - (b) The claim for differential excise duty of ₹.8.98 lakhs on physician's sales for the period September 1997 to February 1998 demanded by Central Excise Dept in respect of Unit I was contested and CESTAT, Bangalore upheld our appeal. However, Commissioner of Central Excise, Bangalore filed a civil appeal in the Supreme court of India against the said order of CESTAT, which is still pending.
 - (c) The claim of duty and penalty of ₹.868,598 for the period May 2000 to November 2001 by Central Excise in respect of Unit III is being contested and under the directions of CESTAT, Mumbai a pre-deposit of ₹.30,000/- has been made. The same is still pending decision.
 - (d) A Sales Tax claim of ₹.749,720/- on treating stock transfer as sales in Ernakulam by the Commercial Taxes, Special Circle I, KGST is being contested and a deposit of ₹.253,729 has been made. The application is being heard by the Deputy Commissioner, Ernakulam and is still pending decision.
 - (e) During the year, the Income Tax Officer (TDS) raised a demand of ₹.89, 50, 429 towards non deduction of TDS under the provisions of Income Tax Act, 1961 for the assessment years 2004-05 to 2008-09 on all principal to principal purchase transactions entered into by it during the said assessment years. The company filed an appeal before the commissioner of income Tax Appeals-V- HMT Bhavan Bangalore against the said order and as per the directions of the commissioner, the company deposited 25% of the demand amounting to ₹.22, 37,610/-. The said appeal is still pending. The management is however, confident of favorable appeal order.
 - (f) The Company is also involved in other lawsuits, claims, investigations and proceedings including patent and commercial matters, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business
- 25) The company, though has initiated the process, but is yet to obtain confirmation from suppliers who have registered themselves under the Micro Small Medium Enterprise Development Act, 2006 (MSMED Act, 2006). Based on the information available with the company, the balance due to Micro & Small Enterprises as defined under the MSMED Act, 2006 is ₹.NIL. Further, no interest during the year has been paid or payable under the terms of the MSMED Act, 2006.

Year	Amount
	(₹)
2002-03	1,71,432
2003-04	I,84,828
2004-05	49,859
2005-06	۱,65,07۱
2006-07	1,25,370
2007-08	3,73,096
2008-09	1,74,815
Total	1,244,471

26) Unclaimed Dividends on Equity Shares:

27) Calculation of EPS (Basic and Diluted)

		Year ended March 31, 2010	Year ended March 31, 2009
١.	Opening No of shares	10,483,224	10,446,224
2.	Total Shares Outstanding	10,483,224	10,483,224
3.	Weighted average number of shares	10,483,224	10,455,474
4.	Profit after Taxation available to Equity Shareholder	(134.08)	300.27
5.	EPS	(1.28)	2.87
	DILUTED		
6.	Weighted average number of shares (including employee Stock options dilution)	10,527,910	10,546,718
7.	Diluted EPS	(1.27)	2.85

- 28) During the financial year 2007-2008, the company entered into a share purchase agreement with the promoters and shareholders of Basav Chem Limited to acquire 100% control through purchase of existing Equity shares held by them. In accordance with the agreement, the company purchased 100,000 equity shares of ₹ 10/- each @ ₹. 5/-per share and paid the amount directly to the erstwhile shareholders. Also, the Company cleared Basav Chem Ltd's secured and unsecured loans. Further, during the year, the Company has already filed for amalgamation of Basav Chem limited with itself. An amount of ₹. 6,460,000/- (PY. 6,461,537) paid by the company towards discharge of Basav Chem Limited's liabilities is disclosed as advance to subsidiary.
- 29) The Company is primarily engaged in a single business segment of manufacturing and marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as ONE entity, for its various activities and is governed by a similar set of risks and returns.

Geographical segments

In the view of the management, the Indian and Export Markets represent geographical segments

Sales by market:

The following is the distribution of the Company's sales by geographical market:

GEOGRAPHICAL SEGMENTS	2009-2010	2008-2009
India	494,154,644	690,513,589
Other than India	587,360,998	368,465,586
Total	108,151,564	1058,979,175

Assets and additions to fixed assets by geographical area: The following table shows the carrying amount of segment assets and additions to fixed assets by geographical area in which the assets are located

Particulars	2009-	2010	2008-2	2009
	India	Others*	India	Others*
Carrying amount of segment assets	1,019,624,139	172,314,970	1,064,251,470	103,156,765
Additions to fixed assets	12,924,382		302,376,908	

* Others represent receivables from debtors located outside India.

30) Figures in brackets pertain to previous year.

31) Previous year figures have been regrouped /rearranged wherever necessary.

As per our report of even date

For OSTAWAL & JAIN Chartered Accountants ICAI FRN No. 002491S

T. D. Jain Partner M. No. 012034

Bangalore 09.08.2010

S. Ramji AVP Finance & Company Secretary

Dr. S. Prasanna Director

Shailesh Siroya Managing Director

FOR & ON BEHALF OF THE BOARD

Bal Pharma Limited

(Amount in ₹)



CA	SH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2010		(Rupees in '000)
		31.03.2010	31.03.2009
Α	CASH FLOW FROM OPERATING ACTIVITIES		
	Profit Before Tax	(7,782)	40,537
	Adjustments for :		
	Gratuity	486	1,803
	Depreciation	28,070	18,341
	Misc.expenditure written off	5,274	5,658
	Others-ESOP amortisation	(436)	710
	Interest Received	(729)	(1,080)
	Dividend Income	(9)	(8)
	Diminition in value of investment	346	-
	Provision no longer payable	-	(68)
	Profit on sale of fixed assets	(18,883)	178
	Interest Paid	56,614	39,267
	Operating Profit before working capital changes	62,952	105,338
	Adjustments for:		
	(Increase)/Decrease in inventories	(46,855)	15,639
	R& D Expenditure	(8,531)	(8,734)
	(Increase)/ Decrease in trade & other Payables	(21,925)	85,168
	(Increase)/ Decrease in trade & other Receivables	(29,810)	(60,120)
	Income Tax Paid	(7,649)	(9,567)
	NET CASH FROM OPERATING ACTIVITES	(114,770)	22,386
		(51,818)	127,724
В	CASH FLOW FROM INVESTMENT ACTIVITIES		
	Purchase of Fixed Assets	(12,924)	(113,842)
	Increase/Decrease in CWIP	3,988	-
	Sale of Fixed Assets	54,995	1,230
	Dividend Income	9	8
	Net Cash from investing Activites	46,067	(112,604)
С	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds from ESOP allotment	-	583
	Proceeds(Payments) from Long term borrowings	(1,929)	(5,660)
	Working Capital Borrowings	82,628	49,202
	Payments of Unsecured Loans	(8,195)	(23,358)
	Interest paid on borrowings	(56,614)	(39,267)
	Interest received	729	1,080
	Dividend & dividend tax paid	(9,199)	(12,222)
	Net Cash from financing Activities	7,420	(29,642)
	NET INCREASE IN CASH & CASH EQUIVALENTS (A+B+C)	1,670	(14,522)
	Opening Cash	14,478	29,000
	Closing Cash	16,148	14,478
	NET CASH CHANGE	1,670	(14,522)

Notes:

I. Direct Taxes paid is treated as arising from Operating Activities and is not bifurcated between operating investing and financing activities 2. Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date

For **OSTAWAL & JAIN** Chartered Accountants ICAI FRN No. 002491S

T. D. Jain Partner M. No. 012034 **S. Ramji** AVP Finance & Company Secretary

Dr. S. Prasanna Director Shailesh Siroya Managing Director

FOR & ON BEHALF OF THE BOARD

Bangalore 09.08.2010

42



BA	LANCE SHEET ABSTRACT AND COMPANY'S	GENERAL PROFILE	E	
ī	REGISTRATION	8368	STATE CODE	₹ 000's 08
	Balance sheet Date	31.03.2010		
II	CAPITAL RAISED DURING THE YEAR			
	Public issue	NIL	Right issue	NIL
	Bonus issue	NIL	Private placement	NIL
111	POSITION OF MOBILISATION AND DEPLOYMEN	T OF FUNDS		
	Total Laibilities	966261	Total Assets	966261
	SOURCE OF FUNDS			
	Paid-up Capital	104832	Secured Loans	544090
	Reserves & Surplus	255466	UnSecured Loans	97
	Deferred Tax	61775		
	APPLICATION OF FUNDS			
	Net Fixed Assets	493831	Net Current Assets	41559
	Investments	550	Misc.Expenditure	52321
D/	REPEORMANCE OF THE COMPANY			
IV	PERFORMANCE OF THE COMPANY			
	Turnover	1091657	Profit After Tax	(13408)
	Total Expenditure	1099439	Earnings per share	(1.28)
	Profit Before Tax	(7782)	Dividend	-

IV GENERIC NAME OF THREE PRINCIPAL PRODUCTS OF THE COMPANY AS PER MONETARY TERMS:

Item Code (ITC code)	29420029
Production Description	Gliclazide
Item Code (ITC code)	30042064
Production Description	Azithromycin
Item Code (ITC code)	29333990
Production Description	Ebastine



CONSOLIDATED BALANCE SHEET AS AT 31.03.2010

	SCH	AS AT 31.03.2010		AS AT 3	.03.2009
		₹.	₹.	₹.	₹.
SOURCES OF FUNDS					
I. SHAREHOLDERS' FUND					
a. Share Capital	1	104,832,240		104,832,240	
b. Reserves & Surplus	2	252,789,177	357,621,417	267,513,407	372,345,647
	-				072,010,017
II. LOAN FUNDS				((2,200,022	
a. Secured Loans	3	544,090,068		463,390,933	
b. Unsecured Loans	4	97,470	544,187,538	8,292,182	471,683,115
III. DEFERRED TAX LIABILITY (NET)	5		62,367,814		57,874,479
TOTAL			964,176,769		901,903,241
APPLICATIONS OF FUNDS					
I. FIXED ASSETS	6				
a. Gross Block		649,871,809		674,548,419	
b. Less: Accumulated Depreciation		152,364,081		125,263,149	
c. Net Block		497,507,728		549,285,270	
d. Add: Capital Work in Progress			497,507,728	3,987,740	553,273,010
d. Add. Capital Work in Hogiess			477,307,720	<u> </u>	555,275,010
II. INVESTMENTS	7		150,000		150,000
III. CURRENT ASSETS, LOANS & ADVANCES	8				
a. Inventories		286,224,499		238,861,362	
b. Sundry Debtors		319,172,267		292,858,622	
c. Cash & Bank Balances		16,148,069		14,888,989	
d. Loans & Advances		70,494,902		67,208,357	
Total (A)		692,039,737		613,817,330	
CURRENT LIABILITIES & PROVISIONS	9				
a. Current Liabilities		269,612,188		291,104,407	
b. Provisions		8,229,146		23,632,106	
				-,,	
Total (B)		277,841,334		314,736,513	
NET CURRENT ASSETS (A-B)			414,198,403		299,080,817
IV. INTANGIBLE ASSETS					
	10	91,254,578		83,059,313	
Gross Carrying Amount	10				
Less: Cumulative Amortisation & impairment loss		38,933,940		33,659,899	
Net Carrying Amount			52,320,638		49,399,414
TOTAL			964,176,769		901,903,241
NOTES ON ACCOUNTS	20				
As per our report of even date					
For OSTAWAL & JAIN			FOR &	ON BEHALF OF	THE BOARD
ICAI FRN No. 002491S					
Chartered Accountants					
T.D. Jain	S Ramii	D.,	S Prasanna	Shailad	Sirova

T. D. Jain Partner M. No. 012034 **S. Ramji** AVP Finance & Company Secretary

Dr. S. Prasanna Director **Shailesh Siroya** Managing Director

Bangalore 09.08.2010

CONSOLIDATED PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

Particulars	SCH	31.03	.2010	31.03.2009		
		₹.	₹.	₹.	₹.	
I. INCOME						
Sales & Services	11	1,081,515,642		1,065,543,117		
Less : Excise Duty		19,263,191		29,564,312		
,			1,062,252,452		I,035,978,805	
Other Income	12		29,427,974		1,224,247	
			1,091,680,426		1,037,203,052	
II. EXPENDITURE						
Cost of Materials Consumed	13	600,000,868		532,067,548		
Manufacturing Expenses	14	59,752,653		49,001,944		
Employees Remuneration & Benefits	15	114,096,703		103,063,735		
Selling & Distribution Expenses	16	185,431,959		195,170,006		
Administration Expenses	17	44,972,928		45,260,689		
Financial Expenses	18	62,604,479		47,122,664		
Amortization of Intangible Assets	19	5,274,041		5,657,090		
Depreciation	6	28,589,912	1,100,723,543	18,858,089	996,201,764	
III. Profit for the year	0	20,307,712	(9,043,117)	10,050,007	41,001,288	
Add /(Less) : Prior Year Adjustment			(18,860)		(444,280)	
IV. Profit Before Income Tax			(9,061,977)		40,557,008	
Provision for Income Tax - Current Year			(7,001,777)		1,629,325	
Provision for wealth tax			52,795		40,613	
(Excess) / Short Provision for Tax - Earlier Years			680,134			
Deferred Tax (As Per AS 22)			4,493,335		(1,318,398) 7,930,104	
Fringe Benefit Tax			4,475,555			
V. Profit After Tax					2,346,766	
			(14,288,241)		29,928,598	
VI. Balance Brought Forward From Previous Year			90,661,732		69,931,770	
			76,373,491		99,860,368	
VII. Appropriations						
Proposed Dividend:						
- Equity Shares		-		7,862,418		
Provision for Corporate Tax on Dividend						
- Equity Shares		-		1,336,218		
			-		9,198,636	
VIII. Balance Carried to Balance Sheet			76,373,491		90,661,732	
EARNINGS PER SHARE						
Basic EPS			(1.36)		2.85	
Diluted EPS			(1.36)		2.85	
No: of Equity Shares			10,483,224		10,483,224	
NOTES ON ACCOUNTS	20					

As per our report of even date For **OSTAWAL & JAIN** ICAI FRN No. 002491S Chartered Accountants

T. D. Jain Partner M. No. 012034 **S. Ramji** AVP Finance & Company Secretary

Dr. S. Prasanna Director Shailesh Siroya Managing Director

FOR & ON BEHALF OF THE BOARD

Bangalore 09.08.2010



SCHEDULES FORMING PART OF THE CONSOLIDATED BALANCE SHEET AS AT 31.03.2010

		3.2010	31.03	
	₹.	₹.	₹.	₹.
SCHEDULE - I SHARE CAPITAL				
AUTHORISED				
11,000,000 (P Y 11,000,000) Equity Shares of ₹ 10 each 400,000 (P Y 400,000) Redeemable Preference Shares of ₹ 100 each	110,000,000 40,000,000	150,000,000	110,000,000 40,000,000	150,000,000
ISSUED, SUBSCRIBED & PAID UP				
EQUITY SHARE CAPITAL				
10,483,224(P Y 10,483,224) Equity Shares of ₹ 10 each fully paid		104,832,240		104,832,240
		104,832,240		104,832,240
 3,040,000 equity shares of ₹ 10/- each have been issued as Bonus Shares b capitalisation of reserves 	Ŷ			
 NIL (P.Y. 37,000)equity shares of ₹ 10/- each have been allotted to the eligible employees of the Company on exercise of the vested stock options is accordance with the terms of the 'Bal Pharma Limited' ESOP. (Refer note 16 Schedule 20) 	n			
SCHEDULE - 2				
RESERVES & SURPLUS				
I. Capital Reserve	-	4,905,725	-	4,905,725
2. Securities Premium Opening Balance	145,637,950		144,720,350	
Add: Premium on Esop Allotment	143,037,730	145,637,950	917,600	145,637,950
			717,000	
3. General Reserve		24,015,000		24,015,000
4 Employee Stock options outstanding Balance at the beginning	3,293,745		4,038,600	
Add : Options granted	-		-	
Less : Transferred to securities premium account on exercise of options	-		704,850.00	
Less : Options forfeited/surrendered	1,190,625		40,005	
Balance at end of the Year (A)	2,103,120		3,293,745	
Deferred stock compensation cost				
Balance at the beginning	1,000,745		1,750,844	
Add : Options granted	-		-	
Less : Options forfeited/surrendered Less : Amortization	1,190,625		40,005	
Balance at the end of the year (B)	(435,989) 246,109		710,094	
(A) - (B)	240,109	1,857,011	1,000,745	2,293,000
5. P & L Account -Surplus				
Opening Balance	90,661,732	76 272 401	69,931,770	00 ((1 7 2 2
Add: Surplus for the year	(14,288,241)	76,373,491	20,729,962	90,661,732
SCHEDULE - 3		252,707,177		267,513,407
SECURED LOANS				
TERM LOANS				
UTI	-		1,433,132	
EXIM Bank State Bank of Indore	175,154,637		189,660,800	
Others	32,488,866 4,466,087	212,109,590	17,398,455 5,545,977	214,038,364
WORKING CAPITAL LOAN	4,400,007	212,107,370	J,J+J,777	217,030,307
Canara Bank	166,419,609		92,594,271	
Exim Bank	34,530,834		14,100,334	
Punjab National Bank	129,204,629		88,691,617	
		221 000 170		
ICICI Bank Ltd.,	1,825,406	331,980,478	53,966,347	249,352,569



SCHEDULES FORMING PART OF THE CONSOLIDATED BALANCE SHEET AS AT 31.03.2010 (Contd..)

	31.03.201	0	31.03.2009	
	₹	₹	₹	₹
SCHEDULE - 4				
UNSECURED LOANS				
Punjab National Bank		97,470	6	,169,002
Department of Scientific and industrial Research		-	2	,123,180
		97,470	8,	292,182
SCHEDULE - 5				
DIFFERED TAX LIABILITY				
Opening Balance		57,874,479	49	,944,375
Add: Liability created for the year		4,493,335	7	,930,104
		62,367,814	57	,874,479

SCHEDULE 6 FIXED ASSETS AS ON 31.03.2010

		GROSS	BLOCK		DEPRECIATION				NET BLOCK	
ASSETS	AS AT	Additions	Deletion	AS AT	AS AT	For	Deletion	AS AT	AS AT	AS AT
	01.04.2009			31.03.2010	01.04.2009	the Year		31.03.2010	31.03.2010	31.03.2009
Leasehold Land	12,583,430.00	-	-	12,583,430	-	146,982	-	146,982	12,436,448	12,493,430
Freehold Land	29,015,735	-	23,318,252	5,697,483	-	-	-	-	5,697,483	29,105,735
Building	203,264,052	2,034,757	10,762,500	194,536,309	25,499,598	6,630,856	1,108,167	31,022,287	163,514,022	177,764,454
Plant & Machinery	200,790,931	2,168,999	297,329	202,662,601	36,944,690	9,602,581	41,876	46,505,395	156,157,206	163,846,241
Utilities	105,839,528	2,333,780	3,222,911	104,950,397	24,794,155	4,976,575	338,937	29,431,793	75,518,604	81,045,373
Furniture & Fixtures	14,641,027	2,924,145	-	17,565,172	5,178,029	1,017,550	-	6,195,579	11,369,593	9,462,998
Misc Fixed Assets:	91,278,298	1,965,483	-	93,243,781	27,108,590	4,566,428	-	31,675,018	61,568,763	64,169,708
Vehicles	17,135,418	1,497,218	-	18,632,636	5,738,087	1,648,940	-	7,387,027	11,245,609	11,397,331
Total	674,548,419	12,924,382	37,600,992	649,871,809	125,263,149	28,589,912	I,488,980	152,364,081	497,507,728	549,285,270
Previous Year	373,491,524	303,171,537	21,114,642	674,548,419	107,099,261	18,858,089	694,201	125,263,149	549,285,270	266,392,263
Capital Work-in Progres	S									3,987,740

SCHEDULE - 7 INVESTMENTS

QUOTED :				
Non Trade : (at Cost) (Market Value as on 31.03.2010 not available)				
(i) Lamina Foundries Limited				
10,000 (P.Y. 10,000) Equity Shares of ₹ 10 each fully paid	371,850		371,850	
(ii) Sri Jayalakshmi Autospin Limited	736,000		736,000	
73,600 (P.Y. 73,600) Equity Shares of ₹ 10 each fully paid				
Less: Provision for diminuition in value	(1,107,850)	-	(1,107,850)	-
UN QUOTED :				
Trade :				
The Saraswat Co-operative Bank Limited		100,000		100,000
Non Trade :				
EQUITY SHARES of The Shamrao Vithal Co- Operative Bank Ltd.,				
(5,000 Shares (PY 5,000) of ₹ 10 each fully paid)		50,000		50,000
		150,000		150,000
SCHEDULE- 8				
CURRENT ASSETS, LOANS & ADVANCES				
I. INVENTORIES				
(As valued & certified by the Management)				
Raw Materials	75,208,578		78,991,015	
Packing Materials	20,233,352		14,635,467	
Work in Progress	41,316,481		50,193,765	
Finished Goods	148,136,117		94,005,657	
Stores & Consumables	1,329,971	286,224,499	1,035,458	238,861,362



SCHEDULES FORMING PART OF THE CONSOLIDATED BALANCE SHEET AS AT 31.03.2010 (Contd..)

		31.03.2010 ₹ ₹		.2009
SCHEDULE- 8 (Contd)	₹	₹	₹	₹
2. SUNDRY DEBTORS				
(Unsecured, considered good)				
Debts outstanding for more than six months	58,903,510		55,148,859	
Other Debts	260,268,757	319,172,267	237,709,763	292,858,622
3. CASH & BANK BALANCES				,,-
Cash in Hand	206,487		664,990	
Balance with Scheduled Banks:	ŕ		,	
- in EEFC	733,208		852,333	
- in Fixed Deposit	12,282,950		11,630,591	
- in Current Account	2,925,425	16,148,069	1,741,075	14,888,989
4. LOANS & ADVANCES				
(Unsecured, considered good)				
Advances recoverable in cash or in kind or for value to be received	35,741,758		17,399,666	
Deposit with Govt. dept. & Others	24,346,730		30,710,708	
Advance Income Tax & TDS	1,960,950		12,572,807	
Advance to suppliers	8,207,783		6,166,124	
Indira Vikas Patra	3,000		3,000	
National Savings Certificate	10,725		10,725	
Interest Accured but not due on deposits	223,956	70,494,902	345,328	67,208,357
•		692,039,737	· · · · · ·	613,817,331
SCHEDULE- 9		·		
CURRENT LIABILITIES & PROVISIONS				
CURRENT LIABILITIES				
Trade Creditors :				
- Dues to Medium and small enterprises (Refer notes SI No 24)	-		-	
- Other Dues	171,732,096		164,167,683	
Capital Creditors	4,725,428		17,434,076	
Creditors for Expenses	40,471,617		44,612,096	
Advances from customers	20,308,09 I		27,166,447	
Other Current Liabilities	20,170,471		27,361,670	
Book Overdraft on account of issue of cheques	1,621,309		1,280,091	
Deposits received from customers	9,196,954		8,021,954	
Unclaimed Rights Issue Application Money	141,750		141,750	
Unclaimed Dividends- Equity (Refer Notes SI No 25)	1,244,471	269,612,188	918,641	291,104,407
PROVISIONS				
Gratuity	8,151,133		7,692,748	
Provision for Tax	78,013		4,393,956	
Provision for Fringe Benefit Tax	-		2,346,766	
Dividend Payable (Equity Shares)	-		7,862,418	
Corporate Tax on Dividend Payable:				
Equity Shares	-	8,229,146	1,336,218	23,632,106
		277,841,334		314,736,513



(Amount in ₹)

SCHEDULES FORMING PART OF THE CONSOLIDATED BALANCE SHEET AS AT 31.03.2010 (Contd..)

SCHEDULE - 10 INTANGIBLE ASSETS AS ON 31.03.2010

	Gross Carrying Amount			Cumulative Amortization				Net Carrying amount		
Intangible Assets	As on 01.04.2009	Additions	Gross carrying amount	Aa at 31.03.2010	As on 01.04.2009	Amortiza- tion during the year	Retirement/ Disposal adjustments	As at 31.03.2010	As at 31.03.2010	As at 31.03.2009
			adjustments							
R&D expenses	71,033,217	8,530,889	-	79,564,106	23,114,378	5,045,057	-	28,159,435	51,404,671	47,918,839
Development expenditure	11,690,472	0	-	11,690,472	10,545,521	228,984	-	10,774,505	915,967	1,144,951
Misc.Expenditure (Novosynth)	335,623	10,377	-	346,000	0	346,000	-	0	0	335,623
Total	83,059,312	8,541,266	0	91,600,578	33,659,899	5,620,041	-	38,933,940	52,320,638	49,399,414
Previous Year	73,990,185	8,733,504	-	82,723,689	28,002,809	5,657,090	-	33,659,899	49,399,414	45,987,376

SCHEDULES FORMING PART OF CONSOLIDATED PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

Particulars	2009	-2010	2008-2009		
	₹	₹	₹	₹	
SCHEDULE - 11					
INCOME FROM SALES & SERVICES					
Exports:					
Sales	573,528,355		368,465,586		
Incentives	13,832,643		6,563,942		
	587,360,998		375,029,528		
Domestic Sales	532,014,635		725,861,412		
	1,119,375,633		1,100,890,940		
Less: Goods Returns	40,150,485	1,079,225,148	42,999,917	1,057,891,023	
Conversion charges		2,290,494	, , , , , , , , , , , , , , , , , , , ,	7,652,094	
5		1,081,515,642		1,065,543,117	
SCHEDULE - 12				,,	
OTHER INCOME					
Interest -					
Bank		752,138		1,140,018	
Dividend Income		8,888		8,888	
Foreign exchange fluctuation (Net)		7,849,579		-	
Profit on Sale of Fixed Assets (Net)		18,882,954		-	
Misc. Income		272,633		6,976	
Provisions / Creditors no longer payable written back		1,661,782		68,365	
		29,427,974		1,224,247	
SCHEDULE- 13				<u> </u>	
COST OF MATERIALS CONSUMED					
RAW MATERIALS					
Opening Stock	78,991,015		82,853,95 I		
Add : Purchases	553,156,784		369,453,146		
Less : Closing Stock	75,208,578	556,939,221	78,991,015	373,316,082	
PACKING MATERIALS					
Opening Stock	14,635,467		17,291,457		
Add : Purchases	56,493,994		46,064,651		
Less : Closing Stock	20,233,352	50,896,109	14,635,467	48,720,641	
WORK IN PROGRESS	· · · · · ·				
Opening Stock	50,193,765		55,653,735		
Closing Stock	41,316,481	8,877,284	50,193,765	5,459,970	
FINISHED GOODS	, , ,	, , , -		, , , , , , ,	
Opening Stock	94,005,657		97,431,481		
Less : Closing Stock	148,136,117	(54,130,460)	94,005,657	3,425,824	
Purchase of Traded goods		37,418,713		101,145,031	
5		600,000,868		532,067,548	



SCHEDULES FORMING PART OF CONSOLIDATED PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010 (Contd..)

Particulars	2009	-2010	2008-	2009
	₹	₹	₹	₹
SCHEDULE - 14				
MANUFACTURING EXPENSES				
Consumables and Stores-opening stock	I,035,458		1,269,518	
Add : Purchases	11,548,022		8,384,693	
Less : Closing Stock	1,329,971	11,253,509	1,035,458	8,618,753
Power & Fuel	19,324,998		19,470,973	
Vater Charges	I,200,085		I,090,004	
aboratory and Testing	5,884,750		5,375,265	
abour charges paid	6,814,670	33,224,503	4,782,349	30,718,591
Repairs & Maintenance:				
Building	82,736		129,312	
Machinery	4,617,648		3,598,525	
Others	7,334,324	12,034,708	4,735,729	8,463,566
excise Duty on Finished Goods stock		3,239,934		1,201,034
		59,752,653	-	49,001,944
CHEDULE - 15			=	
MPLOYEES REMUNERATION & BENEFITS				
alaries Wages & Allowances		90,708,363		77,086,372
onus & Exgratia		3,087,895		3,284,876
F & E.S.I Contributions		7,027,215		7,050,877
mployees Welfare		6,499,426		6,193,566
ecruitment & Training		711,408		1,157,316
Gratuity		458,385		2,060,634
mortisation of deferred stock compensation cost		(435,989)		710,094
emuneration to Directors		6,040,000		5,520,000
		114,096,703	-	103,063,735
CHEDULE - 16			=	
ELLING & DISTRIBUTION EXPENSES				
dvertisement		221,768		269,822
eminar, Conference & Exhibition Expenses		3,686,942		2,925,755
reight & Handling Charges on Export Sales		26,913,697		15,980,426
Commission on Sales		4,188,078		4,896,422
ield Staff Salaries & Incentives		55,669,865		68,902,125
ield Staff Travelling Expenses		33,583,783		37,261,036
reight Outwards & Others		6,217,441		8,741,193
reakages & Expired Goods		21,719,582		7,761,790
Other Selling Expenses		20,119,804		32,646,992
ales Promotional Items		13,110,999		15,784,445
		185,431,959	-	195,170,006



Particulars	2009	-2010	2008-2009		
	₹	₹	₹	₹	
SCHEDULE - 17					
ADMINISTRATION EXPENSES					
Travelling expenses - Inland					
- Directors	280,313		427,375		
- Others	2,911,546		4,464,535		
Travelling expenses - Foreign					
- Directors	2,333,171		566,754		
- Others	3,521,625	9,046,655	2,694,781	8,153,445	
Repairs and Maintenance - Office	I,483,53I		1,925,688		
Rates & Taxes	2,555,971		906,529		
Conveyance	2,745,689		3,257,862		
Postage, Telegram & Telephone	3,777,953		3,878,385		
Legal & Professional charges	4,734,166		5,208,344		
Printing & Stationery	3,752,312		3,792,802		
Insurance	2,847,093		2,388,674		
Rent	5,929,704		5,675,948		
Donations	26,500		14,401		
Directors Sitting fees	34,200		65,000		
Electricity Charges	819,142		752,729		
Audit Fees	367,775		362,096		
Balances / Advances/ baddebts written off	23,554		2,140,852		
Security Charges	I,594,029		962,491		
Registration Fees	1,119,363		80,327		
Vehicle Operation and Maintenance	2,123,690		2,442,600		
Foreign exchange fluctuation (Net)	-		748,638		
Loss on Sale of Fixed Assets (Net)	-		177,771		
Subscription & Membership	1,089,118		2,000,786		
Diminition in the value of Investment	346,000		-		
Miscellaneous Expenses	556,482	35,926,273	325,321	37,107,244	
		44,972,928		45,260,689	
SCHEDULE - 18			-		
FINANCIAL CHARGES					
Interest on Term Loan	27,089,227		7,945,183		
Interest on Working Capital Loan	27,682,559		29,103,721		
Other Interest	I,842,33I	56,614,117	2,218,093	39,266,997	
Bank Charges		5,990,363		7,855,667	
		62,604,479	-	47,122,664	
SCHEDULE - 19			=		
AMORTISATION OF INTANGIBLE ASSETS					
Development Expenses - Amortized		228,984		228,984	
R&D Expenses - Amortized		5,045,057		5,428,106	
		5,274,041	-	5,657,090	

SCHEDULES FORMING PART OF CONSOLIDATED PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010 (Contd..)



SCHEDULE 20-NOTES TO CONSOLIDATED ACCOUNTS:

A. SIGNIFICANT ACCOUNTING POLICIES

a) BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements of Bal Pharma Limited and its subsidiaries ('the group' or 'the Company') have been prepared and presented in accordance with Indian Generally Accepted Accounting Principles ('GAAP') under the historical cost convention on the accrual basis. GAAP comprises accounting standards notified by the Central Government of India under section 211(3C) of the Companies Act, 1956, other pronouncements of Institute of Chartered Accountants of India, the provisions of Companies Act, 1956 and guidelines issued by Securities and Exchange Board of India. Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

The Management evaluates and adopts all recently issued or revised accounting standards on an ongoing basis.

b) USE OF ESTIMATES

The preparation of the consolidated financial statements in conformity with GAAP requires the management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to contingent liabilities as at the date of the consolidated financial statements and reported amounts of revenues and expenditures for the year. Actual results could differ from those estimates. Any revision to accounting estimates is recognized prospectively in the current and future periods.

c) PRINCIPLES OF CONSOLIDATION

The consolidated financial statements are prepared in accordance with 'AS-21' "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.

The Consolidated Financial Statements relate to Bal Pharma Limited. ("the Company") and its Subsidiary Companies ("the Group"). The consolidated Financial Statements have been prepared on the following basis:

The financial statements of the Company and the subsidiaries have been combined on a line by line basis by adding together the book values of like items of assets, liabilities, income and expenses after eliminating intra group balances/ transactions and resulting unrealized profits or losses in full. Unrealized losses resulting from intra group transactions have also been eliminated except to the extent that recoverable value of related assets is lower than their cost to the group.

The excess/deficit of cost to the parent company of its investment in the subsidiaries over its portion of equity at the respective dates on which investments in such entities were made is recognized in the financial statements as Goodwill/Capital Reserve.

The consolidated financial statements are presented, to the extent possible, in the same format as that adopted by the parent company for its separate financial statements.

The consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances.

The Subsidiary Companies considered in the consolidated financial statements are

Name of the Company	Country of incorporation	Voting power held as at 31 March 2010 (in percentage)
Basav Chem Limited	India	100%

d) **REVENUE RECOGNITION**

Revenue from domestic sale of goods is recognized when significant risks and rewards in respect of ownership of products are transferred to customers. Revenue from export sales is recognized when the significant risks and rewards of ownership of products are transferred to the customer, which is based upon the terms of the applicable contract.

Revenue from product sales is stated inclusive of Excise Duty and exclusive of returns, sales tax and applicable trade discounts and allowances.

Service income is recognized as per the terms of contracts with customers when the related services are performed, or the agreed milestones are achieved.

Dividend income is recognized when the unconditional right to receive the income is established. Income from interest on deposits, loans and interest bearing securities is recognised on the time proportionate method.

Export entitlements under the Duty entitlement Pass Book ('DEPB") and Focus Marketing incentive scheme are recognized as income when the right to receive credit as per the terms of the scheme is established in respect of the exports made and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Profit on sale of investments is recorded on transfer of title from the company and is determined as the difference between the sales price and the then carrying value of the investment.

Bal Pharma Limited

e) FIXED ASSETS

Fixed assets are carried at the cost of acquisition or construction less accumulated depreciation. The cost of fixed assets includes non refundable taxes, duties, freight and other incidental expenses related to the acquisition and installation of the respective assets. Borrowing costs directly attributable to acquisition or construction of those fixed assets which necessarily take a substantial period of time to get ready for their intended use and all pre-operative expenses till the commencement of commercial production are capitalized.

Advances paid towards the acquisition of fixed assets outstanding at each balance sheet date and the cost fixed assets not ready for their intended use before such date are disclosed under capital work-in-progress.

f) **DEPRECIATION**

Depreciation on owned fixed assets of the parent Company is provided for on the straight line method as per the rates and in the manner prescribed under Schedule XIV of the Companies Act 1956. Whereas depreciation on fixed assets of the Subsidiary (Basav Chem Limited) is provided for on the written down value method as per the rates and in the manner prescribed under the schedule XIV of the Companies Act 1956. Depreciation is calculated on a pro-rata basis from the date of installation till the date the assets are sold or disposed. Premium on leasehold land is amortized over the initial period of lease. Individual low cost assets (acquired for less than ₹ 5,000/-) are entirely depreciated in the year of acquisition.

g) VALUATION OF INVENTORIES

Inventories are valued at the lower of cost and net realizable value. Cost of inventories comprises all cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition.

The methods of determining cost of various categories of inventories are as follows:

Raw materials	First in-first-out (FIFO)
Stores and spares	First in-first-out (FIFO)
Work-in-process and finished goods (manufactured)	FIFO and including an appropriate share of production overheads
Finished goods (traded)	Actual cost of purchase

h) RETIREMENT BENEFITS

A. Gratuity

In accordance with Indian laws, Bal Pharma Limited and its subsidiary in India provide for gratuity, a defined benefit retirement plan covering all eligible employees of the Company and its subsidiary. In accordance with the payment of Gratuity Act, 1972, the Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment of an amount based on the respective employee's salary and tenure of employment and vesting occurs upon completion of five years of service. The measurement date used for determining retirement benefits for gratuity is March 31.

Provision for gratuity & compensated absences is made on the basis of actuarial valuation at the balance sheet date, carried out by an independent actuary.

Contributions payable to the recognised provident fund, which is defined contribution scheme, are charged to the profit and loss account.

B. Short Term Employees Benefits

Short term employee benefits are recognized as an expense at the undiscounted amount in the profit and loss account of the year in which the related service is rendered. These benefits include leave travel allowance, bonus/performance incentives.

i) INVESTMENTS

Investments are either classified as current or long-term based on the management's intention at the time of purchase. Current investments are carried at the lower of cost and fair value. Long-term investments are carried at cost and provisions recorded to recognize any decline, other than temporary, in the carrying value of each investment.

j) FOREIGN CURRENCY TRANSACTIONS AND BALANCES

Foreign currency transactions are recorded using the exchange rates prevailing on the dates of the respective transactions. Exchange differences arising on foreign currency transactions settled during the year are recognized in the profit and loss account.

Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date, not covered by forward exchange contracts, are translated at year-end rates. The resultant exchange differences are recognized in the profit and loss account. Non-monetary assets are recorded at the rates prevailing on the date of the transaction.

k) EXPENDITURE ON RESEARCH AND DEVELOPMENT

In accordance with the Accounting Standard 26 on Intangible Assets, the Management has recognized Revenue Expenditure, direct as well as allocated, on R & D projects for development of new products and processes as Intangible Assets, since it is of the opinion that future economic benefits that are attributable to the asset will flow to the enterprise and the cost of the asset can be measured reliably. These assets shall be amortized over a period of ten years starting from the year of commercial production. However, Revenue Expenditure on projects, which have become unsuccessful are charged off as an expense in the year in which they are abandoned. Capital expenditure incurred on research and development is capitalized as fixed assets and depreciated in accordance with the depreciation policy of the company.

I) LEASES

Leases under which the company assumes substantially all the risks and rewards of ownership are classified as finance leases. Such assets acquired on or after April 01, 2001 are capitalized at fair value of the asset or present value of the minimum lease payments at the inception of the lease, whichever is lower.

Lease payments under operating leases are recognized as an expense in the statement of profit and loss on a straight-line basis over the lease term.

m) INCOME TAX EXPENSE

Income tax expense comprises current tax and deferred tax charge or credit.

Current tax

The current charge for income taxes is calculated in accordance with the relevant tax regulations applicable to the Company.

Deferred tax

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantially enacted by the balance sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realization of such assets. Deferred tax assets are reviewed at each balance sheet date and is written-down or written-up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realised.

n) EARNINGS PER SHARE

In determining earnings per share, the company considers the net profit after tax and includes the post tax effect of any extraordinary / exceptional item. The number of shares used in computing basic earnings per Share is the weighted average number of shares outstanding during the period. The number of shares used in computing diluted earnings per share comprises the weighted average shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. The dilutive potential equity shares are deemed converted as of the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares have been adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. the average market value of the outstanding shares).

o) EMPLOYEES STOCK OPTION SCHEMES

In accordance with the Securities and Exchange Board of India guidelines, the excess of the market price of shares, at the date of grant of options under the Employee Stock Option Schemes, over the exercise price is treated as employee compensation and amortized over the vesting period.

p) PROVISIONS AND CONTINGENT LIABILITIES

The Company creates a provision when there is a present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.



q) IMPAIRMENT OF ASSETS

The Company assesses at each balance sheet date whether there is any indication that an asset may be Impaired. If any such indication exists, the Company estimates the recoverable amount of the asset. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the profit and loss account. If at the balance sheet date there is an indication that if a previous assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of depreciated historical Cost.

B. NOTES ON ACCOUNTS

I) National Savings Certificates have been deposited with Commercial Tax Department.

2) EXPORT BENEFITS:

The Company has accounted an amount of \mathbf{T} 13,832,643/- (P.Y. \mathbf{T} 6,563,942/-) being the net amount of credit under the DEPB and other schemes as announced by the Import Export Policy. The same will be utilized for off-setting the customs duty on future imports. The accumulated amount outstanding on this account as on 31.03.2010 is \mathbf{T} 11, 415,647/- (P.Y. \mathbf{T} 9,131,052/-) and the same is reflected under loans and advances.

3) MARKET DEVELOPMENT EXPENSES:

Expenditure incurred on Market development amounting to ₹ 228,984/- (P.Y.₹ 228,984/-) has been written off during the year. Balance on this account as on 31.03.2010 is ₹ 9, 15,967/- (P.Y.₹ 1,144,951/-).

4) RESEARCH & DEVELOPMENT REVENUE EXPENSES:

An amount of ₹ 8,530,889/- (P.Y. ₹ 8,733,504/-) has been incurred during the year on research and development of new products and processes in the R & D Centre. The same is proposed to be amortized over a period of 10 years commencing from the year of commercial production. Amount written off during the year on account of the above was ₹ 5,045,057/- (P.Y. Rs 5,428,106/-) the balance on this account as on 31.03.2010 is ₹ 51,404,671/- (P.Y. Rs 47,918,839/-).

- 5) During the year an amount of ₹ NIL (P.Y. ₹ 25,133,403/-) being interest on term loans for acquisition of qualifying capital assets was capitalised.
- 6) The Company has provided for ₹ 7, 15,595 /- (P.Y.₹ 5, 99, 217/-) being Excise Duty on Finished Goods lying at various manufacturing units as at 31.03.2010.

7) BREAK-UP OF DEFERRED TAX ASSETS AND LIABILITIES:

	31.03.2010	31.03.2009
	₹	₹
Deferred tax Assets recognized for timing differences due to:		
A. Current Liabilities	3,251,704	2,991,323
B. Sec 40a(ia) Disallowances	229,700	229,70
C. Current Year Loss	2,584,977	-
D. Provision for diminution in the value of investment	114,933	-
	6,181,314	3,221,023
Deferred tax Liabilities recognized for timing differences due to:		
A. Depreciation and other differences in block of fixed assets	59,157,687	50,508,556
B. Others	9,391,441	10,586,946
	68,549,128	61,095,502
Net Deferred Tax Liabilities	62,367,814	57,874,479
Charge to Profit & Loss Account	4,493,335	7,930,104

8) CONTINGENT LIABILITIES NOT PROVIDED FOR (in Rupees)

a) Guarantees issued by Company's bankers ₹ 6,810,977/- (P.Y. ₹ 20,936,720/-)

b) Letter of credit ₹ 54,582,725/- (P.Y. Rs 71,135,406/-).

c) Estimated value of contracts remaining to be executed on capital account and not provided for ₹ NIL /- (P.Y. ₹ 1,434,335/-)



CIF VALUE OF IMPORTS : 9)

VAL	LUE OF IMPORTS :		(Amount in ₹)
		31.03.2010	31.03.2009
I.	Raw Materials	322,103,581	186,572,876
2.	Capital Goods (Including spares & components)	51,597	4,616,402
		320,975,758	191,189,278

10) A. **EXPENDITURE IN FOREIGN CURRENCY**

		31.03.2010	31.03.2009
a.	Travelling Expenditure	1,612,475	2,462,114
b.	Registration Fee	1,077,345	1,708,986
c.	Commission on Export sales	1,413,580	2,597,789
d.	Stall & Exhibition Expenses	905,992	
e.	Sales Promotion	2,215,914	1,114,997
		7,225,306	7,883,886

B) EARNINGS IN FOREIGN CURRENCY

	31.03.2010	31.03.2009
a. FOB Value of Exports	538,692,125	349,531,750

II) Gratuity & Leave Encashment Plan:

The following table set out the status of the plan as required under AS 15(revised):

Change in defined benefit obligation

(Amount in Rupees)

	Gra	Gratuity	
	As at 31.03.2010	As at 31.03.2009	2009-10
Openin g defined benefit obligation	10,548,499	9,126,598	
Interest Cost	723,403	663,065	
Current Service Cost	1,782,325	2,064,547	838,235
Benefits Paid	(428,340)	667,198	
Actuarial losses/(Gain)	(1,818,827)	(638,513)	837,437
Closing defined benefit obligation	10,807,060	10,548,499	I,675,672

Change in Plan Aseets

Plan Assets at beginning of the year at fair value	2,855,751	3,269,573	
Expected Return plan assets (estimated)	211,300	231,000	
Contributions			
Benefits Settled	(428,340)	(667,198)	
Actuarial gain/(loss)	17,216	22,376	
Plan Assets at the end of the year at fair value	2,655,927	2,855,751	

Reconciliation of present value of the obligation and fair value of the plan assets

Fair Value of plan assets at the beginning of the year	7,692,748	2,855,751	
Present value of the defined benefit obligation at the end of the year	10,549,892	10,548,499	(1,675,672)
Assets/(Liability) recognized in the balance sheet	(7,921,645)	(7,692,748)	(1,675,672)



Cost for the period

	As at 31.03.2010	As at 31.03.2009	2009-10
Current Service Cost	1,782,325	2,064,547	838,235
Interest ost	723,403	663,065	
Expected Return on Plan Assets	(211,300)	(231,000)	
Net Actuarial (Gain)/ Loss recognized for the year			837,437
	(1,836,043)	660,889	
Expense/(Income) recognized in the P/L A/c	458,385	2,060,634	1,675,672

Movement in the Liability recognized in Balance sheet

Opening Liability	7,692,748	5,632,114	
Expense/income recognized for the period as above	458,385	2,060,634	1,675,672
Contribution paid			
Closing Liability	8,151,133	7,692,748	I,675,672

Assumptions at the valuation date

Discount Factor	7.00%	7.00%	8.00%
Salary Escalation Rate	5.50%	5.50%	5.50%
Rate of Return (Expected) on Plan Assets	8.00%	8.00%	
Retirement Age	58	58	58

12) SECURITY FOR LOANS IN SCHEDULE (3) TO BALANCE SHEET:

- 12.1 Hire purchase finance provided by various financial institutions is secured by a charge on the assets financed by the respective institutions.
- 12.2 The Working Capital Loan financed by Canara Bank, ICICI Bank, Punjab National Bank, and EXIM Bank under a Consortium arrangement with pari passu charge is secured against hypothecation of stock and book debts and first charge on fixed assets other than those financed by the term lending institutions.
- 12.3 Loan obtained from State Bank of Indore is secured by hypothecation of assets of Unit II and Unit IVI, and Unit IV funded by them.
- 12.4 Secured loans obtained from EXIM Bank of ₹ 21.55 Crores towards establishment of Formulation Plant at Uttaranchal first pari pause charge on the entire immovable and Hypothecation of whole of moveable fixed assets, both present and future of the Company including:
 - (a) Moveable plant and machinery, Equipment, Appliances, furniture, vehicles, machinery spares and stores, tools and accessories, whether or not installed and
 - (b) Related movables in the course of transit or delivery whether now belonging or which may hereafter belong to the Company or which may be held by any person at any place within or outside India to the order or disposition of the company and all document or title including bills of lading, shipping documents, policies of insurance and other instruments and documents relating to such movables together with benefits of all rights thereto.
- 12.5 All the Secured Loans have been guaranteed by two Directors including Managing Director in their personal Capacity.
- 13) Balances of Sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any.
- 14) In the opinion of the Board of directors adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.
- 15) The Company's significant leasing arrangements are in respect of operating leases for premises (office, stores, godowns, residential, guest houses, etc.) Theses are cancelable operating leases and these lease agreements are normally renewed on expiry. The aggregate lease rentals payable are charged as rent under Schedule 17.

16) EMPLOYEE STOCK OPTION SCHEME

Bal Pharma Limited's Employee stock option scheme – 2006 (ESOP 2006) : The Company instituted the 2006 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on 23-09-2004. The Scheme covers all non promoter directors and employees and its subsidiaries. Under the scheme, the compensation Committee of the Board ('the Committee') shall administer the Scheme and grant stock options to eligible directors and employees of the Company and its subsidiaries. The Committee shall determine the employees eligible for receiving the options, the number of options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for the options issued on the date of the grant.

The market value of a share on each grant date is defined as the average of the two weeks high and low price of the share preceding the date of grant of option on the stock exchange where there is highest trade volume during that period.

In case of termination of employment, all non-vested options would stand cancelled. Options that have vested but have not been exercised can be exercised within the time prescribed under each option agreement by the Committee, failing which they would stand cancelled.

The company under ESOP-2006 had granted 2, 19,500 options to eligible employees. The vesting period for the options granted varies from 12 to 60 months.

* Stock option activity under ESOP-2006 was as follows :

Particulars	31.03.2010	31.03.2009
Options outstanding at the beginning	172,900	2,12,000
Add: Options Granted		
Less: Options forfeited/Surrendered	62,500	2,100
Less: Options exercised		37,000
Options outstanding at the end	110,400	172,900

* Exercise Price : ₹ 15.75/-

17) During the year Novosynth Research labs Private Limited, a 100% subsidiary of Bal Pharma Ltd. applied for striking off its name from the register as defunct company under section 560 of the Companies Act, 1956. pursuant to the above, the company has provided for diminution in the value of its investment in the said subsidiary.

18) RELATED PARTY DISCLOSURES:

A. Related parties where control / significant influence exist or with whom transactions have taken place during the year :

i) Enterprises where principal / promoter shareholders have control or significant influence (Significant interest entities):

Micro Labs Ltd – Enterprise owned by some of the promoter shareholders

iii) Others:-

(a)	Desa Marketing International	-	Enterprise owned by the Managing Director of the Company.
(b)	Siroya Developers (P) Ltd.	-	Enterprise owned by relatives of Managing
			Director of the Company.
(c)	Siroya Constructions	-	Enterprise over which the Managing Director of the Company
			exercises joint control with other Partners.
ov m	anagorial Porsonnal represented	on th	no hoard

B. Key managerial Personnel represented on the board:

 Managing Director
- Whole time Director
- Director

C. Particulars of related party transactions :

The following is a summary of significant related party transactions:

(in Rupees)

		31.03.2010	31.03.2009
i)	Sales to Significant interest entities	16,860,572	3,757,522
ii)	Purchases from Significant interest entities	6,851,437	27,001
iii)	Commission paid to Enterprise owned by the Managing Director of the Company	7,891,216	4,505,022
iv)	Repayment of advance from significant interest entities	80,00,000	
v)	Customer advances from significant interest entities		80,00,000
vi)	Interest Paid to significant interest entities	4,66,667	
vii)	Repayment of advance from enterprises over which Managing Director	90,620	
	of the Company exercises joint Control with other partners		
viii)	Advance given to enterprises over which Managing Director of the Company exercises joint Control with other partners	32,352	

D. Details of remuneration paid to the Managing Director and Whole-time Directors are given in Note.No.19 of Schedule 20.



	e Company has the following amounts due from / to related parties:	21.02.0010	21.02.0000
	Particulars	31.03.2010	31.03.2009
i)	Due from related parties :		
	a. Significant interest entities (Included in Sundry Debtors)	6,014,741	104,730
	b. Enterprise in which Managing Director of the Company exercises joint		
	Control with other partners (included in loans and advances		58,268
i)	Due to related parties		
	Enterprises owned by Managing Director of the Company	3,475,539	4,607,429
	(Included in current liabilities)		
ii)	Significant interest entities (included in current liabilities)		80, 00,000

19) Particulars of Managerial Remuneration:

The remuneration paid to Managerial personnel during the year :

	Managing Director		Whole time Directors	
	31.3.2010	31.3.2009	31.3.2010	31.3.2009
Salaries & Allowances	4,000,000	3,600,000	20, 40,000	19, 20,000
Commission	Nil	Nil	Nil	Nil
Perquisites	Nil	Nil	Nil	Nil

20) Auditor's Remuneration

	31.3.2010	31.3.2009
Statutory Audit Fees	2,27,575	I,70,000
Tax Audit Fees	50,000	50,000
Other services	40,200	84,521
Reimbursement of out of pocket expenses	50,000	30,000
	3,67,775	3,34,521

21) Details of Imported & Indigenous Raw Materials, Stores & Spare Parts consumed :

	31.03.2010	% of Total Consumption	31.03.2009	% of Total Consumption
Raw Materials				
Imported	195,507,115	35.1%	192,601,014	51.6%
Indigenous	361,432,106	64.9%	180,715,068	48.4%
Total	556,939,221		373,316,082	
Stores & Spares Imported	NIL	0%	NIL	0%
Indigenous	11,253,509	100%	86,18,753	100%

22) QUANTITATIVE INFORMATION

a) Installed capacity (as certified by the Management)

PRODUCT	UNIT	31.03.2010	31.03.2009	
Tablets	Million Nos.	3770	3770	
Capsules	Million Nos.	100	100	
Liquids	Kilo Litres	750	750	
Ointment	Metric Tonne	75	75	
IV-Fluids	Million Nos.	07	07	
Eye / Ear Drop	Million Nos.	19	19	
Bulk Drugs	Metric Tonne	38	38	

b) Licensed Capacity -- Not Applicable

Notes : Installed capacities are as certified by Management and have not been verified by the auditors as this a technical matter.

Sl.no	Particulars	Unit	Openin	g Stock	Produc	tion and Pu	rchase	Sales		Closing Stock	
		No.	qty	value	qty	Qty	Value	qty	Value	qty	Value
Ι	Tablets	000 Nos	29754.6	55282.7	426455.12	705.06	13324.39	446103.73	409807.71	10811.04	109773.75
			(23523)	(86568)	(674973)	(119759.3)	(57864.6)	(788500.7)	(533711.3)	(29754.6)	(55282.7)
2	Capsules	000 Nos	5625	6468.7	32933.42	126.42	5850.80	32610.48	71097.63	6074.35	23970.11
			(2507)	(3824)	(24950)	(24260.5)	(32330.7)	(46092.5)	(61164.8)	(5625)	(6468.7)
3	Liquids	Kilo Ltrs	91.5	3296.1	26487.96	1704.36	15404.30	8841.21	103913.57	19442.61	4881.72
			(72.1)	(2590)	(1299.7)	(48.1)	(9738.I)	(1328.4)	(70780.2)	(91.2)	(3296.1)
4	Ointments	Kgs	19439.9	28666.I	35551.49	179.14	3839.23	51538.92	21881.43	3631.618	2813.62
			(2216)	(3235)	(62985.6)	(3983)	(1211.6)	(49744.7)	(84566)	(19439.9)	(28666.1)
5	EED	Million	0.1	265.7	3.73			۱.8	5692.22	2.028	1999.43
			(0.001)	(7.00)	(5.4)	()	()	(5.3)	(8462.9)	(0.1)	(265.7)
6	Bulk Drugs	Kgs	4.0	26.3	64733.75			61960.00	449112.19	2777.50	4697.48
			(194)	(1208)	(38650.3)	()	()	(38840.3)	(292642)	(4.0)	(26.3)

c) Particulars of Production, Sale and Stock

(Values in '000's)

d) RAW MATERIALS CONSUMED

RAW MATERIALS CONSUMED	UNIT	QUANTITY	VALUE (₹ 000)
Powder	Kgs	۱,029,73۱	523,943
		(807,985)	(358,183)
Liquids	Ltrs	608,125	25,327
		(431,381)	(10,430)
Capsule	000'Nos	123,703	7,669
		(59,390)	(4,703)

- 23) (a) The claim for differential excise duty of ₹ 1,034,757 on Physi¬cian Samples demanded by the Central Excise Dept in the year 1999-2000 was decided in Company's favor by CESTAT in the year 2006-2007. However, the Commissioner of Central Excise, Bangalore filed a civil appeal in the Supreme Court of India against the said order of CESTAT, which is still pending.
 - (b) The claim for differential excise duty of ₹ 8.98 lakhs on physician's sales for the period September 1997 to February 1998 demanded by Central Excise Dept in respect of Unit I was contested and CESTAT, Bangalore upheld our appeal. However, Commissioner of Central Excise, Bangalore filed a civil appeal in the Supreme court of India against the said order of CESTAT, which is still pending.
 - (c) The claim of duty and penalty of ₹ 868,598 for the period May 2000 to November 2001 by Central Excise in respect of Unit III is being contested and under the directions of CESTAT, Mumbai a pre-deposit of ₹ 30,000/- has been made. The same is still pending for discussion.
 - (d) A Sales Tax claim of ₹ 749,720/- on treating stock transfer as sales in Ernakulam by the Commercial Taxes, Special Circle I, KGST is being contested and a deposit of ₹ 253,729 has been made. The application has being heard by the Deputy Commissioner, Ernakulam & is still pending for discussion.
 - (e) During the year Income Tax Officer (TDS) raised a demand of ₹ 89,50,429 towards non deduction of TDS under the provisions of Income Tax Act, 1961 for the assessment year 2004-05 to 2008-09 on all principal to principal purchase transactions entered into by it during the said assessment years. The company filed an appeal before the commissioner of income Tax Appeals-V HMT Bhavan Bangalore against the said order and as per direction of the commissioner the company deposited 25% of the demanded amount amounting to ₹ 22, 37,610/-. The said appeal is still pending. The management is however confident of favourable appeal order.
 - (f) The Company is also involved in other lawsuits, claims, investigations and proceedings including patent and commercial matters, which arise in the ordinary course of business, however, there are no such matters pending that the company expects to be material in relation to its business
- 24) The company though has initiated the process, but is yet to obtain confirmation from suppliers who have registered themselves under the Micro Small Medium Enterprise Development Act, 2006 (MSMED Act, 2006). Based on the information available with the company, the balance due to Micro & Small Enterprises as defined under the MSMED Act, 2006 is ₹ NIL. Further, no interest during the year has been paid or payable under the terms of the MSMED Act, 2006.

25) Unclaimed Dividends on Equity Shares:	Year	Amount
		(₹)
	2002-03	1, 71,432
	2003-04	I, 84,828
	2004-05	49,859
	2005-06	1, 65,071
	2006-07	1, 25,370
	2007-08	3, 73,096
	2008-09	1, 74, 815
	Total	1,244,471
26) Calculation of EPS (Basic and Diluted)		

Calculation of EPS (Basic and Diluted)

SI No.	Particulars	Year ended 31 March 2010	Year ended 31 March 2009
١.	Opening No of shares	10,483,224	10,446,224
2.	Total Shares Outstanding	10,483,224	10,483,224
3.	Weighted average number of shares	10,483,224	10,455,474
4.	Profit after Taxation available to Equity Shareholder	(142.88)	299.27
5.	EPS	(1.36)	2.87
	DILUTED		
6.	Weighted average number of shares (including employee stock option dilution)	10,527,910	10,546,718
7.	Diluted EPS	(1.36)	2.85

27) The Company is primarily engaged in a single business segment of manufacturing and marketing of Pharmaceutical Formulations and Active Pharmaceutical Ingredients and is managed as ONE entity, for its various activities and is governed by a similar set of risks and returns.

Geographical segments

In the view of the management, the Indian and Export Markets represent geographical segments.

Sales by market:

The following is the distribution of the Company's sales by geographical market:

Geographical segments	2009-2010	2008-2009
India	494,154,644	690,513,589
Other than India	587,360,998	375,029,528
Total	1,081,515,642	1065,543,117

Assets and additions to fixed assets by geographical area: The following table shows the carrying amount of segment assets and additions to fixed assets by geographical area in which the assets are located.

Particulars	2009-2	2010	2008-2009		
	India	Others*	India	Others*	
Carrying amount of segment assets	1,017,382,495	172,314,970	1,064,251,470	103,156,765	
Additions to fixed assets	12,924,382		303,171,537		

*Others represent receivables from debtors located outside India

29) Figures in brackets pertain to previous year.

30) Previous year figures have been regrouped /rearranged wherever necessary.

As per our report of even date For OSTAWAL & JAIN ICAI FRN No. 002491S **Chartered Accountants**

T. D. Jain Partner M. No. 012034

S. Ramji AVP Finance & Company Secretary Dr. S. Prasanna Director

Shailesh Siroya Managing Director

FOR & ON BEHALF OF THE BOARD

Bangalore 09.08.2010



CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2010

		(₹ in '000
	31.03.2010	31.03.2009
CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	(9,062)	40,557
Adjustments for :		
Gratuity	458	2,060
Depreciation	28,590	18,858
Misc.expenditure written off	5,274	5,658
Others-ESOP amortisation	(436)	710
Interest Received	(729)	(1,080
Dividend Income	(9)	(8)
Diminition in value of investment	346	
Provision no longer payable	-	(68
(Profit)/Loss on Sale of Fixed Assets	(18,883)	178
Interest Paid	56,614	39,26
Operating Profit before working capital changes	62,163	106,132
Adjustments for		
	(44 055)	15 (20
(Increase)/Decrease in inventories	(46,855)	15,639 (8,734
Research and Development Expenditure	(8,531)	· · ·
(Increase)/ Decrease in trade & other Payables	(21,722)	85,24
(Increase)/Decrease in trade & other Receivables	(29,876)	(59,235
Income Tax paid	(7,395)	(10,132
	(114,379)	22,783
NET CASH FROM OPERATING ACTIVITES CASH FLOW FROM INVESTING ACTIVITIES	(52,216)	128,91
Purchase of Fixed Assets	(12,924)	(114,637
(Increase)/Decrease in CWIP	3,988	(111,037
Sale of Fixed Assets	54,995	1,23
Dividend Income	9	1,23
Dividend income	46,068	(113,399
CASH FLOW FROM FINANCING ACTIVITIES	-10,000	(113,377
Proceeds from ESOP allotment		58
Proceeds(Payments) from Long term borrowings	(1,929)	(5,660
Workign Capital Borrowings	82,628	49,20
Payments of Unsecured Loans	(8,197)	(23,358
Interest paid on borrowings	(56,614)	(39,267
Interest received	729	(37,207
Dividend & dividend tax paid	(9,199)	(12,222
	7,418	(29,642
NET INCREASE IN CASH & CASH EQUIVALENTS (A+B+C)	1,271	(14,126
Opening cash	1,271	29,00
Closing Cash	14,077	14,87
NET CASH CHANGE	10,140	(14,126
Notes:	1,271	(17,120
 Direct Taxes paid is treated as arising from Operating Activities and is not bifurcated between operating 		
	,	
investing and Financing Activities.		
2. Previous year figures have been regrouped / reclassified wherever necessary.		
per our report of even date	FOR & ON BEHALI	
r OSTAWAL & JAIN		OF THE BOAN

Chartered Accountants

T. D. Jain Partner M. No. 012034

S. Ramji AVP Finance & Company Secretary Dr. S. Prasanna Director **Shailesh Siroya** Managing Director

Bangalore 09.08.2010

DIRECTORS' REPORT

Your Directors have pleasure in presenting the Annual Report together with the Audited Accounts of your Company for the financial year ended on 31st March, 2010.

I. FINANCIAL RESULTS:

			(₹. in Lakhs)
Par	rticulars	2009-10	2008-09
I)	Total Income	47.56	20.40
2)	Profits before Depreciation and provision for Taxation	(7.60)	5.37
Les	s: Depreciation	5.20	5.17
Pro Les	fits before Taxation s s:	(12.80)	0.20
3)	Provision for Taxation	(2.65)	-
4)	Fringe Benefit Tax	-	0.11
5)	Deferred Tax	(1.35)	1.07
6)	Extraordinary/ Non recurring items	- (4.00)	- (1.18)
		(8.80)	0.99
Ad	d:		
7)	Profit & Loss Account balance at the beginning of the year	-	-
8)	Profit made available for appropriation	-	-
Les	ss:		
9)	Proposed Dividend on Equity Shares	-	-
10)	Tax on dividends		
11)	Balance Carried to Balance Sheet	(8.80)	0.99

2. DIVIDEND:

Your Board has not recommended any dividend for the year 2009-10.

3. **PERFORMANCE**:

Your Compay's total income of ₹. 47.56 Lakhs includes ₹. 47.33 Lakhs as conversion charges from its holding Company, Bal Pharma Limited.

4. PROSPECTS FOR THE CURRENT YEAR:

The amalgamation proceedings of Basav Chem Limited with Bal Pharma Limited is before the honorable high court of Karnataka.

5. SECRETARIAL COMPLIANCE CERTIFICATE:

Your Board in its meeting held on 22.07.2009 has appointed Mr. Vijayakrishna K T, Company Secretary in whole-time practice, Bangalore under Section 383A of the Companies Act, 1956 to issue Secretarial Compliance Certificate for the year 2009-10.

6. PARTICULARS OF EMPLOYEES:

There was no employee whose remuneration was in excess of the limits prescribed under Section 217(2A) of the Companies Act, 1956

7. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND FOREIGN EXCHANGE OUTGO:

Intimation pursuant to Section 217(1)(e) of the Companies Act, 1956, read with the Companies (Disclosure of Particulars in the Report of the Board of Directors) Rules, 1988 is not given as there is nothing to report

8. DIRECTORS' RESPONSIBILITY STATEMENT:

In compliance to the provisions of Section 217(2AA) of the Companies Act, 1956, your Directors wish to confirm with reference to statement of Accounts for the financial year ended on 31.03.2010:

- (i) that in preparing the Annual Accounts, all applicable Accounting Standards have been followed;
- (ii) that the accounting policies adopted are consistently followed and the judgements or estimates made are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and Loss Account of the Company for the financial year;
- (iii) that the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing/detecting fraud and other irregularities;
- (iv) that the Directors have prepared the annual accounts on 'going concern' basis.

9. DEPOSITS:

As on date of the Report, the Company has not accepted any public deposits.

10. DIRECTORS:

As on date, your Board consists of following directors:

- 1) Mr. Shailesh Siroya 2) Mr. Shrenik Siroya
- 3) Dr. G.S.R. Subba Rao

Mr. Shailesh Siroya retire by rotation at the Annual General Meeting of the Company and being eligible, offer himselves for reappointment. Your Directors have pleasure in recommending his reappointment.

II. AUDITORS:

Messrs Ostawal & Jain, Chartered Accountants, Auditors of the Company, retire at the Annual General Meeting and are eligible for reappointment.

12. APPRECIATION:

The Directors place on record their appreciation of the co-operation and guidance provided by Banks and financial institutions, members of the medical profession, customers, suppliers and other business associates. Your Directors also place their appreciation of the good work rendered by all the employees. The Directors express their gratitude to all shareholders for the confidence reposed in the Management.

For and on behalf of the Board of Directors

Sangli	Dr. G. S. R. Subba Rao	Shailesh Siroya
9 th August, 2010	Director	Director

AUDITOR'S REPORT

TO THE MEMBERS OF BASAV CHEM LIMITED

We have audited the attached Balance Sheet of BASAV CHEM LIMITED as at 31st March 2010, the Profit and Loss Account for the year ended on that date annexed thereto and the cash flow statement for the year ended on that date, which we have signed under reference to this report. These financial statements are the responsibility of the Company's Management. Our responsibility is to express an opinion on these financial statements based on our audit.

We have conducted our audit in accordance with auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes, examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by Management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

As required by the Companies (Auditor's Report) Order, 2003 as amended by the Companies (Auditor's Report) (Amendment) order, 2004 issued by the Central Government of India in terms of section 227 (4A) of the Companies Act, 1956 and on the basis of such checks as we considered appropriate and according to the information and explanations given to us, we set out in the annexure a statement on the matters specified in paragraphs 4 and 5 of the said order.

Further to our comments in the Annexure referred to in paragraph 3 above, we report that:

- We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purpose of our audit;
- In our opinion, proper books of accounts as required by law have been kept by the Company so far as appears from our examination of those books;
- The Balance Sheet, the Profit and Loss Account and the Cash Flow Statement dealt with by this report are in agreement with the books of account;
- (iv) In our opinion, the Balance Sheet, the Profit and Loss Account and the Cash Flow Statement dealt with by this report comply with the Accounting Standards referred to in sub-section (3C) of Section 211 of the Companies Act, 1956 to the extent applicable;
- (v) On the basis of the written representations received from the directors, as on 31 March 2010 and taken on record by the Board of Directors, we report that none of the directors is disqualified as on 31 March 2008 from being appointed as a Director in terms of clause (g) of sub-section (1) of section 274 of the Companies Act, 1956 ; and
- (vi) In our opinion and to the best of our information and according to the explanations given to us, the said accounts, together with the notes thereon, give the information required by the Companies Act, 1956 in the manner so required and give a true and fair view

in conformity with the accounting principles generally accepted in India:

- (a) in the case of the Balance Sheet, of the state of affairs of the Company, as at 31st March 2010;
- (b) in the case of the Profit and Loss Account, of the Loss for the year ended on that date; and
- (c) in the case of the Cash Flow Statement, of the cash flows for the year ended on that date.

For **Ostawal & Jain** Chartered Accountants ICAI FRN No.002491S

	Sd/-
	T. D. JAIN
Bangalore	Partner
Date: 09.08.2010	M.M.No: 12034

ANNEXURE TO THE AUDITOR'S REPORT

Annexure referred to in Paragraph 3 of the report of the Auditors to the members of BASAV CHEM LIMITED for the year ended 31st March 2010:

- 1. The Company has maintained proper records showing full particulars including quantitative details and situation of its fixed assets. These fixed assets were physically verified by management at reasonable intervals during the year. No material discrepancies were noticed on such physical verification. Substantial part of fixed assets have not been disposed off during the year, which will affect its status as going concern.
- The Company does not carry on any own manufacturing or trading activity. The Company is in the business of manufacturing of Pharmaceutical products on job work basis. Accordingly sub-clause (a), (b) and (c) of clause 4(ii) of the order are not applicable.
- (a) The Company has not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained under section 301 of the Companies Act, 1956. Accordingly Sub Clauses (b), (c) and (d) of clause 4(iii) of the Order are not applicable.
 - (b) The Company has taken interest free unsecured loan from Companies, firms or other parties covered in the register maintained under Section 301 of the Companies Act, 1956. The Company has taken interest free unsecured advance from its holding company. The maximum balance outstanding during the year was ₹.64, 86,537/- and the year end balance of advance was ₹.64, 60,000/-.
 - (c) Based on the information received and the explanations given, the terms and conditions of the advance are prima facie not prejudicial to the interest of the Company.

Basav Chem Limited

- (d) As informed to us, the repayment of the dues was regular during the year.
- 4. In our opinion, and according to the information and explanations given to us, there are adequate internal control procedures commensurate with the size of the Company and nature of its business, for the purchase of inventory and fixed assets and for the sale of services. We have not observed any major weakness in the internal control system during the course of our audit.
- 5. (a) According to the information and explanations given to us and relevant records produced before us, the particulars of contracts or arrangements referred to in Section 301 of the Companies Act, 1956 have been entered in the register required to be maintained under that section.
 - (b) According to information and explanations given by the management and relevant records produced before us, we are of the opinion that transactions made in pursuance of such contracts or arrangements have been made at prices which are reasonable having regard to prevailing market prices.
- 6. The Company has not accepted any deposits from the public and consequently, the directives issued by the Reserve Bank of India and the provisions of Section 58A, 58AA or any other relevant provisions of the Act and the rules framed there under are not applicable to the Company.
- 7. The provisions of clause 4(vii) of the Order are not applicable to the Company.
- 8. As informed to us, the Central Government has not prescribed maintenance of cost records under section 209(1)(d) of the Companies Act, 1956.
- 9. a) According to the information and explanations given to us and on the basis of our examination of books of account, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Investor Education and Protection Fund, Employees' State Insurance, Income Tax, Sales Tax, Wealth Tax, Customs duty, Excise duty, Cess and any other material statutory dues during the year with the appropriate authorities.
 - b) According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Sales Tax, Income Tax, Wealth Tax, Service Tax, Customs Duty, Excise Duty, Cess and other material statutory dues were in arrears as at 31 March 2010 for a period of more than six months from the date they became payable.
 - c) According to the information and explanations given to us, there are no amounts in respect of Provident Fund, Income Tax, Sales Tax, Wealth Tax, Service Tax, Customs Duty, Excise duty and Cess that have not been deposited with appropriate authorities on account of any dispute.
- 10. The Company has accumulated losses in excess of 50% of its net worth as at the end of the financial year. The Company has incurred cash losses in the financial year under report however there were no cash losses in the immediately preceding financial year.

- 11. The Company has not defaulted in repayment of dues to its bankers or to any financial institution. The Company did not have any outstanding debentures during the year.
- 12. According to the information and explanations given to us and based on the documents and records produced before us, the Company has not granted any loans and/or advance on the basis of security by way of pledge of shares, debentures and other securities. Accordingly, clause 4(xii) of the Order is not applicable.
- 13. In our opinion and according to the information and explanations given to us, the nature of activities of the Company does not attract any special statue applicable to chit fund, nidhi or mutual benefit fund/society. Accordingly, clause 4(xiii) of the Order is not applicable.
- 14. In our opinion and accordingly to the information and explanations given to us, the Company does not deal in shares, securities, debentures and other investments. Accordingly clause 4(xiv) of the Order is not applicable. The shares, securities, debentures and other investments are held by the Company in its own name.
- 15. Accordingly to the information and explanations given to us, the Company has not given any guarantee for loans taken by others from bank or financial institutions. Accordingly, clause 4(xv) of the Order is not applicable.
- 16. In our opinion and according to information and explanations given to us and on the basis of examination of books of accounts, the Company has not taken any term loan during the year. Accordingly, clause 4(xvi) of the Order is not applicable.
- 17. According to the information and explanations given to us, and on an overall examination of Balance sheet and Cash Flow Statement of the Company, funds raised by the Company on short-term basis have not been used to finance Long-Term Investments.
- The Company has not made any allotment of shares during the year. Accordingly, clause (xviii) of the Order is not applicable.
- 19. The Company has not issued any debentures. Hence the requirements of clause (xix) of paragraph 4 of the Order are not applicable to the Company.
- 20. The company is not listed and hence, provisions of clause 4(xx) of the Order are not applicable.
- 21. During the course of our examination of the books of account carried out in accordance with the generally accepted auditing practices in India and according to the information and explanations given to us, we have neither come across any instance of fraud on or by the Company, noticed or reported during the year, nor have we been informed of such case by the Management.

For **Ostawal & Jain** Chartered Accountants ICAI FRN No.002491S

Bangalore Date: 09.08.2010 Sd/- **T. D. JAIN** Partner M.M.No: 12034

BASAV CHEM LIMITED

ANNUAL ACCOUNTS 2009 - 2010

BALANCE SHEET AS AT 31.03.2010

	SCH		AT 31.03.2010	AS A ₹.	T 31.03.2009 Ŧ
SOURCES OF FUNDS		₹.	₹.	۲.	₹.
I. SHAREHOLDERS' FUND					
a. Share Capital	I		1,000,000		1,000,000
b. Reserves & Surplus	2		1,405,725		1,405,725
II. LOAN FUNDS					
a. Secured Loans			-		-
b. Unsecured Loans	3		6,460,000		6,461,537
III. DEFERRED TAX LIABILITY (NET)	4		592,215	_	727,135
TOTAL		:	9,457,940	-	9,594,397
APPLICATIONS OF FUNDS					
I. FIXED ASSETS	5				
a. Gross Block		10,637,318		10,637,318	
b. Less: Accumulated Depreciation		6,960,965		6,441,251	4 10 4 0 4 7
c. Net Block			3,676,353		4,196,067
II. INVESTMENTS	6		100,000		100,000
III. CURRENT ASSETS, LOANS & ADVANCES	7				
a. Inventories b. Sundry Debtors		- 1,095,649		- 817,121	
c. Cash & Bank Balances		-		398,873	
d. Loans & Advances		942,004		1,154,235	
Total (A)	-	2,037,653		2,370,229	
CURRENT LIABILITIES & PROVISIONS	8				
a. Current Liabilities		708,819		505,605	
b. Provisions		229,488		268,758	
Total (B)		938,307		774,363	
NET CURRENT ASSETS (A-B)			1,099,346		1,595,866
IV. Intangible Assets			-		-
V. Profit and Loss account (Debit Balance)	9		4,582,241		3,702,464
TOTAL		-	9,457,940	-	9,594,397

As per our report of even date

For **OSTAWAL & JAIN** Chartered Accountants ICAI FRN No. 002491S

T. D. Jain Partner M. No. 012034 Dr. G. S. R. Subba Rao Director FOR & ON BEHALF OF THE BOARD

Shailesh Siroya Managing Director

Bangalore 09.08.2010

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

	SCH	Year Ended 31.03.2010		Year Ended 31.03.2009		
		₹.	₹.	₹.	₹.	
I. INCOME						
Conversion Charges Income		4,732,622		-		
Rental Income		-		1,980,000		
Other Income	10	23,344	4,755,966	59,620	2,039,620	
			4,755,966	_	2,039,620	
II. EXPENDITURE				_		
Manufacturing Expenditure	11	2,530,891		110,876		
Employees Remuneration & Benefits	12	2,339,265		931,518		
Administration Expenses	13	626,733		425,598		
Financial Expenses	14	507		868, ا		
Depreciation		519,714	6,017,110	517,028	I,986,888	
III. Profit for the year			(1,261,144)		52,732	
Add/(Less): Prior Year Adjustment			(18,860)	_	(33,000)	
IV. Profit Before Income Tax			(1,280,004)		19,732	
Provision for Income Tax - Current Year			-		940	
(Excess) / Short Provision for Tax - Earlier Years			(265,307)		-	
Deferred Tax (As Per AS 22)			(134,920)		107,423	
Fringe Benefit Tax			-		10,650	
V. Profit After Tax			(879,777)	_	(99,281)	
VI. Balance Carried to Balance Sheet			(879,777)	_	(99,281)	
Earnings per share						
Basic EPS			(8.80)		(0.99)	
Diluted EPS			(8.80)		(0.99)	
No. of Equity Shares			100,000		100,000	
NOTES ON ACCOUNTS	15					

As per our report of even date For **OSTAWAL & JAIN** Chartered Accountants ICAI FRN No. 002491S

T. D. Jain Partner M. No. 012034

Bangalore 09.08.2010

Dr. G. S. R. Subba Rao Director FOR & ON BEHALF OF THE BOARD

Shailesh Siroya Managing Director

SCHEDULES FORMING PART OF THE BALANCE SHEET AS AT 31.03.2010

	AS AT 31.03.2010	AS AT 31.03.2009	
	₹. ₹.	₹. ₹.	
SCHEDULE - I			
SHARE CAPITAL			
AUTHORISED			
2,00,000 (P Y 2,00,000) Equity Shares of ₹. 10 each	2,000,000	2,000,000	
ISSUED, SUBSCRIBED & PAID UP			
EQUITY SHARE CAPITAL			
100,000 (P Y 100,000) Equity Shares of ₹ 10 each fully paid (The entire share capital is being held by M/s. Bal Pharma Limited, the			
holding company)	1,000,000	I ,000,000	
	1,000,000	1,000,000	
SCHEDULE - 2			
RESERVES & SURPLUS			
I. Capital Reserve	1,405,725	l,405,725	
	1,405,725	1,405,725	
SCHEDULE - 3			
UNSECURED LOANS			
M/s. Bal Pharma Limited (100% Holding Company)	6,460,000	6,461,537	
	6,460,000	6,461,537	
SCHEDULE - 4			
DEFFERED TAX LIABILITY			
Opening Balance	727,135	619,712	
Add: Liability created for the year	(134,920)	107,423	
	592,215	727,135	

SCHEDULE 5

FIXED ASSETS AS ON 31.03.2010

	GROSS BLOCK			DEPRECIATION				NET BLOCK		
ASSETS	As at 01.04.2009	Additions	Deletions	As At 31.03.2010	As at 01.04.2009	For the year	Deletions	As at 31.03.2010	As at 31.03.2010	As at 31.03.2009
Land	90,000	-	-	90,000	-	-	-	-	90,000	90,000
Factory Building	3,401,220	-	-	3,401,220	I,874,403	152,681	-	2,027,084	1,374,136	1,526,817
Plant & Machinery	6,775,831	-	-	6,775,831	4,365,196	335,319	-	4,700,515	2,075,316	2,410,635
Utilities	60,157	-	-	60,157	11,098	8,880	-	19,978	40,179	49,059
Laboratory Equipments	258,247	-	-	258,247	166,167	12,808	-	178,975	79,272	92,080
Furniture & Fixtures	24,181	-	-	24,181	19,776	797	-	20,573	3,608	4,405
Computers	27,682	-	-	27,682	4,611	9,228	-	13,839	13,843	23,071
Total	10,637,318	-	-	10,637,318	6,441,251	519,714	-	6,960,965	3,676,353	4,196,067
Previous Year	9,842,689	794,629	-	10,637,318	5,924,223	517,028	-	6,441,251	4,196,067	3,918,466

SCHEDULES FORMING PART OF THE BALANCE SHEET AS AT 31.03.2010 (Contd.)

	AS AT 31	.03.2010	AS AT 31.03.2009		
	₹. ₹.		₹.	₹.	
SCHEDULE - 6					
INVESTMENTS					
UN QUOTED :					
Non Trade :					
(i) The Saraswat Co-Operative Bank Limited		100,000		100,000	
4,000 (P.Y. 4000) Equity Shares of ₹. 25 each fully paid					
		100,000	-	100,000	
SCHEDULE- 7					
CURRENT ASSETS, LOANS & ADVANCES					
I. SUNDRY DEBTORS					
(Unsecured, considered good)					
Debts outstanding for more than six months	-		-		
Other Debts*	1,095,649	1,095,649	817,121	817,12	
* Due from M/s Bal Pharma Limited, the holding company					
2. CASH & BANK BALANCES					
Cash in Hand	-		395,711		
Balance with Scheduled Banks:					
- in Current Account	<u> </u>	-	3,162	398,873	
3. LOANS & ADVANCES					
(Unsecured, considered good)					
Advances recoverable in cash or in kind or for value to be received	334,182		169,878		
Advance Income Tax & TDS	571,882		929,557		
Deposit with Govt. department and other	35,940	942,004	54,800	1,154,235	
		2,037,653		2,370,229	
SCHEDULE- 8			-		
CURRENT LIABILITIES & PROVISIONS					
A. CURRENT LIABILITIES					
Creditors for Expenses	387,261		375,771		
Book overdraft on account of issue of cheques	11,508		-		
Other Current Liabilities	310,050	708,819	129,834	505,605	
B. PROVISIONS					
Gratuity	229,488		257,168		
Provision for Tax	-		940		
Provision for Fringe Benefit Tax	-	229,488	10,650	268,758	
		938,307		774,363	

SCHEDULES FORMING PART OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

		2009-2010		2008-2009		
	₹	₹	₹	₹		
SCHEDULE - 9						
Profit and Loss Account (Debit Balance)						
I. P & L Account						
Opening Balance	3,702,464		3,603,183			
Add : Loss for the year	879,777	4,582,241	99,281	3,702,464		
		4,582,241		3,702,464		
SCHEDULE - 10						
OTHER INCOME						
Interest Income		23,344		59,620		
		23,344		59,620		
SCHEDULE - 11						
EMPLOYEES REMUNERATION & BENEFITS						
MANUFACTURING EXPENSES						
Power and Fuel Charges	988,062		-			
Laboratory Expenses	28,395		-			
Consumables & Stores	711,765		-			
Electrical Maintenance	66,886		-			
Factory Maintenance	150,549		88,058			
Freight Charges	60,354		-			
Machinery Maintenance	265,010		22,818			
Water Charges	108,900					
Other Manufacturing Expenses	150,970	2,530,891	-	110,876		
		2,530,891		110,876		
SCHEDULE - 12						
EMPLOYEES REMUNERATION & BENEFITS						
Salaries & allowances	2,106,816		528,835			
Employer's contribution to P.F	90,648		89,147			
Bonus	50,104		-			
Employees Welfare	119,377		56,368			
Gratuity	(27,680)	2,339,265	257,168	931,518		
		2,339,265		931,518		

	2009-	2009-2010		2009
	₹	₹	₹	₹
SCHEDULE - 13				
ADMINISTRATION EXPENSES				
Travelling Expenses	128,964		75,766	
Freight outward	85,705		-	
Vehicle Maintenance	17,423		14,098	
Rates & Taxes	14,800		77,066	
Rent	12,000		-	
Postage & Courier Charges	65,708		21,569	
Office Maintenance	74,920		49,625	
Legal & Professional charges	24,250		26,762	
Printing & Stationery	89,112		10,386	
Insurance	-		12,774	
Pooja Expenses	4,400		-	
Audit Fees	27,575		27,575	
Advertisement	-		23,244	
Membership & subscription	2,000		17,001	
Telephone Charges	52,629		69,672	
Miscellaneous Expenses	27,247	626,733	60	425,598
		626,733		425,598
SCHEDULE - 14				
FINANCIAL CHARGES				
Bank Charges		507		I ,868
		507		I ,868

SCHEDULES FORMING PART OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2010

SCHEDULE 15

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS FOR THE YEAR ENDED 31.03.2010

A. SIGNIFICANT ACCOUNTING POLICIES

a) BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements are prepared and presented in accordance with Indian Generally Accepted Accounting Principles ('GAAP') under the historical cost convention on the accrual basis. GAAP comprises accounting standards notified by the Central Government of India under section 211(3C) of the Companies Act, 1956, other pronouncements of Institute of Chartered Accountants of India, the provisions of Companies Act, 1956 and guidelines issued by Securities and Exchange Board of India. Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

The Management evaluates and adopts all recently issued or revised accounting standards on an ongoing basis.

b) USE OF ESTIMATES

The preparation of the financial statements in conformity with GAAP requires the management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to contingent liabilities as at the date of the financial statements and reported amounts of revenues and expenditure for the year. Actual results could differ from those estimates. Any revision to accounting estimates is recognized prospectively in the current and future periods.

c) **REVENUE RECOGNITION**

Rental income is recognized on accrual basis over the lease term.

Service income is recognized as per the terms of the contracts with customers when the related services are performed, or the agreed milestones are achieved.

Dividend income is recognized when the unconditional right to receive the income is established. Income from interest on deposits, loans and interest bearing securities is recognised on the time proportionate method.

Profit on sale of investments is recorded on transfer of title from the company and is determined as the difference between the sales price and the then carrying value of the investment.

d) FIXED ASSETS

Fixed assets are carried at the cost of acquisition or construction less accumulated depreciation. The cost of fixed assets includes non refundable taxes, duties, freight and other incidental expenses related to the acquisition and installation of the respective assets. Borrowing costs directly attributable to acquisition or construction of those fixed assets which necessarily take a substantial period of time to get ready for their intended use are capitalized.

Advances paid towards the acquisition of fixed assets outstanding at each balance sheet date and the cost fixed assets not ready for their intended use before such date are disclosed under capital work-in-progress.

e) **DEPRECIATION**

Depreciation on fixed assets is provided for on the Written down value method as per the rates and in the manner pre¬scribed under Schedule XIV of the Companies Act 1956. Depreciation is calculated on a pro-rata basis from the date of installation till the date the assets are sold or disposed. Individual low cost assets (acquired for less than ₹. 5,000/-) are entirely depreciated in the year of acquisition.

f) INVESTMENTS

Investments are either classified as current or long-term based on the management's intention at the time of purchase. Current investments are carried at the lower of cost and fair value. Long-term investments are carried at cost and provisions recorded to recognize any decline, other than temporary, in the carrying value of each investment.

72

g) FOREIGN CURRENCY TRANSACTIONS AND BALANCES

Foreign currency transactions are recorded using the exchange rates prevailing on the dates of the respective transactions. Exchange differences arising on foreign currency transactions settled during the year are recognized in the profit and loss account.

Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date, not covered by forward exchange contracts, are translated at year-end rates. The resultant exchange differences are recognized in the profit and loss account. Non-monetary assets are recorded at the rates prevailing on the date of the transaction.

h) INCOME TAX EXPENSES

Income tax expense comprises current tax and deferred tax charge or credit.

Current tax

The current charge for income taxes is calculated in accordance with the relevant tax regulations applicable to the Company.

Deferred tax

Deferred tax charge or credit reflects the tax effects of timing differences between accounting income and taxable income for the period. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantially enacted by the balance sheet date. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realised in future; however, where there is unabsorbed depreciation or carry forward of losses, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets. Deferred tax assets are reviewed at each balance sheet date and is written-down or written-up to reflect the amount that is reasonably/virtually certain (as the case may be) to be realised.

i) EARNINGS PER SHARE

In determining earnings per share, the company considers the net profit after tax and includes the post tax effect of any extraordinary / exceptional item. The number of shares used in computing basic earnings per share is the weighted average number of shares outstanding during the period. The number of shares used in computing diluted earnings per share comprises the weighted average shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares.

j) PROVISIONS AND CONTINGENT LIABILITIES

The Company creates a provision when there is a present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

k) IMPAIRMENT OF ASSETS

The Company assesses at each balance sheet date whether there is any indication that an asset may be Impaired. If any such indication exists, the Company estimates the recoverable amount of the asset. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the profit and loss account. If at the balance sheet date there is an indication that if a previous assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of depreciated historical Cost.

I) RETIREMENT BENEFITS

A. Gratuity

In accordance with Indian laws, the company provides for gratuity, a defined benefit retirement plan covering all eligible employees of the Company. In accordance with the payment of Gratuity Act, 1972, the Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment of an amount based on the respective employee's salary and tenure of employment and vesting occurs upon completion of five years of service. The measurement date used for determining retirement benefits for gratuity is March 31.

Provision for gratuity & compensated absences is made on the basis of actuarial valuation at the balance sheet date, carried out by an independent actuary.

Contributions payable to the recognized provident fund, which is defined contribution scheme, are charged to the profit and loss account.

B. Short Term Employees Benefits

Short term employee benefits are recognized as an expense at the undiscounted amount in the profit and loss account of the year in which the related service is rendered.

B. NOTES ON ACCOUNTS

- I) During the financial year 2007-2008, the promoters and the shareholders of the company entered into an agreement with Bal pharma Limited for the sale of company's shares. Pursuant to the agreement, Bal Pharma Limited acquired 100% control through purchase of existing Equity shares held by them @ ₹. 5/- per share and paid the amount directly to the erstwhile shareholders. Also, Bal Pharma Limited, cleared the companies secured and unsecured loans. Further, during the year, the company has already filed for amalgamation with Bal Pharma Ltd, its holding company. An amount of ₹.6, 460,000/- outstanding to Bal Pharma Ltd. towards discharge of Company's liabilities is disclosed under unsecured loans.
- 2) The company has received rental income of ₹.NIL (P.Y. 1,980,000/-) which is in respect of factory building and all its other fixed assets given on cancelable operating lease to Bal Pharma Limited.

3) BREAK-UP OF DEFERRED TAX ASSETS AND LIABILITIES:

	31.03.2010	31.03.2009	
	₹.	₹.	
Deferred tax Assets recognized for timing differences due to:			
A. Current Liabilities	70,912	87,411	
	70,912	87,411	
Deferred tax Liabilities recognized for timing differences due to:			
A. Depreciation and other differences in block of fixed assets	663,127	814,546	
	663,127	814,546	
Net Deferred Tax Liabilities	592,215	727,135	
Charge to Profit & Loss Account	(134,920)	107,423	

4) RELATED PARTY DISCLOSURES:

- A. Related parties where control / significant influence exists or with whom transactions have taken place during the year :
 - i) Holding Company: Bal Pharma Limited
- B. Key managerial Personnel represented on the board:

Mr. Shailesh D.Siroya Mr. Shrenik D Siroya

C. Particulars of related party transactions :

	31.03.2010	31.03.2009
	₹.	₹.
The following is a summary of significant related party transactions		
i) Rental income from holding company	-	1,980,000
ii) Job work charges from holding company	4,732,622	-
iii) Repayment of loan to holding company	1,537	-

D. The Company has the following amounts due from / to related parties:

	31.03.2010	31.03.2009
	₹.	₹.
i) Due from related parties		
a. Holding Company (Included in Sundry Debtors)	1,095,641	817,121
ii) Due to related parties		
Holding Company (Included in unsecured loans)	6,460,000	6,461,537

(Amount in ₹)

5) Auditor's Remuneration

	31.03.2010	31.03.2009
	₹	₹
Statutory Audit Fees	27,575	27,575
	27,575	27,575

6) Quantitative information as required by clause 3(ii) part II of schedule VI of Companies Act, 1956 is either nil or not applicable.

7) The company though has initiated the process but is yet to obtain confirmation from suppliers who have registered themselves under the Micro Small Medium Enterprise Development Act, 2006 (MSMED Act, 2006). Based on the information available with the company, the balance due to Micro & Small Enterprises as defined under the MSMED Act, 2006 is ₹.NIL. Further, no interest during the year has been paid or payable under the terms of the MSMED Act, 2006.

8) CONTINGENT LIABILITIES NOT PROVIDED FOR (in Rupees)

- a) Guarantee issued by Company's bankers ₹. NIL (P.Y. ₹. NIL).
- b) Letter of credit ₹. NIL (P. Y. NIL).
- c) Estimated value of contracts remaining to be executed on capital account and provided for ₹. NIL(P.Y. NIL).

9)	CIF VALUE OF IMPORTS : (in Rupees)	31.03.2010 NIL	31.03.2009 NIL
10)	A. EXPENDITURE IN FOREIGN CURRENCYB. EARNINGS IN FOREIGN CURRENCY (in Rupees)	NIL NIL	NIL NIL

11) Gratuity and Leave Encashment plan

The following table set out the status of the plan as required under AS 15(revised)

Change in defined benefit obligation	Gratuity (ι	Gratuity (unfunded)		
	2009-10	2008-09	2009-10	
Opening defined benefit obligation	257,168	224,911		
Interest Cost	18,002	16,868		
Current Service Cost	31,363	32,346	19,112	
Benefits Paid				
Actuarial losses/(Gain)	(77,045)	(16,957)	2,555	
Closing defined benefit obligation	229,488	257,168	21,667	

Change in Plan Aseets

Plan Assets at beginning of the year at fair value	 	
Expected Return plan assets (estimated)	 	
Contributions	 	
Benefits Settled	 	
Actuarial gain/(loss)	 	
Plan Assets at the end of the year at fair value	 	

Reconciliation of present value of the obligation and fair value of the plan assets

Fair Value of plan assets at the beginning of the year			
Present value of the defined benefit obligation at the end of the year	(229,488)	(257,168)	(21,667)
Assets/(Liability) recognized in the balance sheet	(229,488)	(257,168)	(21,667)

Cost for the period

Current Service Cost	31,363	32,346	19,112
Interest Cost	18,002	l 6,868	
Expected Return on Plan Assets			
Net Actuarial (Gain)/ Loss recognized for the year	(77,045)	(16,957)	2,555
Opening plan assets recognized on 01 April 2008		224,911	
Expense/(Income) recognized in the P/L A/c	(27,680)	257,168	21,667

Movement in the Liability recognized in Balance sheet

Opening Liability	257,168		
Expense/income recognized for the period	(27,680)	257,168	21,667
Contribution paid			
Closing Liability	229,488	257,168	21,667

Assumptions at the valuation date

Discount Factor	7.00%	7.00%	8.00%
Salary Escalation Rate	5.50%	6.00%	5.50%
Rate of Return (Expected) on Plan Assets			
Retirement Age	58	58	58

12) Calculation of EPS (Basic and Diluted)

SI No.	Particulars	Year ended 31 March 2010	Year ended 31 March 2009
Ι.	Opening No of shares	100,000	100,000
2.	Weighted average number of shares	100,000	100,000
3.	Profit after Taxation (₹ in lacs)	(8.80)	(.99)
4.	EPS	(8.80)	(0.99)
	DILUTED		
5.	Weighted average number of shares	100,000	100,000
6.	Diluted EPS	(8.80)	(0.99)

13) Balances of Sundry debtors, sundry creditors, loans and advances, receivables and payables are subject to confirmation/reconciliation, if any.

14) In the opinion of the Board of directors adequate provision has been made in the accounts for all known liabilities and the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the value stated in the balance sheet.

15) Previous year figures have been regrouped /rearranged wherever necessary.

As per our report of even date For **OSTAWAL & JAIN** Chartered Accountants ICAI FRN No. 002491S

T. D. Jain Partner M. No. 012034

Bangalore 09.08.2010 Dr. G. S. R. Subba Rao Director FOR & ON BEHALF OF THE BOARD

Shailesh Siroya Managing Director

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2010

			(₹ in '00
		31.03.2010	31.03.2009
Α	CASH FLOW FROM OPERATING ACTIVITIES		
	Profit Before Tax	-1280	20
	Adjustments for :		
	Depreciation	520	517
	Gratuity	-28	257
	Operating profit before working capital changes	-788	794
	Adjustments for :		
	Increase/ (Decrease) in Trade & other payables	203	77
	Increase/ (Decrease) in Trade & Other Receivables	-66	885
	Income Tax Paid	254	-565
	Net Cash from Operating Activities	391	397
		-397	9
	CASH FLOW FROM INVESTMENT ACTIVITIES		
	Purchase of Fixed Assets	0	-795
		0	-795
	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds from Long Term Borrowings	0	0
	Share Application money	0	0
	Unsecured Loans	-2	0
	Interest paid	0	0
	Dividend & Tax on Dividend paid	0	0
	Net Cash from financing activity	-2	0
	NET INCREASE IN CASH & CASH EQUIVALENTS (A+B+C)	-399	396
	Opening cash	399	3
	Closing Cash	0	399
	NET CASH CHANGE	-399	396
	Notes:		
	 Direct Taxes paid is treated as arising from Operating Activities and is not bifurcated between operating, investing and Finanancing Activities 		
	2. Previous year figures have been regrouped / reclassified wherever necessary.		

As per our report of even date For **OSTAWAL & JAIN** Chartered Accountants ICAI FRN No. 002491S

T. D. Jain Partner M. No. 012034 Dr. G. S. R. Subba Rao Director FOR & ON BEHALF OF THE BOARD

Shailesh Siroya Managing Director

Bangalore 09.08.2010

BA	LANCE SHEET ABSTRACT AND COMPANY	S GENERAL PROFILE	E	
				₹ 000's
I	REGISTRATION	49815	STATE CODE	08
	Balance sheet Date	31.03.2010		
П	CAPITAL RAISED DURING THE YEAR			
	Public issue	NIL	Right issue	NIL
	Bonus issue	NIL	Private placement	NIL
ш	POSITION OF MOBILISATION AND DEPLOYME	NT OF FUNDS		
	Total Liabilities	9457	Total Assets	9457
	SOURCE OF FUNDS			
	Paid-up Capital	1000	Secured Loans	6460
	Reserves & Surplus	1406	UnSecured Loans	592
	Deferred Tax	592		
	APPLICATION OF FUNDS			
	Net Fixed Assets	3676	Net Current Assets	1099
	Investments	100	Misc. Expenditure	-
IV	PERFORMANCE OF THE COMPANY			
	Turnover	4735	Profit After Tax	(880)
	Total Expenditure	6035	Earnings per share	(8.80)
	Profit Before Tax	(1280)	Dividend	-

ELECTRONIC CLEARING SERV To : M/s. Bal Pharma Limited, Bangalore - 560 099.	ICE (ECS) MANDATE FORMAT
I wish to participate in the Electronic Clearing Service introduced by Reserv to which you may electronically credit the payment due to me against the	e bank of India. As requested, I give below the details of my bank account, reference folio number mentioned against Point 1 :
I. Ref Folio No. / Client I.D. No. with D.P.I.D. No : 2. Particulars of the Bank :	
3. a. Name of the Bank :	
b. Branch Address :	
c. 9 digit code number of the Bank & Branch as appearing on the MICR cheque issued by the bank*	
d. Account type (Please tick) : :	Savings Current Cash Credit
e. Ledger Folio No. (if any) of your bank account : f. Account No. :	
I hereby declare that the particulars given above are correct and complete before the relevant book closure date (s). If the payment transaction is c	L I undertake to inform any subsequent changes in the above particulars lelayed or not effected at all for any reason(s) beyond the control of the
Company, I would not hold the Company responsible. Date :	Signature of the first holder
(*) The nine digit code number of your bank and branch is mentioned on th following is not necessary if a blank cancelled cheque leaf or photocopy of	e MICR band next to the cheque number (The
VERIFICATION BY	
Certified that the particulars furnished above are correct as per our record	15.
Bank's Stamp : Date :	Signature of the Authorised Official from the Bank
····¥	
	trial Area, Hosur Road, Bangalore - 560 099.
No. of Shares	Folio/Client I.D. No with D.P.I.D. No.
To be handed over at the entrance of the meeting hall Name and Address	
	23rd Annual
	General Meeting 27.09.2010
I hereby certify that I am a Registered Shareholder of the Company. I hereby record my presence at the above Annual General Meeting of t A Member/Proxy wishing to attend the meeting must complete this Att	
Name of Proxy (if any) in BLOCK LETTERS	Signature of Member / Proxy
Bal Pharm Regd. Office : 21 & 22, Bommasandra Indust	rial Area, Hosur Road, Bangalore - 560 099. PROXY FORM
No. of Shares	Folio/Client I.D. No with D.P. I.D. No.
I/We	
of being a member / members of BAL PHARMA LIMITED hereby appoint	
of or failing h	im / her
of or failing h of as n 23rd Annual General Meeting of the Members of Bal Pharma Limited to be Vidya Bhavan, Race Course Road, Bangalore - 560 001.	ny / or proxy to attend and vote for me/us on my / our behalf at the e held on Monday, the 27th September, 2010 at 10.00 a.m. at Bharatiya
	Affix Revenue Stamp
NOTE : Any member entitled to attend and vote at the meeting is entitled to appoint a proxy to duly completed should be deposited at the Registered Office of the Company at Bangalore not le	

×

FINANCIAL SUMMARY - LAST 10 YEARS AT A GLANCE

(₹ in Lakhs)

	2009-10	2008-09	2007-08	2006-07	2005-06	2004-05	2003-04	2002-03	2001-02	2000-01
A.) Sales and Earnings										
Gross Sales	11,216.66	11085.45	9135.98	7861.31	7647.41	6003.73	6204.63	5765.04	4523.67	3796.31
Net Sales	10,815.16	10655.43	9034.56	7618.17	7462.04	5799.26	6046.50	5513.87	4408.72	3771.58
Profit before Tax	(90.62)	405.57	420.30	315.92	357.03	220.22	284.03	275.50	213.10	152.11
Tax	52.26	106.28	134.59	114.23	64.45	32.38	23.81	13.36	14.33	9.42
Profit after Tax	(142.88)	299.29	285.71	201.69	292.58	187.84	260.22	262.14	198.77	142.69
Retained Earnings	(142.88)	207.30	163.50	110.03	200.71	61.86	103.12	149.19	113.47	57.39
B. Assets and Liabilities										
Net Fixed Assets	4,975.08	5532.73	4592.82	3123.62	2222.25	1903.83	1611.32	1439.17	1370.52	1257.89
Investments	1.50	1.50	1.50	15.04	241.37	13.58	13.58	13.58	13.71	11.79
Net Current Assets	4,141.98	2990.81	3476.93	3775.59	4328.40	2959.32	2441.56	2127.18	1753.16	1566.75
Miscellaneous Expenditure	523.21	493.99	463.22	427.80	435.49	436.71	363.43	278.39	210.32	172.85
Share Capital	1,048.32	1048.32	1044.62	1044.62	1044.62	741	973	773	773	773
Reserves & Deferred Tax Liability	3,151.57	3253.88	2958.05	2758.08	2582.35	1623.09	1329.24	1226.14	1073.03	959.68
Loan Funds	544.09	4716.83	4531.81	3539.35	3600.54	2949.35	2127.65	1859.18	1501.68	1276.60
C. Ratios										
Earnings Per Share ₹.	(1.36)	2.85	2.74	1.93	2.90	1.55	2.63	3.34	2.98	1.95
Dividend per Equity share %	-	7.5	10.00	7.5	7.5	7.5	15	12	10	10
Book value per Equity Share ₹.	29.40	36.33	33.54	27.88	26.75	22.15	20.98	21.52	20.72	23.73

BOOK POST

OUR MISSION

A full fledged Global player catering to the needs of medical fraternity and Pharmaceutical Industry



Bal Unit - I at Bangalore

- Plant commissioned in the Year 1992
- WHO GMP Certified & ISO 9001:2000 approved
- Manufacture of Finished Dosage Forms

Bal Unit - 2 at Bangalore

Bal Unit-4 at Uttarakhand

construction area of 88000 sq.ft.

excise free zone

- Plant Commissioned in the year 1996
- Multi Purpose API facility approved as per WHO-GMP guidelines
- Manufacture of Drug Intermediates
- Full fledged R & D lab approved by Department of Science & Technology





• State - of art plant designed for regulated market in

• Formulation Plant in 4 1/2 acres land, having a

Bal Unit - 3 with FFS Technology at Pune

- Plant renovated as per WHO-GMP guidelines
- Engaged in SVP and LVP (Intravenous) by Form Fill & Seal technology

AL PHARMA LIMIT



BAL PHARMA LIMITED

5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India Ph: +91-80-4137 9500 Fax: +91-80-2235 4057 / 2235 4058 Website : www.balpharma.com E-mail: secretarial@balpharma.com

